1
Status: Approved , Date: [ADDRESS_507256] 2019Janssen Research & Development *
Clinical Protocol
SIMPONI®to Arrest β -cell Loss in Type 1 Diabetes
T1GER
Protocol CNTO148DML2001 ; Phase 2a
Amendment 3
SIMPONI®(golimumab )
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen 
Biologics, BV; Janssen -Cilag International NV; Janssen, Inc; Janssen Infectious Diseases BVBA; Janssen 
Sciences Ireland UC; or Janssen Research & Development, LLC. The term “sponsor” is used throughout 
the protocol to represent these various legal entities; the sponsor is identified on the Contact [CONTACT_23756].
This study  will be conducted under US Food & Drug Administration I NDregulations (21 CFR 
Part 312).
Status: Approved
Date: [ADDRESS_507257] 2019
Prepared by: [CONTACT_12945] & Development, LLC
EDMS number :EDMS- ERI-113134249, 4.0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements .
Confidentiality Statement
The information in this document contains trade secrets and commercial information that are privileged or confidential and may 
not be disclosed unless such disclosure is required by [CONTACT_784]. In any event, persons to whom the 
information is disclosed must be informed that the information is privileged or confidentia l and may not be further disclosed by 
[CONTACT_476]. These restrictions on disclosure will apply equally to all future information supplied to you that is indicated as priv ileged or 
confiden tial.
[STUDY_ID_REMOVED]
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
2
Approved , Date: [ADDRESS_507258] POPUL ATION................................ ................................ ................................ .................. 42
4.1. Inclusion Criteria ................................ ................................ ................................ ............................ 43
4.1.1. Inclusion Criteria Applicable to All Subjects ................................ ................................ ............... 43
4.1.2. Additional Inclusion Criteria for Res ponders ................................ ................................ .............. 45
4.2. Exclusion Criteria ................................ ................................ ................................ ........................... 45
4.2.1. Exclusion Criteria applicable to All Subjects ................................ ................................ .............. 45
4.2.2. Additional Exclusion Criteria for Responders ................................ ................................ ............. 49
4.3. Exceptions to Inclusion and Exclusion Criteria for Open -Label Extension Period ........................ 49
4.4. Prohibiti ons and Restrictions ................................ ................................ ................................ ......... 49
5. TREA TMENT A LLOCA TION AND BLINDING ................................ ................................ ................. 50
6. DOSA GE A ND A DMINISTR ATION................................ ................................ ................................ ..52
6.1. Dosage ................................ ................................ ................................ ................................ ........... 52
6.2. Dose Administration ................................ ................................ ................................ ....................... 53
7. TREA TMENT COMPLIA NCE ................................ ................................ ................................ ............ 55
7.1. STUDY AGENT DOSING COMPLIANCE: RECORDING AND W INDOW S................................ .55
7.1.1. Dosing Recording ................................ ................................ ................................ ....................... 55
7.1.2. Dosing Windows ................................ ................................ ................................ ......................... 56
8. PRESTUDY A ND CONCOMI TANT THERA PY................................ ................................ ................ 57
8.1. Required Medications ................................ ................................ ................................ .................... 57
8.2. Permitted Medications ................................ ................................ ................................ .................... 58
8.3. Prohibited Medications ................................ ................................ ................................ ................... 58
9. STUDY EVA LUATIONS ................................ ................................ ................................ .................... 59
9.1. Study Procedures ................................ ................................ ................................ ........................... 59
9.1.1. Overview ................................ ................................ ................................ ................................ .....59
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
3
Approved , Date: [ADDRESS_507259] [ZIP_CODE].1.2. Screening Period ................................ ................................ ................................ ........................ 60
9.1.3. Randomization, Treatment Period, and Follow -up Period ................................ .......................... 62
9.1.4. Optional Screening -Open -Label Extension ................................ ................................ .............. 64
9.1.5. Open -Label Extension Period ................................ ................................ ................................ .....64
9.1.6. All Study Visits -Early Detection of Active Tuberculosis ................................ ............................ 66
9.2. Study Endpoints and Evaluat ions................................ ................................ ................................ ..67
9.2.1. Efficacy  Evaluations ................................ ................................ ................................ .................... 67
9.2.2. Efficacy  Endpoints ................................ ................................ ................................ ...................... 68
9.2.3. Safety Endpoints ................................ ................................ ................................ ......................... 69
9.2.4. Explorator y Endpoints ................................ ................................ ................................ ................. 69
9.3. Clinical Pharmacology ................................ ................................ ................................ .................... 70
9.3.1. Evaluations ................................ ................................ ................................ ................................ .70
9.3.2. Analytical Procedures ................................ ................................ ................................ ................. 70
9.3.3. Pharmacokinetic Parameters ................................ ................................ ................................ .....70
9.3.4. Immunogenicity Assessments (Antibodies to Golimumab) ................................ ........................ 70
9.3.5. Clinical Pharmacology –Open -Label Extension Period ................................ ............................. 71
9.4. Biom arkers ................................ ................................ ................................ ................................ .....71
9.4.1. Biom arkers –Open -Label Extension Period ................................ ................................ .............. 71
9.5. Pharmacogenomic (DNA) Evaluations ................................ ................................ .......................... 72
9.5.1. Pharmacogenomic (DNA) Evaluations –Open -Label Extension Period ................................ ....72
9.6. Safety Evaluations ................................ ................................ ................................ ......................... 72
9.6.1. Safety Evaluations –Open -Label Extension Period ................................ ................................ ...[ADDRESS_507260] COMPLETION/D ISCONTINUA TION OF ST UDY TREA TMENT/ WITHD RAWAL 
FROM THE STUDY ................................ ................................ ................................ ........................... 80
10.1. Completion ................................ ................................ ................................ ................................ .....80
10.2. Discontinuation of Study Treatment/ Withdrawal from the Study ................................ ................... [ADDRESS_507261] Information ................................ ................................ ................................ ........................ 85
11.2. Sample Size Determination ................................ ................................ ................................ ........... 85
11.3. Efficacy  Analyses ................................ ................................ ................................ ........................... 86
11.3.1. Explorator y Efficacy Analyses –Open -Label Extension Period ................................ ................. 87
11.4. Pharmacokinetic Analy ses................................ ................................ ................................ ............. 87
11.5. Immunogenicity Analyses (Antibodies to Golimumab) ................................ ................................ ..87
11.6. Biom arker Analyses ................................ ................................ ................................ ....................... 88
11.7. Pharmacokinetic/Pharmacodynamic Analyses ................................ ................................ .............. [ADDRESS_507262] ................................ ................................ ................................ ........... 96
12.5. Contact[CONTACT_90827] ................................ ................................ ........................... 96
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
4
Approved , Date: [ADDRESS_507263] Quality ................................ ................................ ............ 97
14. STUDY DRUG INFORM ATION................................ ................................ ................................ ......... 97
14.1. Physical Description of Study Drug(s) ................................ ................................ ........................... [ADDRESS_507264] ................................ ................. 100
16.2.3. Informed Consent a nd Assent Form ................................ ................................ ......................... 101
16.2.4. Privacy of Personal Data ................................ ................................ ................................ .......... 102
16.2.5. Long -Term Retention of Samples for Additional Future Research ................................ .......... 103
17. ADM INISTRA TIVE REQUI REM ENTS ................................ ................................ ............................ 103
17.1. Protocol Amendments ................................ ................................ ................................ .................. 103
17.2. Regulatory Documentation ................................ ................................ ................................ .......... 104
17.2.1. Regulatory Approval/Notification ................................ ................................ .............................. [ADDRESS_507265] Identification, Enrollment, and Screening Logs ................................ .............................. 105
17.4. Source Documentation ................................ ................................ ................................ ................. 105
17.5. Case Report Form Completion ................................ ................................ ................................ ....106
17.6. Data Quality Assurance/Quality Control ................................ ................................ ...................... [ADDRESS_507266] Retention ................................ ................................ ................................ ......................... 107
17.8. Monitoring ................................ ................................ ................................ ................................ ....107
17.9. Study Com pletion/Termination ................................ ................................ ................................ .....108
17.9.1. Study Com pletion/End of Study ................................ ................................ ................................ [ADDRESS_507267] OF A TTACHMENTS
Attachment 1: Quantiferon -TB Gold Testing ................................ ................................ .................... 121
Attachment 2: Dose and Device Charts for Study CNTO148DML2001 in Subjects With 
Type1 Diabetes ................................ ................................ ................................ ....... 124
Attachment 2 -A: Dosing Chart for Induction Doses at W eek 0 and W eek 2................................ ....... 124
Attachment 2 -B: Dosing Chart for Maintenance Dosing Regimens at Week 4 through W eek52......125
Attachment 2 -C: Device Selection Chart ................................ ................................ ............................. 126
Attachment 3: Procedures for Performing the Mixed -Meal Tolerance Test ................................ ....127
Attachment 4: Hepatitis B Virus (HBV) Screening ................................ ................................ ........... 131
Attachment 5: Study Defined AST and ALT Norm al Ranges, 2x ULN, and 3x ULN ....................... 132
Attachment 6: Anticipated Events ................................ ................................ ................................ ....133
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
5
Approved , Date: [ADDRESS_507268] OF IN -TEXT TA BLES A ND FIGU RES
TABLES
Table 1: Golim umab SC Dosing Regimens by [CONTACT_402525] W eight Cut -Off For Subjects Who Are 
Randomized to the Golimumab Treatment Group ................................ ................................ ....52
Table 2: Study Agent Dosing Window Table ................................ ................................ .......................... 56
Table 3: Study Agent Dosing Window Table –Open -Label Extension Period ................................ ....... 57
FIGURES
Figure 1: Schematic Overview of the Double -Blind Period ................................ ................................ ......34
Figure 2: Overview of the Open -Label Extension Period ................................ ................................ ......... 35
Figure 3: Overlap of simulated golimumab exposure for dosing regimens in current T1D study 
compared to those in pJIA and pediatric UC studies. ................................ ............................... 41
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
6
Approved , Date: [ADDRESS_507269] 2019PROTOCOL A MENDMENT SUMMA RY OF CHA NGES T ABLE
DOCUMENT HISTORY
Document Date
Amendment 3 22Aug 2019
Amendment 2 09 May 2016
Amendment 1 02 Jun 2016
Original Protocol 26 Apr 2016
Amendment 3 ( 22August2019)
Overall Rationale for the Amendment: Subsequent to the granting of a single patient investigational 
new drug for a subject who had shown an increase in C-peptide at Week 52 and who had an insulin 
dose-adjusted HbA1c (IDAA1 c) score less than 9, the Data Monitoring Committee recommended to 
re-start active treatment for other subjects showing a similar response profile.
Section number
and Nam eDescription of Change Brief Rationale
Time and Events Schedule Created the time and events schedule for 
open -label extension period and defined 
timepoints and study procedures for this 
period. The existing schedule was 
indicated for double -blind period.
Abbreviations used in the table w ere 
mentioned in the footnote.To accommodate the ope n-label 
extension period of the study.
Synopsis;
2.1. Objectives, Endpoints, and 
Hypothesis;
[IP_ADDRESS]. Exploratory Efficacy 
Endpoints –Open -Label Extension 
Period;
[IP_ADDRESS]. Safety Endpoints –Open -
Label Extension Period;
11.3.1. Exploratory Efficacy 
Analy ses –Open -Label Extension 
Period;
11.9. Safety Endpoints and 
AnalysesThe endpoints for open -label extension 
period w ere defined.
6.2. Dose Administration A reference to Section 9.1.[ADDRESS_507270] 30 minutes 
following dosing.
Synopsis;
3.1. Overview  of Study Design;
4.1.2. Additional Inclusion Criteria 
for Responders
9.1.1. Overview;
[IP_ADDRESS]. Efficacy EvaluationThe requirement and timing of mixed-
meal tolerance test (MMTT) was 
differentiated for the double -blind and 
open -label extension periods.To check for any changes in 
C-peptide AUC and to clarify 
the timing of 4 -hour MMTT for 
the double -blind and open -label 
extension periods.
Synopsi s;
3.1. Overview  of Study Design;
4.1.2. Additional Inclusion Criteria 
for Responders;
9.1.1. Overview;
[IP_ADDRESS]. Efficacy EvaluationThe requirements for C -responders 
lacking IDAA1c score were mentioned.To accommodate the 
C-responders without IDAA1c 
score.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
7
Approved , Date: [ADDRESS_507271] 2019Section number
and Nam eDescription of Change Brief Rationale
Synopsis;
3.1. Overview  of Study DesignThe study design was amended to indicate 
that responders would have an option to 
restart active therapy while non -
responders w ould continue to follow  the 
originally planned study design. The 
definition and cr iteria for responders w ere 
defined.The data monitoring committee 
(DMC) for the study 
recommended that responders 
should have an option to receive 
active therapy.
Synopsis;
3.2.1. Blinding, Control, Study 
Periods, Treatment GroupsThe criteria for unblind ing subjects after 
database lock of double -blind period w as 
specified. Requirement of full renewed 
informed consent was mentioned. 
Additionally, the conditions under which 
the subjects can continue off -therapy 
follow -up period w ere stated.Follow ing an ame ndment in the 
study design, the 
blinding/unblinding 
requirements and a renew ed 
informed consent process for 
the off -therapy follow -up period
required an update.
Synopsis;
3.2.1. Blinding, Control, Study 
Periods, Treatment Groups;
16.2.3. Informed Consent and 
Assent FormSpecified that signing of new ICF/assent 
forms will be required if subject meets the 
responder ’scriteria and enters the 
open -label extension period.To clarify the requirement of 
informed consent and assent 
forms for open -label extension 
period.
1. Introduction The author reference ‘Lind M, 2014’ w as 
removed since the reference number was 
cited.To maintain consistency in 
citation of reference numbers 
instead of author names.
3.1. Overview  of Study Design The follow ing text was modified as:
Follow ing initial study screening, 
subjects must be randomized within [ADDRESS_507272] data base lock 
was defined.Follow ing an amendment in the 
study design, the data base lock 
due to inclusion of the open -
label extension period was 
defined.
4.1.1. Inclusion Criteria Applicable
to All Subjects Criterion 6;
4.4. Prohibitions and Restrictions 
Criteria 3, 4, and 6;
8.3. Prohibited Medications.The criteria w ere updated to include open -
label extension period.To indicate that the criteria w ere 
applicable for open -label 
extension per iod as w ell.
Synopsis;
4.1.2. Additional Inclusion Criteria 
for RespondersAdditional inclusion criteria for 
“responders” who were to receive active 
drug in the open -label extension period 
was defined.To identify patients eligible to 
continue receiving t herapy in 
the open label extension period.
4.2.1. Exclusion Criteria applicable 
to All Subjects Criteria 22 and 23 
(General Restrictions)The criteria w ere m odified to indicate that 
they were not applicable for the 
CNTO148DML2001 trial.To exclude 
CNTO148DML2001 trial from 
the exclusion criteria.
4.2.2 Additional Exclusion Criteria 
for RespondersAdditional exclusion criteria for 
“responders” was defined.Individuals who do not meet 
response criteria will not be 
eligible for open -label extension 
period.
4.3. Exceptions to Inclusion and 
Exclusion Criteria for Open -Label 
Extension PeriodThe exceptions to the initial inclusion and 
exclusion criteria for the subjects from 
open -label extension period were stated.To include subjects who may be 
older th an [ADDRESS_507273] 
become auto -antibody negative, 
and negative Epstein -Barr Virus 
(EBV )polymerase chain 
reaction ( PCR )results.
4.4. Prohibitions and Restrictions 
Criteria 5 and 7Modified the term ‘through Week 104’ to 
‘throughout the study’To accom modate the open -label 
extension period of the study.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
8
Approved , Date: [ADDRESS_507274] 2019Section number
and Nam eDescription of Change Brief Rationale
5. Treatment Allocation and 
BlindingModified the following text: The Study 
Responsible Physician will remain blinded 
throughout the study double -blind period
to subject level treatment assignment and 
dosing regimen. To follow  the amended study 
design and indicate that 
blinding is specific to double -
blind period.
5. Treatment Allocation and 
BlindingRevised the following text to exclude 
the term ‘final’: Site investigators and 
personnel, and the subjects/caregivers 
will remain blinded until after the 
final Week 104 DBL (DBL 2) has 
occurred.
Added the following text: An 
exception to this rule will be m ade for 
those subjects who are meeting the 
responder criteria at Week 52 of the 
double -blind period. These w ill be 
unblinded to determine eligibility for 
re-starting active treatment during the 
open -label extension period.To clarify that Week 104 DBL 
is not the final DBL and specify 
the condition for unblinding.
6.1. Dosage The responders will not undergo an 
induction regimen but will start w ith the 
maintenance dose was specified. The 
reason for this was also specified.To clarify that no induction 
regime n will be used to avoid 
risk for immunogenicity or 
hypersensitivity reactions.
7.1.1. 1.Dosing Recording;
9.1.1. Overview;
9.1.2. 1.Screening Period;
9.6.1.Safety Evaluations;
9.8. Data to be Collected by 
[CONTACT_402526] -label 
extension period w as specified.To clarify usage of paper diaries 
instead of eDiaries for the 
open -label extension period.
8.1. Required Medications A reference to Section 9.8 w as provided to 
indicate paper diary usage for open -label 
extension period.
Synopsis;
2. Objectives, Endpoints, and 
HypothesisAdded objective and endpoint for open -
label extension period and clarified that 
the existing objectives and endpoints 
belonged to double -blind period.To accommodate the open -label 
extension period and 
differentiate and provide clarity 
betw een the double -blind and 
open -label extension periods. 3.1. Overview  of Study Design Added schematic overview of the 
open -label extension period.
Renamed Figure 1 title from 
‘Schematic Overview of the Study’ to 
‘Schematic Overview of the Double -
Blind Period ’.
6.1. Dosage;
Table 1Study agent dosage and timings of dosage 
calculation for open -label extension 
period w ere m entioned. 
6.2. Dose Admin istration Responsibility and timings of study agent 
administration for responders in the 
open -label extension period was added.
[IP_ADDRESS]. Dosing Recording –Open -
Label Extension PeriodA separate section to define the dose 
recording for open -label extension period 
was added.
[IP_ADDRESS]. Dosing Windows -Open -
Label Extension PeriodA separate section to define the dosing 
windows for open -label extension period 
was added.
8.1. Required Medications; The timing of recording insulin use for 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
9
Approved , Date: [ADDRESS_507275] 2019Section number
and Nam eDescription of Change Brief Rationale
9.8. Data to be Collected by 
[CONTACT_402527] -label extension period was added.
9.1.1. Overview;
16.1. Study -Specific Design 
ConsiderationsBlood volume collection for open -label 
extension period w as added.
[IP_ADDRESS]. Screening Period –
Open -Label Extension Period;
9.1.4. Optional Screening –
Open -Label Extension PeriodA separate section to define the screening 
period for the open -label extension period 
was added.
[IP_ADDRESS]. Efficacy Evaluations –
Open -Label Extension Period;
9.3.5.Clinical Pharmacology –
Open -Label Extension Period;
9.4.1. Biomarkers –Open -Label 
Extension Period.;
9.5.1. Pharmacogenomic (DNA) 
Evaluations –Open -Label 
Extension Period;
9.6.1. Safety Evaluations –Open -
Label Extension PeriodSeparate sections for efficacy, clinical 
pharmacology, biom arkers, 
pharmacogenomic, and safety evaluations 
that pertain to open -label extension period 
were added. 
9.1.5. Open -Label Extension Period The different periods, ie, active treatment, 
and post -treatment visit for the open -label 
extension period w ere des cribed. The 
study agent self -administration and study 
procedures at different timepoints were 
also described.
9.1.6. All Study Visits –Early 
Detection of Active TuberculosisA reference to Section [IP_ADDRESS] was added 
to indicate the procedure to be follow ed if 
the QuantiFERON -TB Gold test is 
indeterminate. 
10.1. Completion The study completion criteria for open -
label extension period w as specified and 
the text was modified as : A subject w ill be 
considered to have completed the study if 
he or she has completed assessments at 
Week 104 of the study off-therapy 
follow -up period or Week 60 of the 
open -label extension period of the 
study.
10.2. Discontinuation of Study 
Treatment/W ithdrawal from the 
StudyA reference to Section [IP_ADDRESS] was added 
under the TB screening criteria for subject 
to deem ineligible. 
11. Statistical Methods The definition on baseline measurement 
for the open -label extension period w as 
added and the existi ng definition w as 
indicated for the double -blind period. 
11.3.1. Exploratory Efficacy 
Analyses –Open -Label Extension 
PeriodThe exploratory efficacy analyses for 
open -label extension period were added.
8. Prestudy and Concomitant 
TherapyThe recording of prestudy therapi[INVESTIGATOR_402480] -blind 
period.To clarify that the prestudy 
therapi[INVESTIGATOR_402481] -
blind period.
9.8. Data to be Collected by 
[CONTACT_402528] -blind period.To specify the condition when 
the BG readings from 
glucometer be transmitted.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
10
Approved , Date: [ADDRESS_507276] 2019Section number
and Nam eDescription of Change Brief Rationale
Synopsis;
[IP_ADDRESS]. Efficacy Evaluations –
Open -Label Extension Period;
9.8. Data to be Collected by 
[CONTACT_402529] -label extension period 
were defined.To provide acceptable glucose 
monitoring techniques for open -
label extension period.
9.9. Injection Site Reaction 
MonitoringModified the followin g text: A physician 
must be immediately available at the site 
during the first 3 dose administrations of 
study agent for the double -blind period 
and open label treatm ent period.To clearly define the 
availability of physician at the 
site during study agent dose 
administrations.
10.2. Discontinuation of Study 
Treatment/Withdrawal from the 
StudyAdded the following text: Subjects w ho 
permanently discontinue active treatment 
during the open -label extension period 
will have their end -of-study visit followed 
by[CONTACT_7620] -treatment visit 10 weeks later.To define that an end -of-study 
visit will be performed for the 
subjects who discontinue active 
treatment during open -label 
extension period.
10.2. Discontinuation of Study 
Treatment/Withdrawal from the 
StudyThe w ithdraw al criteria for responders 
was specified. Withdraw al criteria are based 
on deterioration of C -peptide 
AUC and/or remission score, 
similar to eligibility criteria
Synopsis;
11. Statistical MethodsSpecified that hypotheses testing for open -
label ex tension phase will not be 
performed and data generated will be 
summarized descriptively.Provided for data analyses of 
open -label extension portion.
11.10.Statistical Methods Added the following text: The DMC 
serves the IAC function.To clarify that the DMC is also 
the IAC for the study.
11.4. Pharmacokinetic Analyses;
11.5. Immunogenicity Analyses 
(Antibodies to Golimumab);
11.6. Biomarker Analyses;
11.7. 
Pharm acokinetic/Pharmacodynamic 
Analyses;
11.9. Safety Endpoints and 
AnalysesA statement to indica te that the analyses 
performed for double -blind period w ere 
applicable for the open -label extension 
period w as mentioned.To specify the analyses for the 
open -label extension period.
11.8. Pharmacogenomic analyses Added the pharmacogenomic analyses for 
the open -label extension period.
Abbreviations New  abbreviations, ie, C responders, C+R 
responders, IDAA1c, PCR, OL, and R 
responders w ere added.To accommodate the ne w 
terms/abbreviations from the 
additions/revisions to the 
protocol.
References Follow ingliterature references w ere 
added,
Fonolleda M, Murillo M, Vazquez F, 
Bel J, Vives -Pi M. Remission Phase 
in Paediatric Type 1 Diabetes: New  
Understanding and Emerging 
Biomarkers. Horm Res Paediatr 
2017;88:307 –315
Max Andersen MLC et al. Partial 
remission d efinition: Validation based 
on the insulin dose -adjusted HbA1c 
(IDAA1C) in 129 Danish children 
with new -onset type 1 diabetes. 
Pediatr Diabetes. 2014;15(7):469 –
476.References added to support the 
updated study design
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
11
Approved , Date: [ADDRESS_507277] 2019Section number
and Nam eDescription of Change Brief Rationale
Mortensen H. B., Hougaard P., Sw ift 
P., et al. New  definition for the partial 
remission per iod in children and 
adolescents with type 1 diabetes. 
Diabetes Care. 2009;32(8):1384 –
1390.
Nagl K, Hermann JM, Plamper M, et 
al. Factors contributing to partial 
remission in type 1 diabetes: analysis 
based on the insulin dose -adjusted 
HbA1c in 3657 childre n and 
adolescents from [LOCATION_013] and 
Austria. Pediatr Diabetes 
2017;18:428 -434.
Throughout Minor formatting, editorial, or spelling 
changes were made.
The term ‘participant’ was replaced 
with ‘subject’ across the protocol for 
consistency.Minor, therefore have not been 
summarized.
Added ’OL’ before w eek numbers that 
pertained to the open -label extension 
period.
Added ‘double -blind’ against week 
numbers or periods that pertained to 
the double -blind peri od.To differentiate betw een 
open -label extension and 
double -blind periods.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
12
Approved , Date: [ADDRESS_507278] 2019SYNOPSIS
SIMPONI®to Arrest β -cell Loss in Type 1 Diabetes
SIMPONI®(golimumab) is a fully human monoclonal antibody which binds to human tumor necrosis 
factor alpha (TNFα) with high affinity and specificity and neutralizes TNFα bioactivity. Golimumab was 
first approved by [CONTACT_6581] (FDA) in 2009 and has been shown to 
be safe and efficacious in adults with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing 
spondylitis (AS), and ulcerative colitis (UC). Additionally, golimumab has been evaluated in studies 
conducted under a n Investigational New Drug (IND) for the treatment of polyarticular juvenile idiopathic 
arthritis (pJIA; 2 up to 18 years of age), and pediatric UC (2 up to 18 years of age).
Similar to these above conditions, Type 1 diabetes (T1D) is an autoimmune disorde r with severe 
sequelae, but there are noapproved disease modifying therapi[INVESTIGATOR_402482] T1D. Children and young 
adults are those that most frequently develop T1D and have the most urgent need for a disease modifying  
therapy to reduce the associated short-and long-term morbidity and mortality. This study will evaluate 
whether golimumab administered subcutaneously (SC) in this population with newly diagnosed T1D has 
the potential to maintain residual β -cell function and improve metabolic control.
OBJECT IVES, ENDPOINTS, AND HYPOTHESIS
Double -Blind Period
Objectives Endpoints
Primary Objective and Endpoints
 To determine if golimumab can preserve β-cell 
function in children and young adults with 
newly diagnosed T1D. The Mixed -meal Tolerance Test (MMTT) -
stimulated 4-hour C-peptide area under the 
concentration -time curve (AUC) at Week 52.
Secondary Objectives and Endpoints: Efficacy 
 To evaluate the impact of golimumab on 
measures of diabetes control in this subject 
population.
To evaluate the off-therapy durability of 
golimumab on measures of diabetes control in 
this subject population.  Change from baseline in insulin use in units 
per kilogram body weight per day over time.
Change from baseline in HbA1c over time.
Hypoglycemic event rates (defined as blood 
glucose levels (BG) of ≤70, 55, and 
35mg/dL or clinical sequelae in the absence 
of a BG reading) through Week 52, after 
Week 52 through Week 104, and the entire 
study.
MMTT -stimulated 4-hour C-peptide AUC 
over time.
Secondar y Objective and Endpoints: Safety 
 To determine the safety  and tolerability of 
golimumab in children and young adults with 
T1D. Proportion of subjects with treatment -
emergent adverse events (AEs) and severe 
AEs through Week 52 and 104.
Proportion of subje cts with severe infections 
through Week 52 and 104.
Proportion of subjects with study agent 
injection site reactions through Week 52.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
13
Approved , Date: [ADDRESS_507279] 2019Objectives Endpoints
Secondary Objective and Endpoints: Pharmacokinetics (PK ) and Immunogenicity 
 To evaluate the PK and immunogenicity of 
golimumab in this specific subject population 
with T1D. Summary of serum golimumab 
concentrations and the PK profile after 
induction and maintenance dosing.
Incidence and titers of antibodies to 
golimumab. 
Exploratory Objective and Endpoints: Immunologic and Metabolic
 To evaluate how golimumab impacts 
immunologic profiles and indicators of β-cell 
stress, and the correlation with efficacy and 
safety endpoints in this study. Correlation of cellular and serologic immune 
profiles with clinical metabolic outcomes on-
therapy (Weeks 12, 26, 38, and 52) and 
off-therapy (Weeks 78 and 104).
Relationship of exploratory markers of β-cell 
stress and survival with clinical metabolic 
outcomes on-therapy (Weeks 12, 26, 38, and 
52) and off -therapy (Weeks 78 and 104).
Open -Label Extension Period
Objective Endpoint
 To evaluate additional one year of safety and 
exploratory efficacy endpoints in those 
participants that have shown a particular 
response in the double -blind period . Continue to evaluate safety and exploratory
efficacy endpoints as per the Time and 
Events Schedule (open -label extension 
period) and no new efficacy hypotheses will 
be tested compared to the double -blind 
period.
Hypothesis
The primary hypothesis to be tested in this study is that golimumab is superior to placebo in maintaining 
β-cell function in children and young adults with newly diagnosed T1D as measured by [CONTACT_51867] -meal 
tolerance test ( MMTT )-stimulated [ADDRESS_507280] profile at Week 52 which includes :
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
14
Approved , Date: [ADDRESS_507281] [ZIP_CODE]. C-peptide and Remission score* responders (C+R responders): either having an increase in 
C-peptide AUC versus baseline or having a stable C-peptide AUC, not decreasing more than 5% 
versus baseline and having a remission score ≤9.
OR
2. C-peptide responders (C responders ): either having an increase in C-peptide AUC versus baseline or 
having a stabl e C-peptide AUC, not decreasing more than 5%versus baseline but not meeting a 
remission score of ≤9. Their remission score ,however ,must be <12.
OR
3. Remission score responders (R responders): having a remission score ≤9 but not meeting C-peptide 
response as defined above . However, their C-peptide AUC decline from baseline should be less than 
or equal to 30% compared to baseline .
*Insulin Dose Adjusted HbA1c: IDAA1 c= A1C (percent) + [4 × insulin dose (units per kilogram per 
24h)].
This study will enroll male and female subjects [ADDRESS_507282] been recently 
diagnosed with T1D and are able to be randomized within 100 days of diagnosis. A target of 
approximately 81subjects will be randomly assigned in a 2:1 ratio to receive golimumab or placebo, 
administered SC for 52weeks and monitored for an additional 52 weeks. Subjects will be randomized to 
receive active therapy (golimumab) or placebo and be stratified based on C-peptide AUC levels of 
<0.66 pmol/mL or≥0.66 pmol/mL from a 4-hour MMT T conducted at study screening. The protocol will 
give the option for study agent administration by [CONTACT_402530], ie, 
self-administration, after proper training .
An independent Data Monitoring Committee will be commissioned to continually assess the safety of 
study subjects .
Following database lock for the double -blind treatment period (Week 52), subjects who are still in the 
off-therapy follow -up period (Week 52to 104 visits),who were on active drug during the double -blind 
period and who meet the response criteria will be offered the option to participate in the open -label 
extension period if eligibility criteria are met. Prior to initiating open -label screenin g assessments , 
subjects and parents/legal guardians will sign updated informed consent form /assent forms.
Subjects who did not meet the response criteria at Week [ADDRESS_507283] POPULATION
Male or female subjects 6 through 21 years of age who meet the American Diabetes Association (ADA)
standard T1D criteria within [ADDRESS_507284] 1 of the 
following diabetes -related autoantibodies obtained at study screening:
Glutam icacid decarboxylase (GAD -65)
IA-2
ZnT8
ICA; or
Insulin (if obtained within 10 days of the onset of exogenous insulin therapy)
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
15
Approved , Date: [ADDRESS_507285] a stimulated C-peptide level ≥0.2 pmol/mL following a 4-hour MMTT 
obtained at study screening.
The responder sfor open -label extension period must meet the MMTT criteria at Screening for the 
open -label extension period. If the most recent MMTT is <[ADDRESS_507286] recent safety laboratory samples drawn within 1 month prior to screening do 
not need a repeat; eligibility will be assessed based on these most recent laboratory tests.For 
C-responders who are lacking the necessary information to calculate IDAA1c score, an HbA1 cwill be 
performed and 10 days of insulin dose information will be required.
DOSAGE AND ADMINISTRATION
All study agent (golimumab or placebo) will be administered subcutaneously using a sponsor -supplied, 
single -use administra tion device. This will be either the commercially available prefilled syringe with 
needle guard (the PFS-Ultrasafe [PFS -U]), designed to deliver a single, fixed dose of 50mg, or the 
investigational VarioJect injection device (“VarioJect ”) which deliver sasingle, variable dose of 10 to 
45mg in 5 mg increments. Identical devices containing placebo will be used to deliver a volume 
equivalent to that of active treatment for subjects randomized to the placebo arm.
EFFICACY EVALUATIONS
The following efficacy e valuations will be assessed:
A 4-hour MMTT will be performed to assess C-peptide levels and the C-peptide AUC at screening
and Week s12, 26, 38, 52, 78, and 104of the double -blind period .During the open -label extension 
period , a 4-hour MMTT will be perfo rmed at OL screening (unless performed <3 months ago), OL
Week 28 ,and OL Week 52.For C -responders who are lacking the necessary information to calculate 
IDAA 1cscore, an HbA1 cwill be performed and 10 days of insulin dose information will be 
required. For additional details, see the Time and Events Schedule.
Blood glucose levels between visits will be obtained by [CONTACT_402531] -glucometer readings.
During the open -label extension period, subjects may use either fingersticks or continuous glucose 
moni toring (CGM) at the discretion of the investigator and/or according to local practice. The 
subjects will not be required to download BGvalues from the eDiary .
Hemoglobin A1c (as % HbA1c) and insulin as U/kg body weight/day. AnHbA1c measurement will 
be do ne at each study visit and subjects should record the type and amount of ins ulin they have used 
during the 7-day period immediately preceding each study visit. During the open -label extension 
period, subject will record insulin usage on paper diary for 10 days prior to each study visit.
Hypoglycemic events, defined as a BG level of ≤70 mg/dL or clinical sequelae consistent with 
hypoglycemia without a BG reading, will be documented throughout the study.
Records of glucose measurements, insulin use and hypoglycemic events and communication with the 
subject will be kept in source documentation, on the appropriate case report form , or in the patient 
diary.
CLINICAL PHARMACOLOGY EVALUATIONS
Serum samples will be used to evaluate the pharmacokinetics (PK), the immunogenicity of golimumab 
(antib odies to golimumab) , and pharmacodynamics (PD; free/total TNF )at the timepoints presented in 
the Time and Events Schedule .
Serum golimumab concentrations will be summarized for each treatment group over time. If necessary , a 
population PK analysis will be performed to characterize the PK of golimumab as well as to identify and 
quantify important covariates of PK using a nonlinear mixed effects modeling approach. If visual trends 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
16
Approved , Date: [ADDRESS_507287] 2019are observed, a suitable PK/pharmacodynamic model may be developed to describe the 
exposure -response relationship.
To assess the immunogenicity of golimumab, detection of antibodies to golimumab will be performed 
using a validated assay method. Serum samples will be evaluated for antibodies binding to golimumab 
and the titer of confirmed positive samples and the incidence of antibodies to golimumab will be reported. 
Other analyses may be performed to more fully characterize the immunogenicity of golimumab in this 
population .
BIOMARKER EVALUATIONS
Serum and cell-based biomarkers will be evaluated for inflammation -associated proteins, changes in 
immune cell subsets, and will be used to better understand the biology of T1D, to provide a biological 
assessment of theresponse of subjects to treatment with golimumab, to analyze differences between 
responders and nonresponders, and to determine if the markers can be used to classify patients as 
potential responders prior to treatment.
PHARMACOGENOMIC (DNA) EVALUATIONS
Apharmacogenetics blood sample for molecular major histocompatibility complex (MHC )haplotypi[INVESTIGATOR_402483]. Expl oratory pharmacogenomic resear ch may 
consist of the analysis of one or more genetic markers throughout the genome in relation to golimumab or 
T1D clinical endpoints. Participation in exploratory pharmacogenetics research is optional. Subjects will 
need to provide consent /assent to participate in the exploratory phase of the pharmacogen etics resea rch.
Pharmacogenomic assessment of molecular MHC haplotype and insulin DNA methylation will not be 
performed for the open -label extension period. The open -label extension period will include PBMC 
sample collection and serum biomarker sample collection.
SAF ETY EVALUATIONS
Monitoring and evaluation of subjects in this study will focus on study agent, device -related, and 
disease -related safety issues. Monitoring will include physical examinations, clinical laboratory tests, vital 
signs, concomitant medications , and adverse events , including injection site reactions.
STATISTICAL METHODS
Descriptive statistics (eg, mean, median, standard deviation [SD], minimum, and maximum) will be used 
to summarize continuous variables. Counts and percentages will be used to summarize categorical 
variables. Graphic data displays may also be used to summarize the data.
The sample size calculation is based on the primary endpoint, an MMTT 4-hour C-peptide AUC at 
Week 52. Due to skewed C -peptide AUC data, normalizing transformation of log (AUC +1) is applied for 
sample size assessment. The method has been well accepted and used in numerous clinical studies . Based 
on published data, a common SDof log (AUC+1) of 0.215 is assumed, and the back -transformed means 
for 4-hour C-peptide AUC areassumed to be0.385 and 0.635 for the placebo and golimumab groups 
respectively, ie the expected treatment difference (back -transformed) is 0.25. With 81 subjects (54 on 
golimumab and 27 on placebo) and an alpha of 0.05 (2 -sided), there is 90% power to detect the treatment 
difference through a two -sample t -test.
All efficacy analyses will be performed on the modified intent -to-treat (mITT) population unless 
otherwise specified. The mITT population includes all randomized subjects who have received at 1dose 
of study agent. The primary efficacy endpoint will be analyzed by [CONTACT_2329] a mixed model for repeated 
measures .
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
17
Approved , Date: [ADDRESS_507288] 60% of subjects complete their Week [ADDRESS_507289] to facilitate planning of future studies.
All the efficacy endpoints defined for the double -blind period will be exploratory for the open -label 
extension period and will be summarized descriptively; there will be no hypotheses testing during the 
open -label extension period . Disease progression will be compared between the double -blind period and 
the extension period in subjects who attended the open -label extension period if deemed reasonable.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
18
Approved , Date: [ADDRESS_507290] 2019TIME A ND EVENTS SCHE DULE
Double -Blind Period
Screening Through Off -therapy Follow -up
Study Designation Screening Active Treatm entb,c Off-therapy Follow -
upd
Study Weeka-4 to -1 0 2 4 8 12 18 26 33 38 45 52 [ZIP_CODE]
(EOSV)r
Study Daya(visit window  in 
days)-28 to -1 115
(±1)29
(±1)57
(±3)85
(±3)127
(±3)183
(±3)232
(±7)267
(±3)316
(±7)365
(±3)547
(±10)729
(±10)
Study Procedure
Screening/Administrative
Informed consent/assent 
(ICF)X
Pharm acogenetics 
consent/assente X
Inclusion/exclusion criteria 
evaluation/reviewX X
Dispense electronic diary 
(eDiary) and glucometer and 
trainingfX
Clinical Assessments / Ongoing Review
Full Physical examination X X
Brief physical examination X X X X X X X X X X X X
Vital signs X X X X X X X X X X X X X X
Height & Body weight 
measurementX X X X X X X X
Medical history and 
demographicsX
Interval history and eDiary 
reviewX X X X X X X X X X X X X
Previous/concomitant 
medication reviewX X X X X X X X X X X X X X
Adverse events X X X X X X X X X X X X X
Tuberculosis (TB) exposure 
review X X X X X X X X X X X X X X
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
19
Approved , Date: [ADDRESS_507291] 2019Screening Through Off -therapy Follow -up
Study Designation Screening Active Treatm entb,c Off-therapy Follow -
upd
Study Weeka-4 to -1 0 2 4 8 12 18 26 33 38 45 52 [ZIP_CODE]
(EOSV)r
Study Daya(visit window  in 
days)-28 to -1 115
(±1)29
(±1)57
(±3)85
(±3)127
(±3)183
(±3)232
(±7)267
(±3)316
(±7)365
(±3)547
(±10)729
(±10)
Study Procedure
Randomization and Study Agent Administration
Randomization X
Dose determination and 
modificationX X X X
Required study agent 
administration at study siteg X X X X X X X X X
Subjects participating in self -adm inistrationb
Injection training by [CONTACT_402532] X X X
Distribute study agent 
injection devicesX X X X X XgX Xg
Return study agent injection 
devicesX X X X X X X X
Subject Reported Data / eDiary Review
Glucometer reading review X X X X X X X X X X X X X
Insulin use report review X X X X X X X X X X X X X
Hypoglycemia event revie w X X X X X X X X X X X X X
Study agent self -
administration reviewb X X X X X X X X
Clinical Laboratory Assessments
4h -Mixed -meal tolerance 
test (MMTT)h X X X X X X X
HbA1c X X X X X X X X X X X X X X
Type [ADDRESS_507292] X
Serum pregnancy testjX
Urine pregnancy testjX X X X X X X X X X X X X
Hem atologykX X X X X X X X X
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
20
Approved , Date: [ADDRESS_507293] 2019Screening Through Off -therapy Follow -up
Study Designation Screening Active Treatm entb,c Off-therapy Follow -
upd
Study Weeka-4 to -1 0 2 4 8 12 18 26 33 38 45 52 [ZIP_CODE]
(EOSV)r
Study Daya(visit window  in 
days)-28 to -1 115
(±1)29
(±1)57
(±3)85
(±3)127
(±3)183
(±3)232
(±7)267
(±3)316
(±7)365
(±3)547
(±10)729
(±10)
Study Procedure
ChemistrykX X X X X X X X X
Viral serologylX
Polymerase chain reaction 
(PCR) Viral loadm X X X X X X X
Clinical Pharmacology
Golimumab concentrationnX X X X X X X X X X X X
Antibodies to golimumabnX X X X X X X X
Free/total TNFαnX X X X X X X X X X X X
Biom arkers and Pharm acogenomicss
Major histocompatibility 
complex (MHC) haplotypeo X
Peripheral blood 
mononuclear cell (PBMC) 
sample collectionpX X X X X X X
Serum biomarker samplepX X X X X X X
DNA methylation 
(Optional)q X X X X X X X
Abbreviations: eDiary =electronic diary, EOSV=End of Study Visit, ICF=informed consent, IDAA1c=insulin dose-adjusted HbA1c, MHC=major histocompatibility 
complex, MMTT=m ixed-meal tolerance test, PBMC=peripheral blood mononuclear cell, PCR=polymerase chain reaction, TB=tuberculosis, TNFα=tumor necro sis 
factor alpha
a.The study visit Week and target study visit Day are indicated and calculated based on the day of rand omization. Acceptable w indows for study visits in days before 
(-) or after (+) target study visit day are indicated and based on if study agent dosing will be given at that visit and time e nrolled in the study.
b.Subjects/ caregivers will be given the option for at home “self -administration” for study agent doses after Week 4, since the dosing schedule for subject is q2w  
through Week 52. Training on self -administration will be provided at Weeks 0, 2, and 4. (See Section 6.2for details). These subjects will record data regarding self -
administration in an eDiary (See Section 7.1.1 ) or if self -administering at the site, the data w ill be recorded in the study site’s documents, not in the eDiary.
c.Subjects not participating in self -administration will schedule study agent dosing -only visits every 2 week s through Week 52 (see Section 9.1.3 ).
d.The 52 -week off -therapy follow -up phase of the study begins after the completion of all assessments and admi nistration of study agent for Week 52.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
21
Approved , Date: [ADDRESS_507294] the option to participate in 
the additional pharmacogenomic (PG) evaluations in this study and to do so subjects/caregivers must sign the PG informed cons ent/assent form indicating 
willingness to participate. These optional PG samples will be collected only from subj ects who sign the PG informed consent/assent.
f.For those who do not meet study criteria or choose not to participate in this study, instructions on how to return the eDiary and glucometer will be gi ven.
g.This does not represent all study agent dosings. Stu dy agent is to be administered every 2 weeks. At Weeks 0, 2, and 4, administration will occur during study visits. 
At week 8, 12, 18, 26, 38 and 52 study visits where study agent will be administered, either subjects/caregivers or study sta ff may administe r the injection .At the 
required visits in this table, draw ing of pharmacokinetic/immunogenicity (ie, golimumab concentration and antibodies to golimumab) samples must take place 
prior to study agent administration at visits where study agent dosing occurs . Following study agent administration subjects will be observed for 30 minutes for 
symptoms of injection reactions. At Week 33 and Week 45, pharmacokinetic samples will be drawn and resupply of study agent in jection devices will occur; no 
dosing will occu r at these 2specific study visits.
h.The MMTT willbe a [ADDRESS_507295]. All other blood samples should be draw n prior to the MMTT. When 
MMTT occurs on study agent dosing days, study agent should be administered after the MMTT.
i.Type 1 diabetes autoantibodies including glutamic acid decarboxylase (GAD -65), insulin, IA -2, ZnT8 and ICA.
j.Females of childbearing potential must have a negative serum pregnancy at screening and a negative urine pregnancy te st prior to administration of study agent.
k.Specifics tests are described in Section 9.6. Note: Fasting lipid panel only done at screening, Week 12, 26, 38, 52, 78 and 104. Coagulation panel (PT/PTT/INR) 
only done at screening.
l.Viral serology panels to include: CMV, EBV, HepB, HepC, HIV.
m.Quantitative PCR testing for CMV and EBV.
n.Thesame serum samples may be used for the measurement of golimumab co ncentration, detection of antibodies to golimumab and amounts of free/total TNF . 
Draw ing of these samples must take place prior to study agent administration at visits where study agent dosing occurs. Prior ity of analysis depending on sample 
volume is: PK , ADA, NAB, total TNF, free TNF. Additional serum samples for golimumab concentration and Total/Fr ee TNFα w ill be collected at Week 33 and 
Week 45.
o.Required pharm acogenomic assessment of molecular MHC haplotype.
p.Anticipated assessments may include T -andB-cell subset analysis by [CONTACT_402533]/cytokine profiling.
q.Optional pharmacogenomics assessments anticipated to include insulin DNA methylation.
r.End of Study Visit assessments: May be used in instances where subjects withd raw early from the study, see Section 10.2.
s.All biomarker and pharmacogenomics samples must be collected prior to study agent administration .
.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
22
Approved , Date: [ADDRESS_507296]-Treatm entd
Study WeekaOL 0 OL 2 OL 4 OL12 OL 20 OL 28 OL 36 OL 44OL 52 
(EOSV)nOL [ADDRESS_507297] 
dose
Study Daya(visit window  in days) -14 to -1 115
(±1)29
(±3)85
(±3)141
(±3)197
(±3)253
(±3)309
(±3)365
(±3)421
(±7)
Study Procedure
Screening/Administrative
Informed consent/assent (ICF) Xp
Inclusion/exclusion criteria 
evaluation/reviewX X
Dispense dosing, insulin and 
hypoglycemia paper diarye X X X X X X X X X
Clinical Assessments / Ongoing Review
Full Physical examination X X X
Brief physical examination X X X X X X X X
Vital signs X X X X X X X X X X X
Height & Body weight measurement X X X X X
Interval history and paper diary 
reviewX X X X X X X X X
Previous/concomitant medication 
reviewX X X X X X X X X X X
IDAA1c X X X X X X X X X X
Adverse events X X X X X X X X X X X
Tuberculosis (TB) exposure review X X X X X X X X X X X
Randomization and Study Agent Administration
Dose determination and 
modificationX X X X
Required study agent administration 
at study sitef X X X X X X X X
Subjects participating in self -adm inistrationb
Injection training by [CONTACT_402534]®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
23
Approved , Date: [ADDRESS_507298]-Treatm entd
Study WeekaOL 0 OL 2 OL 4 OL12 OL 20 OL 28 OL 36 OL 44OL 52 
(EOSV)nOL [ADDRESS_507299] 
dose
Study Daya(visit window  in days) -14 to -1 115
(±1)29
(±3)85
(±3)141
(±3)197
(±3)253
(±3)309
(±3)365
(±3)421
(±7)
Study Procedure
Distribute study agent injection 
devicesX X X X X X
Return study agent injection devices X X X X X X
Subject Reported Data / Paper Review
Insulin use report review X X X X X X X X X X
Hypoglycemia event revie w X X X X X X X X X X
Study agent self -administration 
reviewb X X X X X X X
Clinical Laboratory Assessments
4h -Mixed -meal tolerance test 
(MMTT)g X X X
HbA1c X X X X X X X X X X X
QuantiFERON -Gold test X
Serum pregnancy testhX
Urine pregnancy testhX X X X X X X X X X
Hem atologyiX X X X X X X
ChemistryiX X X X X X X
Viral serologyjX
Polymerase chain reaction (PCR) 
Viral loadk X X X X
Clinical Pharmacology
Golimumab concentrationlX X X X X
Antibodies to golimumablX X X X X X
Free/total TNFαlX X X X X X
Biom arkers and Pharm acogenomicso
Peripheral blood mononuclear cell 
(PBMC) sample collectionm X X
Serum biomarker samplemX X
Abbreviations: EOSV=End of Study Visit, ICF=informed consent, IDAA1c=insulin dose-adjusted HbA1c, MHC=major histocompatibility complex, MMTT=mixed -
meal tolerance test , OL=open -label, PBMC=peripheral blood mononuclear cell, PCR=polymerase chain reaction, TB=tuberculosis, TNFα=tumor necrosis factor alpha
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
24
Approved , Date: [ADDRESS_507300] dose . Acceptable windows for study visits in days before ( -) or 
after (+) target study visit day are indicated and based on if study agent dosing will be given at that visit and time enrolled in the study.
b.Subjects/caregivers will be given the option for at home “self -administration” for study agent doses after OL Week [ADDRESS_507301] is q2w  
through OL Week 50. Training on self -administration will be provided at OL Week 0 (See S ection 6.2for details). These subjects will record data regarding self -
administration in the paper diary (See S ection [IP_ADDRESS] )or if self -administering at the site, the data w ill be recorded in the study site’s documents, not in the paper 
diary .
c.Subjects not participating in self -administration will schedule study agent dosing -only visits every 2 weeks through OL Week 50(see S ection 9.1.3 9.1.5 ).
d.The post -treatment visit will be conducted for all subjects at OL Week 60or 10weeksafter the last dose of study agent to collect SAEs and AEs of interest since 
the last visit unless the subject has died, has been lost to follow -up, or has withdrawn consent .
e.For those who do not meet study criteria or choose not to participate i n this study, instructions on how to return the paper diary will be given.
f.This does not represent all study agent dosings. At OL Weeks 0 ,2, and 4 , administration will occur during study visits. At OL Weeks 12, 20, 28, 36, 44, and 50
study visits where study agent w ill be administer ed, either subjects/caregivers or study staff may administer the injection .At the required visits in this table, 
draw ing of pharmacokinetic/immunogenicity (ie, golimumab concentration and antibodies to golimumab) samples must take place prior to study agent 
administration at visits where study agent dosing occurs. Follow ing study agent administration subjects w ill be observed for [ADDRESS_507302] dose of study agent is to be administered at Week 50. SeeSection 6.1and Section [IP_ADDRESS] .
g.The MMT Twill be a [ADDRESS_507303] prior to administration of study agent.
i.Specifics tests are described in Section 9.6.1 . Note: Lipi[INVESTIGATOR_805] w ill not be measured during the open -label extension period .Coagulation panel (PT/PTT/INR) only done 
at screening.
j.Viral serology panels to include: CMV, EBV, HepB, HepC, HIV.
k.Quantitative PCR testing for CMV and EBV. For the open -label extension pe riod, subjects may begin open -label study agent while EBV PCR results are pending 
and if he/she meets all other inclusion/exclusion criteria. If EBV PCR results come back positive, subject must immediately stop treatment and be w ithdrawn from 
the study .
l.The same serum samples may be used for the measurement of golimumab concentration, detection of antibodies to golimumab and a mounts of free/total TNF . 
Draw ing of these samples must take place prior to study agent administration at visits where study agent dosing occurs. Priority of analysis depending on s ample 
volume is: PK, ADA, NAB, total TNF, f ree TNF.
m.Anticipated a ssessments may include T -and B -cell subset analy sisby [CONTACT_402535]/cytokine profiling.
n.End of Study Visit assessments: May be used in instances where subjects wit hdraw  early from the study, see Section 10.2.Subjects w ho permanently discontinue 
active treatment during the open -label extension period will have their end -of-study visit follow ed by  [CONTACT_7620]-treatment visit 10weeks later.
o.All biomarker and pharmacogenomics samples must be collected prior to stu dy agent administration.
p.The retreatment screening visit should occur w ithin [ADDRESS_507304] occur w ithin 14 days prior to Week 104 .
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
25
Approved , Date: [ADDRESS_507305] aspartate aminotransferase 
AUC area under the concentration -time curve
BCG Bacille Calmette -Guérin 
BG blood glucose
BSA body surface area
C responders C-peptide responders
CD Crohn’s Disease
CDC Centers for Disease Control and Prevention
CDE certified diabetes educator
CL/F apparent total systemic clearance
CMV Cytomegalovirus
CRF case report form(s) (paper or electronic as appropriate for this study)
C+R 
respondersC-peptide and remission score responders
DBL data base lock 
DKA diabetic ketoacidosis 
DMC Data Monitoring Committee
EBV Epstein -Barr virus
eDC electronic data capture
eDiary electronic diary 
FDA Food and Drug Administration
GAD -[ADDRESS_507306] 
MS multiple sclerosis 
MTX methotrexate
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
26
Approved , Date: [ADDRESS_507307] 2019NAb neutralizing antibody
NONMEM NONlinear Mixed Effects Modeling 
NPH Neutral Protamine Hagedorn 
OL open -label
PBMC peripheral blood mononuclear cell
PCR polymerase chain reaction
PD pharmacodynamic(s)
PE physical exam ination
PFS-U UltraSafe Passive® Delivery System assembled with PFS
pJIA polyarticular juvenile idiopathic arthritis
PK pharmacokin etic(s)
PQC Product Quality Complaint
PsA psoriatic arthritis
PsO psoriasis
q2w every [ADDRESS_507308] upper limit of normal
V/F apparent volume of distribution
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
27
Approved , Date: [ADDRESS_507309] [ZIP_CODE]. INTRODUCTION
SIMPONI®(golimumab) is a fully human monoclonal antibody  which binds to human tumor 
necrosis factor alpha (TNFα) with high affinit y and specificity  and neutralizes TNFα bioactivity . 
Golimumab was first approved by [CONTACT_6581] (FDA) in 
2009 and has been shown to be safe and efficacious in adults with rheumatoid arthritis (RA), 
psoriatic arthritis (PsA), anky losing spondy litis (AS), and ulcerative colitis (UC). Additionall y, 
golimumab has been evaluated in studies conducted under an Investigational New Drug (IND) 
for the treatment of polyarticular juvenile idiopathic arthritis (pJIA; 2 up to 18 years of age), and 
pediatric UC (2 up to 18 years of age).
Similar to these above conditions, Type 1 diabetes (T1D) is an autoimmune disorde r with severe 
sequelae, but there are no approved disease modify ing therapi[INVESTIGATOR_402482] T1D. Children 
and young adults are those that most frequently  develop T1D and have the most urgent need for 
a disease modify ing therapy  to reduce associated short -and long-term morbidity  and mortality . 
This study  will evaluate whether golimumab administered subcutaneously  (SC) in this 
population with newly  diagnosed T1D has the potential to maintain residual β-cell function and 
improve metabolic control.
For the most comprehensive nonclinical and clinical information regarding golimumab , refer to 
the latest version of the Investigator's Brochure and Addenda for golimumab .
The term "sponsor" used throughout this document refers to the entities listed in the Conta ct 
Information page(s), which will be provided as a separate document.
Type 1 Diabetes
Type 1 diabetes (T1D) is an autoimmune disease that results in the progressive destruction of 
pancreatic cells leading to an absolute insulin defic iency  and life -long daily  exogenous insulin 
therap y.14,17There is no cure nor approved disease modify ing therapy  for T1D. Every  day, those 
with T1D are impacted by [CONTACT_402536] (BG) checks, diet and exercise. Those with T1D are 
at high risk of acute sequelae from hypo-and hyper-glycemic and in the longer -term severe 
renal, cardiac, and vascular disease.6,17,72Those who develop T1D early in life are at increased 
risk for significant neurocognitive disorder including behavioral issues, lower intellectual 
performance and motor dy sfunction, and associated structural changes in the brain.4,7,44,49Recent 
data indicate that even adhering to the most current recommendations and using the most 
advanced approaches for glycemic control, mortality  for those with T1D is 2-fold greater than 
age-matched controls.45Even though outwardl y those with T1D may appear healthy , they are at 
high risk for a number of severe short -and long-term life-impacting and threatening sequelae 
including sudden death.15,64Most sequelae accumulate over time and do not appear to be 
“preventable” even with the most exacting attempts of exogenous glycemic control, and thus 
those who would most benefit from a disease modify ing therapy  are those who develop disease 
earlier in life.27,41,43,75
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
28
Approved , Date: [ADDRESS_507310] in children and 
young adults with ~20 to 25 cases/100,000/y ear in those younger than 20years old and there is 
approximately  30,000 total new cases of T1D annually  in North America.34,71Due to its 
short -and long-term complications, T1D is both a daily  and life-long burden for individuals and 
their families and also represents significant socioeconomic and societal -medical ramifications, 
which are only going to rise as the worldwide incidence of T1D increases approximately  3%to 
5%annuall y.34,71
Type 1 diabetes (T1D) is the result of immune destruction of the insulin producing β-cells 
located in the islets of Langerh ans in the pancreas and eventual absolute insulin deficiency . It is 
believed that those with a certain genetic susceptibility  encounter an environmental trigger that 
breaks self-tolerance to β-cells, and an autoimmune response to β-cells is initiated.21Over time, 
which may be years in some cases, a critical mass of β-cells is destro yed and normal glycemic 
control cannot be supported. Individuals present with clinical signs and symptoms, including 
polydipsia, polyphagia, polyuria, and often with severe metabolic disturbances, including life-
threatening diabetic ketoacidosis (DK A). Despi[INVESTIGATOR_402484] β -cells at the time of 
clinical diagnosis of T1D, the vast majority  of these, if not all, will be eventually  destro yed.6,[ADDRESS_507311] promise. Small scale trials in the late 1980s and early  1990s using non-specific 
immune suppressants (ie, cyclophosphamide and azathioprine) were able to subdue the 
autoimmune progression of T1D and in some cases reverse insulin needs.9,10,16However, these 
were not considered viable therapi[INVESTIGATOR_402485] -and non -immune tox icities.
Since the advent of more targeted, safer, and better tolerated immune modulators (ie, biologics), 
a number of Phase 2a new-onset T1D clinical studies have been conducted. Some of these have 
been unsuccessful (interleukin [IL] 1βantagonism, thymoglobulin, anti-IL2 
receptor/my cophenolate mofetil ) while some have shown some ability  to slow disease 
progression (abatacept, rituximab, anti-cluster of differentiation -3variants , and 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
29
Approved , Date: [ADDRESS_507312] 2019alefacept).25,26,31,52,55,57,60,61However due to a variety  of reasons, none have been successfully 
developed into an approved disease modify ing therap y for T1D.
Role of TNF αin the Pathogenesis of T1D
Decades of fundamental research on the autoimmune pathogenesis of T1D have demonstrated 
that it results from a complex interplay  of innate and adaptive immune injury  to β-cells involving 
T cells, B cells, antigen -presenting cells, and pro-inflammatory  cytokines .8,30,73In addition, 
recent data indicate that the increases in β-cell damage from meta bolic and pro-inflammatory  
stressors may play an important role in the initiation and propagation of the autoimmune 
response.5,6,73
TNFα is a pro-inflammatory cytokine that has important roles in the immunopathogenesis of a 
number of human autoimmune diseases and current evidence indicates it play s an i ntegral role in 
T1D. As detailed below, it has both 1)activating effects on the T1D autoimmune response and 
2)important direct pro -diabet ogenic metabolic effects.
TNF appears to promote diabetes autoimmunity  by [CONTACT_402537], activating cells and enhancing autoantigen presentation.40,58,73TNFα activates 
vascular endothelium, upregulating major histocompatibility  complex (MHC) I and adhesion 
molecules.4In murine models of T1D, some of the first cells to infiltrate islets are dendritic 
cells.58,73Dendritic cells and other antigen -presenting cells, which are critical for β-cell antigen 
presentation to T cells, are activated by [CONTACT_51004]α by [CONTACT_402538] I and II and 
costimulatory  molecules.38,58TNF also directly  increases MHC I, and synergizes with 
interferon gamma to upregulate MHC II, on β-cells, both of which appear to increase their 
susceptibility  to T-cell killing.5Rodent models of autoimmune diabetes show that antagonizing 
TNF can delay , prevent or reverse disease whereas TNFα production in the pancreas can 
accelerate disease.13,39,[ADDRESS_507313] convincing data of the role of TNFα in T1D pathogenesis in children and young 
adults comes from a randomized, controlled, pi[INVESTIGATOR_402486] 
T1D conducted at the University  of Buffalo.48Eligibility  included subjects aged 3 to 18 years of 
age with recently  diagnosed T1D. Subjects received etaner cept 0.4 mg/kg (maximum 25mg) or 
placebo dosed SC twice weekl y for 24 weeks. The study  enrolled 18 subjects (range 7 to 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
30
Approved , Date: [ADDRESS_507314] 201918years of age, mean ~12.5 years), 10 into the etanercept arm and 8 into the placebo arm. Over 
the treatment period, etanercept -treate d subjects showed a 39% increase in C-peptide production 
(as a measure of endogenous β -cell function) from baseline assessed by  C-peptide area under the 
concentration -time curve (AUC) from a 2-hour mixed -meal tolerance test (MMTT). In contrast, 
the placebo group had a 20% decrease in C -peptide production. In addition, subjects in the active 
arm had improved glycemic control (lower Hemoglobin A1c’s[HbA1c’s]) versus those in the 
placebo group, and a decrease of 18% in daily insulin requirements (units/kg/day ) from baseline 
where the placebo subjects had a 23% increase in requirements. There were no unexpected 
severe AEs in either group. Even though there has not been further evaluation of these very 
impressive findings, they are some of the most promising to date on identify ing an approach to 
modify  T1D disease course. Specificall y, these findings support further evaluation of this 
approach in the target population and provide critical “prospect of benefit” for TNFα -blockade in 
children and young adults with newly  diagnosed T1D.
Differences in Natural History and Pathogenesis of Pediatric versus Adult T1D
Type 1 diabetes usuall y develops in childhood and adolescence, however it can present late in 
adulthood in the 5thand 6thdecades of life, although much less frequently .51,71In addition to 
being more prone to some short -and long-term complications, there are differences in the 
clinical course and response to immune therapi[INVESTIGATOR_402487]/ young adults and older 
adults. This supports the well-accepted observa tions that children suffer from severe diabetes 
symptoms, including polydipsia, polyuria, and weight loss, days or weeks before initial 
diagnosis. Often diagnosis is accompanied by [CONTACT_402539][INVESTIGATOR_402488].6,14,21,23,33,56,62,75Children and young 
adults with ne w-onset T1D usually  have an immediate need for exogenous insulin.
This sharply  contrasts with the experience of adults (mid -20s and above) who often have months 
or years of non-specific symptoms or present asymptomatically  from routine glycemic screening 
and can often be managed for prolonged periods of time (months or years) with diet or oral 
hypoglycemic agents before a demonstrable insulin need. More definitive studies have shown a 
different rate of decline of -cells according toage.14,21Data from the Diabetes Trial Net group 
has demonstrated that “age is the most important factor impacting the rate of decline of 
C-peptide post diagnosis” and with significantly  more rapid rate of decline in those 21years old 
and y ounger versus those [ADDRESS_507315] 
on children and young adults; whereas thymoglobulin appeared to preferentially  spare -cells in 
those older than 21, but not in those y ounger.25,31,55,57,61,[ADDRESS_507316] an age “cut-off” of approximately  
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
31
Approved , Date: [ADDRESS_507317] 201921years old as one that distinguishes many  of the properties of T1D in younger and older adults 
and supports the older age threshold of this study . Clearly , there not only  appears to be important 
clinical pathophy siologic differences in T1D in younger and older individuals, but efficacy  data 
of immune interventions from one age group may  not be extrapolated to the other. Doing so may 
result in making misinformed and inaccurate decisions for further development. It is the 
sponsor’s view that the prospect of benefit for TNFα -blockade in children with newly  diagnosed 
T1D has been demonstrated, and conversel y because of the aforementioned differences in T1D 
disease in younger and older individuals, the study  of older adults (ie, >21 years of age) would 
not be supported. As such, the direct study  of children and young adults with T1D is required to 
develop a disease modify ingtherapy  for those are most afflicted with this disease and will 
benefit the most from such therapi[INVESTIGATOR_014].6,14,[ADDRESS_507318] extensive clinical 
experience and success of biologi c immune modulators used in in a variety of adult and pediatric 
autoimmune diseases . This family ,that also includes infliximab, etanercept, certolizumab pegol,
and adalimumab, cumulatively  has yearsof demonstrated safety  and efficacy  for conditions that 
include adult RA, psoriasis (PsO), PsA, UC, Crohn’s disease (CD) ,AS, and pediatric (pJIA), 
CD, and UC. Specifically , golimumab is currently  approved in adults [ADDRESS_507319] profile of these TNFα blockers is well known. Treatment with 
TNFα -blockers, is associated with increased rates of serious infections including tuberculosis, 
bacterial sepsis, invasive fungal, and other opportunistic infections sometimes leading to 
hospi[INVESTIGATOR_30059], lymphoma and other malignancies, and new or exacerbation of 
congestive heart failure, although with very  low frequencies.22,32,59,68
Based upon their overall positive benefit:risk profile, TNFα -blockers have been studied and 
approved in the [LOCATION_002] and elsewhere for a number of other pediatric autoimmune 
conditions that arguabl y have similar morbidity  and mortality  and impact on life as T1D. 
Specificall y, etanercept has been FDA -approved in children 2 years old and above withpJIA 
since 1999. Infliximab was approved in children 6 years old and above with CD and UC in 2009 
and 2011, respectivel y. Adalimumab was FDA -approved for pJI A in those 2 years old and above 
in 2008 and CD in those 6 years old and above in 2014. As detai led in the next section, 
golimumab has recentl y been studied in over 200 children in pediatric indications. Polyarticular 
juvenile idiopathic arthritis includes experience in children age 2yearsand above and is 
currentl y under review for registration inEurope (Eu), and pediatric UC includes experience in 
children 6 to 17 y ears of age .
Use of golimumab and other TNFα -blockers for both adults and children includes routine 
evaluation of safet y. Subjects in this study  will be extensively  evaluated as occurs with the 
routine use of TNFα -blockers including golimumab in adults and children, (and detailed above), 
subjects in this study  will be thoroughly  assessed for and excluded from participation if they 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
32
Approved , Date: [ADDRESS_507320] risk factors for serious infections (including but not limited to tuberculosis [TB]), 
immunosuppression, malignancy  and cardiac disorders, to limit the chance of untoward and 
adverse effects in this study .
Clinical Studies of Golimumab in Children
A significant portion of the target population in this study is individuals who are less than 
18years of age. Although it is not currently  approved for use in pediatric subjects, golimumab 
has alread y been evaluated in studies enrolling over [ADDRESS_507321] been conducted in the US, EU and other regions globall y. 
Specificall y, SC golimumab was evaluated in children with pJIA (CNTO148JIA3001), and a 
clinical development program with SC golimumab in pediatric UC is currentl y ongoing 
(CNTO148UCO1001). Thus far, golimumab has been well tolerated in both studies in pediatric 
subjects of 2 to <[ADDRESS_507322] been observed.
1.2. Rationale for the Study
This study  will evaluate whether subcutaneousl y administered golimumab canmaintain residual 
β-cell function and improve metabolic control in children and young adults with newl y 
diagnosed T1D.
2. OBJECTIVES , ENDPOINTS , AND HYPOTHESIS
2.1. Objectives and Endpoints
Double -Blind Period
Objectives Endpoints
Primary Objective and Endpoints
 To determine if golimumab can preserve β-cell 
function in children and young adults with 
newly diagnosed T1D. The Mixed -meal Tolerance Test (MMTT) -
stimulated 4-hour C-peptide area under the 
concentration -time curve (AUC) at Week 52.
Secondary Objective s and Endpoints: Efficacy 
 To evaluate the impact of golimumab on 
measures of diabetes control in this subject 
population.
To evaluate the off-therapy durability of 
golimumab on measures of diabetes control in 
this subject population.  Change from baseline in insulin use in units 
per kilogram body weight per day over time.
Change from baseline in HbA1c over time.
Hypoglycemic event rates (defined as BG of 
≤70, 55, and 35mg/dL or clinical sequelae in 
the absence of a BG reading) through 
Week 52, after Week 52 through Week 104, 
and the entire study.
MMTT -stimulated 4-hour C-peptide AUC 
over time.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
33
Approved , Date: [ADDRESS_507323] 2019Objectives Endpoints
Secondary Objective and Endpoints: Safety
 To determine the safety  and tolerability of 
golimumab in children and young adults with 
T1D. Proportion of partic ipants with treatment -
emergent AEs and severe AEsthrough Weeks 52 
and 104.
Proportion of participants with severe 
infections through Weeks 52 and 104.
Proportion of participants with study agent 
injection site reactions through Week 52.
Secondary Objective and Endpoints: Pharmacokinetics (PK ) and Immunogenicity 
 To evaluate the PK and immunogenicity of 
golimumab inthis specific subject population 
with T1D. Summary of serum golimumab 
concentrations and the PK profile after 
induction and maintenanc e dosing.
Incidence and titers of antibodies to 
golimumab.
Exploratory Objective and Endpoints: Immunologic and Metabolic
 To evaluate how golimumab impacts 
immunologic profiles and indicators of β-cell 
stress, and the correlation with efficacy and 
safety endpoints in this study. Correlation of cellular and serologic immune 
profiles with clinical metabolic outcomes on-
therapy (Weeks 12, 26, 38, and 52) and 
off-therapy (Weeks 78 and 104)
Relationship of exploratory markers of β-cell 
stress and survival with clinical metabolic 
outcomes on-therapy (Weeks 12, 26, 38, and 
52) and off -therapy (Weeks 78 and 104).
Open -Label Extension Period
Objective Endpoint
 To evaluate additional one year of safety and 
exploratory efficacy endpoints in those 
participants that have shown a particular 
response in the double -blind period . Continue to evaluate safety and exploratory 
efficacy endpoints as per the Time and 
Events Schedule (open -label extension 
perio d) and no new efficacy hypotheses will 
be tested compared to the double -blind 
period.
2.2. Hypothesis
The primary  hypothesis to be tested in this study is that golimumab is superior to placebo in 
maintaining β-cell function in children and young adults with newly  diagnosed T1D as measured 
by [CONTACT_402540] -stimulat ed 4-hour C -peptide AUC at Week 52.
3. STUDY DESIGN A ND RA TIONA LE
3.1. Overview  of Study  Design
This is a Phase 2arandomized, double -blind, placebo -controlled, parallel -group, multicenter , 
study  of golimumab in subj ects with new -onset T1D.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
34
Approved , Date: [ADDRESS_507324] be randomized within 
28days. Following randomization there will be a double -blind 52-week treatment period with 
study  agent followed by  a 52 -week off -therap y follow -up period.
Responders as defined below will be provided the option to participate in the 52 -week open -label 
(OL) extension period.
The period to enroll all [ADDRESS_507325] approximately 12to 18months.
Schematic overviews of the double -blind study design and open -label extension period are 
provided in Figure 1and Figure 2, respectively .
Figure 1: Schematic Overview of the Double -Blind Period

SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
35
Approved , Date: [ADDRESS_507326] 2019Figure 2: Overview of the Open -Label Extension Period
This study  will enroll male and female subjects [ADDRESS_507327] been recently 
diagnosed with T1D. As described abov e (in Section 1)recent data indicate that the 
immunopathogenesis, disease progression and even response to immune therapi[INVESTIGATOR_402489] T1D versus older adults. There is recent r ecognition by [CONTACT_402541], 
diabetes experts and health authorities that it is important to conduct studies in children with 
T1D directly  to best determine efficacy  in T1D, as long as there is a known and acceptable safety 
profile.28,29,75Additionally, the critical “prospect of benefit” of therapeutic TNF -blockade in 
these younger individuals with new-onset T1D exists based on the aforementioned pi[INVESTIGATOR_402490].48The choice of the upper age cut-off of 
[ADDRESS_507328] of 
this is in those at and above 6 y ears old. This study  will not enroll adults over 21 y ears old due to 
the difference noted above, including that there is not currently  a “prospect of benefit” of 
anti-TNF therapy  in this older population. Most importantly  as the goal for the sponsor is to 
develop a therapy  for those who will most benefit from it, if older adults were to have a poorer 
response to therap y than younger individuals due to some of the reasons discussed above, this 
may result in diluting or missing important findings necessary  to support further development in 
children, adolescents and young adults with T1D who are clearly  those who have the most to 
gain from a disease modify ing ther apy.

SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
36
Approved , Date: [ADDRESS_507329] also show evidence of residual 
endogenous β-cell function , defined by  a C-peptide level of ≥0.2 pmol/m Lfrom a 4 -hour MMTT 
at study  screening, and be able to be randomized within 28 days of screening and 100days of 
diagnosis.19,25,42,61
A target of approximately  81 subjects will be randoml y assigned in a 2:1 ratio to receive 
golimumab or placebo, administered SC for 52 weeks and monitored for an additional 52 weeks. 
Subjects will berandomize dto receive active therap y (golimumab) or placebo andbe stratified 
based on a C-peptide AUC of <0.66 pmol/mL or ≥0.66 pmol/mL  from a 4-hour MMTT 
conducted at stud y screening .
All randomized subjects will receive a total of 27 doses of study agent, either active treatment or 
matched placebo ,administered SC every 2 weeks (q2w).Study  subjects weighing <45kg who 
are randomized to active treatment will receive an induction dose of golimumab 60mg/m2SC at 
Weeks 0 and 2 follo wed by a maintenance dose of 30mg/m2SC at Week 4 and q2w through 
Week 52. Study  subjects weigh ing≥45kg who are randomized to the golimumab treatment 
group will receive an induction dose of golimumab 100mgSCat Weeks 0 and 2 followed by a 
maintenance dose ofgolimumab 50mgSCat Week 4 and q2w through Week 52.Subjects 
randomized to the placebo treatment group will receive aSC placebo injection q2w through 
Week 52to match the active arm (Figure 1).The protocol will give the option for study  agent 
administration by [CONTACT_402542], ie,self-administration ,after 
proper training (see Section 6).
Following randomization and the 52-week treatm ent period, there will be a 52-week off-therap y 
follow -up period focused on determining the off-therap y durabil ity of the effec t of golimumab. 
Thus ,the participation for each subject is 104 weeks.
There will be a number of study  visits that will include extensive metabolic assessments 
including a 4-hour MMTT. These assessments will occur at screening, during the double -blind 
treatment period (Weeks 12, 26, 38,and 52), andthe off-therap y monitoring period (Weeks 78 
and 104). The primary  endpoint analy sis will be derived from data obtained at the double -blind 
Week 52 visit (double -blind period) .During the open -label extension period, a 4-hour MMTT 
will be performed during OL  screening (unless performed <3 months ago) , OL Week 28, and OL 
Week 52. For C-responders who are lacking the necessary  information to calculate IDAA1c 
score, an HbA1 cwill be performed and 10 days of insul in dose information will be required. 
Data from these and other visits will contribute to other key efficacy  and safety endpoints and 
provide pharmac okinetic and exploratory  assessments.
Three data base locks (DBL s)are planned for the study . The first DBL will occur after all 
subjects complete their Week 52 assessments (double -blind period) ,the second DBL will occur 
after the last subject complete sthe off-therapy follow -up period (Week 104), and the third DBL
will occur after the last subject complete sthe open -label extension period .
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
37
Approved , Date: [ADDRESS_507330] 60% of subjects complete their Week [ADDRESS_507331] to facilitate planning of 
future studies.
During the study , all subjects will receive intensive management of their diabetes with 
exogenous insulin according to the current recommendations of the American Diabe tes 
Association (ADA). Subjects and,when applicable ,their caregivers must agree to follow the 
current ADA recommendations of tight glycemic control with specific HbA1c targets . These 
current recommendations are intended to achieve glucose levels that appear to decrease some of 
the short -and long-term sequela eof T1D. This study will include adhering to the ADA’s 
recommended glycemic control guidelines with an HbA1c target of <7.5% in children 17years 
old and y ounger and <7% in those [ADDRESS_507332] profile at Week 52 which includes:
1.C-peptide and Remission score* responders (C+R responders): either having an increase in 
C-peptide AUC versus baseline or having a stable C-peptide AUC, ie, not decreasing more 
than 5% versus baseline and having a remission score ≤9.
OR
2.C-peptide responders (C responders): either having an increase in C-peptide AUC versu s 
baseline or having a stable C -peptide AUC, not decreasing more than 5% versus baseline but 
not meeting a remission score of ≤9. Their remission score ,however ,must be <12.
OR
3.Remission score responders (R responders): having a remission score ≤9 but notmeeting 
C-peptide response as defined above .However, their C-peptide AUC decline from baseline 
should be less than or equal to 30% compared to bas eline.
*Insulin Dose Adjusted HbA1c (IDAA1 c) = A1C (percent) + [4 × insulin dose (units per 
kilogram per 24 h)].24,50,53,54
An independent Data Monitoring Committee will be commissioned to continually  assess the 
safet y of study  subjects . Refer to Section 11.11 , Data Monitoring Committee, for details.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
38
Approved , Date: [ADDRESS_507333] [ZIP_CODE].2. Study Design Rationale
3.2.1. Blinding , Control, Study Periods, Treatment Groups
Blinding and a placebo control will be used in this study  since there is no established comparator 
therap y to prevent β-cell loss in T1D and to reduce potential bias during data collection and 
evaluation of clinical, safety , and exploratory  endpoints.
There will be a 28-day screening period to allow for all assessments required for randomization 
to be conducted . The primary  endpoint will occur at Week 52(double -blind period ). Due to the 
natural history  of β-cell loss following diagnosis, documenting a statistically  significa nt and 
meaningful effect of a β-cell sparing agent in a study  of a reasonable siz e is best accomplished at 
Week52 and allows for important comparisons with other recent immune intervention studies in 
T1D which have useda 52-week primary  endpoint .25,26,31,52,55,57,61Golimumab and other 
TNFα -blockers are usually  prescribed as continual “chronic” therapi[INVESTIGATOR_402491] ;therefore ,the 52-week treatment duration is consistent with these experiences and 
will allow the best opportunity  for evaluating efficacy  of golimumab and ensure robust and 
meaningful safet y evaluations.22,32,59,68Following the primary  endpoint analy sis at Week 52
(double -blind period) , an off-therapy  follow -up period for [ADDRESS_507334] attributes (eg, demographic and 
baseline characteristics and disease severit y) are evenly  balanced across treatment groups, and to 
enhance the validity  of statistical comparisons across treatment groups.
Per inclusion criteria, all randomized subjects will have a C-peptide level of ≥0.2 pmol/mL  from 
a 4-hour MMTT at screening. Stratification will be employ ed based on subjects baseline 
MMTT -stimulated C-peptide AUC level as previou s interventional studies in new-onset T1D 
suggest the response to immune therapi[INVESTIGATOR_402492]-onset T1D studies may be influenced, at least 
in part, by  [CONTACT_1130]’s baseline endogenous β -cell function .31,55Toachiev e balanced populations in 
the 2treatment groups, eligible subjects will be randomized based on 2:1 ratio to receive active 
study  agent or placebo within each stratum (<0.66 pmol/m Lor ≥0.66 pmol/mL ). This
stratification threshold of 0.66 pmol/mL  was chosen based on simulations and calculations 
derived from existing data thatthis level isexpected to be close to the median of the baseline 
MMTT -stimulated 4 -hourC-peptide AUC of the study  population .27,60
Following database lock for the double -blind treatment period (Week 52), subjects who are still 
in the off-therapy  follow -up period (Wee k 52 to104visits ),who were on active drug during the 
double -blind period and who meet the response criteria will beoffered the option to participate 
in the open -label extension period if eligibility  criteria are met. Prior to initiating open -label 
screening assessments , subjects and parents/legal guardians will sign updated informed consent 
form ( ICF)/assent forms.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
39
Approved , Date: [ADDRESS_507335] efficacious. In 
the case of the class of TNF -blockers, there are a variet y of dosing regimens thatare 
disease -specific such as a higher dose regimen of SC golimumab for the treatment of UCas 
compared to that for rheumatic diseases .
The choice of dose and regimen for this study is based upon 3 factors: 1) disease -specific 
considerations of T1D,2) modeling based upon the reported efficacy  of TNFα inhibition of 
etanercept in a p ilot study  in children with T1D, and 3) the sponsor’s safety  and pharmacokinetic
(PK)the experience with golimumab in adults , adolescents and children .48Although, the dose 
regimen of SC golimumab chosen for the present T1D study  has not been studied before, the 
sponsor’s use of golimumab in adult and pediatric subjects with other indications indicate that 
the overall exposures in this study  population are overlappi[INVESTIGATOR_402493] y profile of golimumab is applicable to this study .
1.T1D Disease -Specific Considerations
In T1D, the destruction of β-cells israpid at the time of diagnosis and is considered 
irreversible .6,69,73For aggressive immune -mediated diseases, higher and/or more frequent 
induction doses of anti-inflammatory  therapi[INVESTIGATOR_402494] , and then keep it under control. For 
most autoimmune indications , including pediatric and adult UC and CD, psoriasis, and in some 
cases RA, TNFα –blockers are administered using an induction regimen followed by  [CONTACT_402543].14,22,32,59,68To preserve residual β-cells in newly diagnosed T1D, rapid 
neutralization of the inflammatory ,anti-β-cell response is likely to be key foran effective 
therap y. Golimumab steady -state concentrations are only achieved after at least [ADDRESS_507336] residual β-cells. The induction doses 
will be followed by a lower maintenance dosing in order to maintain steady -state concentrations 
and continue to prevent further β -cell loss.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
40
Approved , Date: [ADDRESS_507337] [ZIP_CODE].Model -Based Prediction of TNFα Suppression in T1D Subjects
To date golimumab has been studied in 2 pediatric populations; pJIA and pediatric UC. In the 
study  of golimumab in children 2 to18 years old with pJIA who were being treated with 
concomitant methotrexate (MTX )the dose was 30 mg/m2SC every  4 weeks (q4w). In the study 
of golimumab in children 6 to18years old with pediatric UC that dose was 90mg/m2SC at
Week 0 and 45 mg/m2SC atWeek 2, and 45 mg/m2SC q4w for children <45 kgand 200mg SC 
at Week 0 and 100mg SC at Week 2, and 100 mg SC q4w in children ≥45kg. The approved 
dose of golimumab in adults (those 18years old and above) with RA, PsA, and AS is 50mg SC 
q4w and for UC is 200mg SC at Week 0, followed by 100 mg SC at Week 2 and then 100mg 
SC q4w.
A mechanistic PK/target engagement (TE)model incorporated PK exposure from a previously 
established population PK model -based on the pJIA population was paired with a target -
mediated drug disposition model to assess the interaction between drug and target and to 
simulate the suppression of TNFα after TNFα –blocker administration. The PK/TE model was 
developed based on the assumption that the etanercept dosing regimen tested in T1D results in 
sufficient TNFα neutralization given the positive results observed in the pi[INVESTIGATOR_402495]-onset T1D.48The golimumab dosing regimen was designed to approximate the extent 
of TNFα suppression obtained using theetanercept dosing regimen in this study  andaccounting 
for the differences in PK and TNFα binding affinity  between golimumab and etanercept. 
Concomitant use of MTX, which is standard of care in pJIA, reduce sgolimumab clearance in 
subjects with this disease , likely  due to suppression of anti-drug antibodies .77Subjects with T1D 
do not receive MTX, therefor e, a56% faster clearance of golimumab in subjects with T1D than 
pJIA subjects was assumed for predicting the PK profile in the T 1D population.
The PK/TE model suggested that an induction dosing regimen of 60 mg/m2 SC (to a maximum 
of 100mg) at Week 0 and Week 2 followed by a maintenance dosing regimen of 30mg/m2SC 
(to a maximum of 50mg) q2w or 60 mg/m2SC (to a maximum of 100mg) q4w results in 
suppression of TNFα to a level approximating that of etanercept. This target would not be 
achieved with a 30mg/m2SC q4w dose. The 30 mg/m2q2w and 60mg/m2q4w maintenance 
dosing regimens would have the same overall exposure (AUC) and similar TNFα suppression; 
however, the 60mg/m2q4w regimen would have higher peak/trough concentration fluctuations 
and thus more fluctuation on suppression of TNFα. It is known that TNFα has direct cytostatic 
and cytocidal effects on β-cells.2,58Thus the TNFα elevations that would be expect ed to occur 
during the troughs with the higher, but less frequent dosing, may result in more damage to 
residual β-cells. As the overall exposure to golimumab with these dosing regimens may be 
considered equivalent, the 30mg/m2SC (to a maximum of 50 mg) q2w dosing regimens was 
preferred due to less peak/trough fluctuation.
3.Comparison of Golimumab Dose Regimens Between the T1D Population with Other 
Disease Populations of Adults and Children
Population PK simulations were performed comparing the proposed T1D dosing regimen with 
dosing regimens that have previously  been studied in the pediatric populations (pJIA and 
pediatric UC, Figure 3Panels A and B, respectively ). The simulations to develop this dosing
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
41
Approved , Date: [ADDRESS_507338] 2019strategy  useddemographics for subjects age6 through 21years based upon the U.S. Centers for 
Disease Control and Preven tion growth charts .18For a child, golimumab 30mg/m2
(50mg/1.67 m2) would be approximately  equivalent to a 50mg dose for an adult subject 
weighi ng 60kg (with a body  surface area [BSA] of 1.67 m2). Thus the 30mg/m2dose is 
expected to be similar to the 50 mg dose in adults and the 60 mg/m2dose to be similar to the 
100mg dose in adults. In adults, golimumab 50mg q4w was the minimum effective dosing 
regimen for the treatment of RA, PsA,or AS. Due to the absence of concomitant MTX in T1D 
subjects, it is expected that a 30 mg/m2q4w dosing regimen that is the pediatric equivalent to the 
adult 50mg q4w dose may not result in sufficient systemic exposure for suppressing TNFα in 
T1D subjects, therefore a higher dose or more frequent dosing interval should be studied. For the 
simulation , a 40 kg weight cut-offwas included (Figure 3Panel A: <40kg: 30mg/m2q4w; 
≥40kg: 50 mg q4w).For the pediatric UC simulations, a 45kg weight cut-offwas implemented
as previously studied, such that subjects <45kg would receiv e 60mg/m2at Weeks 0 and 
2followed by 30mg/m2q2w and subjects ≥45 kg would receive 100 mg at Week 0 and 
2followed by 50 mg q2w. Based on the PK simulations, the proposed T1D dosing regimens 
(<45 kg and ≥45 kg) are expected to result in drug exposure (AUC) between that observed for 
the pJIA with MTX and pediatric UC populations without MTX (Figure 3,Panel A and B), 
although the 30mg/m2q2w maintenance dosing interval will produce slightly  higher trough 
concentrations.
Figure 3: Overlap of simulated golimum ab exposure for dosing regim ens in current T1D study compared 
to those in pJIA and pediatric UC studies .
The safet y and efficacy  of golimumab has been extensively  characterized in adult subjects with
RA, PsA, AS, and UC. In a Phase 2 study  in subjects with RA, 4 different dos ing regimens were 

SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
42
Approved , Date: [ADDRESS_507339] 2019evaluated (50mg q2w or q4w and 100mg q2w or q4w) of which all doses tested were generall y 
well tolerated and effective in maintaining clinical response without dose-related safet y events
through Week 52.35In pJIA, a 30mg/m2q4w dosing regimen was studied up to a maximum of 
50mg (the approved adult RA dose). In pediatric UC, a 45 kg weight cut-off was implemented 
such that subjects below 45 kg received BSA -adjusted doses and subjects at or above 45kg 
received doses according to adult UC dosing regimens (details discussed above) .To date, the 
dosing regimens studied in pediatric patients were well tolerated . Overall no new adverse drug 
reactions were identified . Further, the frequency , type,and severities of the events observed were
similar to those observed in the adult rheumatology  and inflammatory  bowel disease studies .
Since the dosing regimen for golimumab proposed for this study  in T1D subjects is expected to 
result in drug exposures that overlap with those observed in previous pediatric studies with 
golimumab, it is appropriate to also expect that a similar safet y profile will be demonstrated in 
the T1D population planned for enrollment in this trial as that seen in pediatric studies in pJIA 
and UC.
Considering the above -mentioned disease -specific issues of T1D, pharmacologic comparisons of 
golimumab and etanercept and specific experience with golimumab, an induction dosing regimen
of 60 mg/m2SC (to a maximum of 100 mg) at Weeks 0 and 2 ,followed by  a maintenance dosing 
regimen with 30mg/m2SC (to a maximum of 50mg) q2w was selected as the recommended 
dosing regimen in this study . In addition, a weight cut-off (45kg), which has been implemented 
in the clinical pediatri c UC study  of golimumab, will also be studied such that subjects at or over 
the 45kg weight cut-off will receive golimumab using the alread y approved adult PFS-U
presentations .
4. SUBJECT POPULA TION
The inclusion and exclusion criteria for enrolling subjects in this study  are described in the 
following subsections. These criteria are consistent with those for recent interventional studies in 
newly  diagnosed T1D, the targeted subject age range in this study , and recent studies of 
golimumab for other indication s. If there is a question about the inclusion or exclusion criteria 
below, the investigator must consult with the appropriate sponsor representative and resolve any 
issues before enrolling a subject in the study . Waivers are not allowed. Deviations from the 
inclusion and exclusion criteria are not allowed because they can potentially  jeopardize the 
scientific integrit y of the study , and subject safety . Therefore, adherence to the criteria as
specified in the protocol is essential.
Individu als who meet entry  criteria but are not able to be randomized w ithin the allotted time (ie, 
28days from screening) may still participate in the study  so long as they repeat study  screening 
and again meet eligibility criteria. Subje cts may  only  be rescreen ed once.
If a subject is a screen failure but at some point, in the future is expected to meet the subject 
eligibility  criteria, the subject may be rescreened on [ADDRESS_507340] number, undergo the informed 
consent/assent process , and then restart a new screening phase.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
43
Approved , Date: [ADDRESS_507341]'s status changes (including laboratory  results or receipt of additional medical records) 
after screening but before the first dose of study  agent is given such that they no longer meet all 
eligibility  criteria, they  should be excluded from participation in the study .
4.1. Inclusion Criteria
4.1.1. Inclusion Criteria Applicable to A ll Subjects
Each potential subject must satisfy  all of the following criteria to be enrolled in the study :
1. Maleorfemale [ADDRESS_507342] 1 of the following diabetes -related autoantibod ies obtained at 
study  screening :
Glutamic acid decarbox ylase (GAD -65)
IA-2
ZnT8
ICA; or
Insulin (if obtained within 10 day s of the onset of exogenous insulin therapy )
3. Have a peak stimulated C-peptide level ≥0.2 pmol/mL  following a 4-hour MMTT
obtained at study  screening.
4. Be medicall y stable on the basis of physical examination, medical history , and vital 
signs performed at screening. If there are abnormalities, they  must be consistent with the 
underly ing illness in the study  population.
5. Females of childbearing potential must have a negative serum (-human chorionic 
gonadotropin [-hCG]) test at screeni ngand a negative urine pregnancy  test at the 
Week 0 visit.
6. Criteri onmodified per Amendment 3 –open -label extension period
6.1.Females must be either:
Not of childbearing potential: premenarchal; permanentl y sterilized (eg, tubal 
occlusion, hysterec tomy, bilateral salpi[INVESTIGATOR_8820] y); or otherwise be incapable of 
pregnancy ,
OR
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
44
Approved , Date: [ADDRESS_507343] 2019 Of childbearing potential, and if sexually  active, practicing through Week 104and 
open -label extension period ofthe study  be practicing a highl y effective method of 
birth control consistent with local regulations regarding the use of birth control 
methods for subjects participating in clinical studies: eg, established use of oral, 
injected or implanted hormonal methods of contraception; placement of an 
intrauterin e device (IUD) or intrauterine system (IUS); barrier methods: condom 
with spermicidal foam/gel/film/cream/suppository or occlusive cap (diaphragm or 
cervical/vault caps) with spermicidal foam/gel/film/cream/suppository ; male 
partner sterilization (the vasectomized partner should be the sole partner for that 
subject); true abstinence (when this is in line with the preferred and usual lifesty le 
of the subject .
Females of childbearing potential must agree not to donate eggs (ova, oocy tes) for 
the purposes of assisted reproduction through Week 104and open -label extension 
period .
Note: If the childbearing potential changes after start of the study  (eg, female who is not 
heterosexually  active becomes active, premenarchal female experiences menarche) she 
must begin a highl y effective method contraception of birth control, as described 
throughout the inclusion criteria.
Agrees to remain on a highl y effective method of birth control throughout the 
study . 
7. During the treatment period of the study  (from randomization through W eek 52) and for
a minimum of 1spermatogenesis cycle (defined as 90days after receiving the last dose 
of study  agent ), all males must:
Agree to be sexually  abstinent or (2) if sexually  active with a non-pregnant female 
of childbeari ng potential must agree to use a barrier method of contraception (eg, 
condom with spermicidal foam/gel/film/cream/suppository ) and ifsexually  active 
with a female who is pregnant must use a condom .
Agree not to donate sperm.
8. Subjects (or their legally acceptable representatives) are willing and able to adhere to 
requirements, prohibitions, and restrictions specified in this protocol.
9. Subjects (or their legally  acceptable representative) must sign an ICF indicating that he or 
she understands the purpose of, and procedures required for, the study  and is willing to 
participate in the study .Assent is also required of children capable of understanding the 
nature of the study  (typi[INVESTIGATOR_897]  7years of age and older) as described in Section 16.2.3 , 
Informed Consent and Assent Form .
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
45
Approved , Date: [ADDRESS_507344] 201910.Subjects (or their legally  acceptable representative) must sign a separate informed consent 
form if he or she agrees to provide an optional DNA sample for research. Refusal to give 
consent/assent for the optional DNA research sample does not exclude a subject from 
participation inthe study. Assent is also required of children capable of understanding the 
nature of the study (typi[INVESTIGATOR_897]  7years of age and older) as described in Section 16.2.[ADDRESS_507345] be up-to-date with and agree to receive 
routine age-appropriate immunizations according to current Centers for Disease Control 
and Prevention (CDC )guidelines and agree to comply  with the guidelines for 
immunosuppressed individuals and those with chronic disease (diabetes mellitus). 
Specific to the human papi[INVESTIGATOR_28597] (HPV )vaccine, pneumococcal vaccine and any 
non-routine vaccines for immunosuppressed individuals or those with chronic diseases, 
subjects must have received these immunization s or initiated the recommended vaccine 
series and have a completion plan before the first administration of study  agent. 
Documentation of required immunizations or proof of corresponding immunity  (eg, 
vaccination card, medical record, or demonstration of protective antibody  titers) must be 
provided to the study  site.
4.1.2. Additional Inclusion Criteria forResponders
Each responder must also satisfy  the following criteria tobe eligible to restart active treatment:
1.Subjects must meet the MMTT criteria at Screeni ngfor the open -label extension period .If 
the most recent MMT Tis <[ADDRESS_507346] recent safety  laboratory samples drawn within 1 month prior to screening do not 
need a repeat; eligibility will be assessed based on these most recent laboratory  tests.For 
C-responders who are lacking the necessary  information to calculate IDAA1c score, an 
HbA1 cwill be performe d and [ADDRESS_507347] who meets any  of the following criteria will be excluded from participating 
in the study :
Coexisting medical conditi ons or past medical history:
1. Has a history  of significant renal, vascular, pulmonary , gastrointestinal, neurologic, 
hematologic, rheumatologic, or ps ychiatric disease.
[ADDRESS_507348].
3. Has a disease associated with lymphopenia, malignancy , bone marrow or organ 
transplantation, lymphoproliferative disorder, immune deficiency  syndrome (eg, 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
46
Approved , Date: [ADDRESS_507349] 2019severe combined immunodeficiency  syndrome, T-cell deficiency  syndromes, B-cell 
deficiency  syndromes, or chronic granulomatous disease).
4. Has another autoimmune disease (eg, RA, pJIA, PsA, AS, MS, systemic lupus 
erythematosus [SLE], celiac disease [clinicall y symptomatic and antibody  positive, ie, 
tissue transglutaminase IgA] ).excluding clinically  stable autoimmune thyroiditis 
whether treated or untreated .
5. Has nervous system disorder including but not limited to Guillain -Barre Syndrome, 
multiple sclerosis (MS) , or progressive mult ifocal leukoencephalopath y(PML ). 
6. Has known allergies, intolerance and/or hypersensitivity  to human immu noglobulin 
proteins, golimumab or any of its components or its excipi[INVESTIGATOR_840] , or a known allergy  or 
severe sensitivity  to latex (refer tothe SIMPONI and VarioJect Investigator's 
Brochure s).35,[ADDRESS_507350] 1 week apart:
White blood count <3 ,500/μL  or >14,000/μL;
Platelet count <100,000 /μL ; or
Hemoglobin <10 g/dL.
8. Has a diagnosis of liver insufficiency  or disease or hepatic enzy mes equal to or above 
the values below, which represent alanine aminotransferase (ALT )and aspartate 
aminotransferase (AST )≥[ADDRESS_507351] 1 week apart (These values are 
based on the Central Laboratory normal ranges of AST and ALT values 
(Attachment 5)
Aspartate aminotransferase (AST)
Females
96 U/L(age 6)
80 U/L  (age 7 through 17)
68 U/L  (age 18 and above)
Males
118U/L(age 6)
80 U/L  (age 7 through 17)
72 U/L  (age18 and above)
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
47
Approved , Date: [ADDRESS_507352] 2019Alanine aminotransferase (ALT)
Females
68U/L(age 6and above )
Males
68U/L(age 6through 9)
86 U/L  (age10and above )
Infections or predispositions to infections
9. Has active infections, is prone to infections or has chronic, recurrent or opportunistic 
infectious disease, including but not limited to, chronic renal infection, chronic chest 
infection (eg, bronchiectasis), sinusitis, recurrent urinary  tract infection (eg, recurrent 
pyelonephritis, chronic cystitis), Pneu mocy stis carinii, aspergillosis, latent or active 
granulomatous infection, histoplasmosis, or coccidioidomy cosis or an open, draining, 
or infected non -healing skin wound or ulcer.
10. Hasany of the following TB screening criteria:
A history  of latent or active TB prior to screening.
Signs or symptoms suggestive of active TB upon medical history  and/or physical 
examination.
Recent close contact [CONTACT_4490] a person with known or suspected active TB.
A histo ry of or a positive QuantiFERON ®-TB Gold test result at screening (see
Attachment 1 ).
A subject whose first QuantiFERON -TB Gold test result is indeterminate should have 
the test repeated. In the event that the second QuantiFERON -TB Gold test result is 
also indeterminate, the subject should be excluded from the study .Subje cts with a 
negative QuantiFERON -TB Gold test result are eligible to continue with 
pre-randomization procedures. 
11. Has a clinicall y active infection with Epstein -Barr virus (EBV )or an EBV viral load 
≥10,000 copi[INVESTIGATOR_402496] . 
12. Has a clinically  active infection with cytomegalovirus (CMV )or a CMV viral load 
≥10,000 copi[INVESTIGATOR_402496] . 
13. Is infected with human immunodeficiency  virus (HIV), hepatitis B (HBV) or 
hepatitis C (HCV) or at screening tests positive for HIV, HBV (See Attachment 4for 
guidance for HBV test interpretation ), or HCV .
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
48
Approved , Date: [ADDRESS_507353] 2019Concomitant or previous medical th erapi[INVESTIGATOR_223213]:
14. Current orprior (within 30 daysof screening ) treatment that is known to cause a 
significant, ongoing change in the course of T1D or immunologic status, including 
high-dose inhaled, extensive topi[INVESTIGATOR_2855] ,or systemic glucocorticoids.
15. Current or prior (within 30 daysof screening ) use of anti-hypergl ycemic agents, 
including but not limited to metformin, sulfony lureas, glinides, thiazolidinediones, 
exenatide, liraglutide, DPP -IV inhibitors or amy lin.
16. Current or prior (within 30 daysof screening ) useof any medication known to 
influence glucose tolerance including but not limited to atypi[INVESTIGATOR_34922], 
dipheny lhydantoin, thiazide, or other potassium -depleting diuretics, β-adrenergic 
blockers, or niacin .
17. Has ever receive d asystemic immunosuppression medicine or immune modulatory  
biologic therap y, including but not limited to T-or B-cell depleting therapy .
18. Has received or is expected to receive any live viral or live bacterial vaccinations 
from [ADDRESS_507354] study  agent administration.
19. Has had a Bacille Calmette -Guérin (BCG) vaccination within [ADDRESS_507355] study  agent administration.
Reproductive
20. If female, is pregnant, lactating, or breastfeeding, or planning to become pregnant 
while enrolled in this study .
21. If male, plans to father a child while enrolled in this study .
General Restrictions
22. Criterion modified per Amendment 3 –open -label extension period
22.1.Has participated in any interventiona l clinical study within the 6 months prior to 
enrollment or is currently  enrolled in an investigational study (apart from 
CNTO148DML 2001 trial) .
23. Criterion modified per Amendment 3 –open -label extension period
23.1. Has r eceived an investigational drug (including investigational vaccines) or used 
an invasive investigational medical device within [ADDRESS_507356] 
dose of study  agent or is currentl y enrolled in an investigational study (apart from 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
49
Approved , Date: [ADDRESS_507357] 2019CNTO148DML 2001 trial ).
24. Has any condition for which, in the opi[INVESTIGATOR_871], participation would 
not be in the best interest of the subject (eg, compromise the well -being) or that could 
prevent, limit, or confound the protocol -specified assessments.
NOTE: Investigators should ensure that all study  enrollment criteria have been met at screening
and, at randomization. If a subject's clinical status changes (including any available laboratory 
results or receipt of additional medical records) after scree ning but before randomization and the 
first dose of study  agent is given such that he or she no longer meets all eligibility  criteria, then 
the subject should be excluded from participation in the study . Section 9.1.2 , Screening Period , 
describes options for retesting. Section 17.4, Source Documentation, describes the required 
documentation to support meeting the enrollment criteria.
4.2.2. Additional Exclusion Criteria for Responders
1. Subjects having reported clinical ly significant AEs or serious adverse event (SAEs)
deemed to be relate d to the study  agent during the double -blind period (e.g. severe 
infections or h ypersensitivity  reactions) , precluding renewed exposure to golimumab.
[ADDRESS_507358] sand/or caregivers who are unwilling or unable to administer study agent .
4.3. Exceptions to In clusion and Exclusion Criteria for Open -Label Extension 
Period
The responders m ust continue to meet the initial inclusion and exclusion criteria to be eligible for 
the open -label extension period with following exceptions:
1.Autoantibody  status will not be assessed (refer to criteria 2 under Section 4.1.1 ). 
2.Subjects older than 21 years of age are eligible (refer to criteria 1 under Section 4.1.1 ).
3.For the open -label extension period, subjects may begin open -label study agent while EBV 
polymerase chain reaction (PCR )results are pending and if he/she meets all other 
inclusion/exclusion criteria. If EBV PCR results come back positive, subject must 
immediately  stop treatment and be withdrawn from the study .
4.4. Prohibitions and Restrictions
Potential subjects must be willing and able to adhere to the following prohibitions and 
restrictions during the course of the stud y to be eligible for participation:
1. Refer to Section 8for details regarding prohibited and restricted therapy  during the 
study .
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
50
Approved , Date: [ADDRESS_507359] [ZIP_CODE]. Agree to follow the contraceptive requirements as noted in the inclusion criteria.
3. Criterion modified per Amendment 3 –open -label extension period
3.1. Will not receive a live virus or live bacterial vaccination [ADDRESS_507360] study  agent administration.
4. Criterion modified per Amendment 3 –open -label extension period
4.1. Will not receive a BCG vaccination within [ADDRESS_507361] not donate eggs (ova, oocy tes) for the 
purposes of assisted reproduction through outthe study , or if she withdraws early from 
the study  within [ADDRESS_507362] study  agent administration.
6. Criterion modified per Amendment 3 –open -label extension period
6.1. If sexually  active with a female of childbearing potential and has not had a 
vasectom y, males must use a double barrier method of birth control during the study . 
Males must not donate sperm and must agree not to plan a pregnancy  or father a child 
during the 52-week treatment period and the open -label extension period of the trial and 
for 90days after the last study  agent administration, or if he withdraws early  from the 
study  within [ADDRESS_507363] study  agent administration.
7. Criterion modified per Amendment 3
7.1. Mustnot receive investigational drugs, systemic immunosuppressants (including, 
but not limited to cy clophosphamide) or other biologics through out the study .
5. TREA TMENT ALLOCA TION AND BLINDING
Treatment Allocation
Procedures for Randomization and Stratification
Central randomization will be implemented in this study . Subjects will be randomly  assigned to 
1of 2treatment groups based on a computer -generated randomization schedule prepared before 
the study  by [CONTACT_43754]. The randomization will be balanced by 
[CONTACT_111126] y permuted blocks and will be stratif iedonsubjects’ basel ineC-peptide AUC
(<0.66 pmol/mL ,≥0.66 pmol/mL)derived from the4-hour MMTT conducted at screening .The 
interactive web response system (IWRS) will assign a unique treatment code, which will dictate 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
51
Approved , Date: [ADDRESS_507364]'s safet y, the study  blind 
may be broken, and the identity  of the study  agent ascertained. The study  agent number will be 
entered in the case report form (CRF) when the study  agent is administered. The study  agents 
will be identical in appearance and will be packaged in identical containers.
The investigat ive sites will not be provided with randomization codes. The codes will be 
maintained within the IWRS, which has the functionality  to allow the investigator to break the 
blind for an individual subject.
Data that may potentially  unblind the treatment assignment (ie, study  agent serum 
concentrations, anti-golimumab antibodies, and treatment allocation) will be handled with 
special care to ensure that the integrit y of the blind is maintained and the potential for bias is 
minimized. This can include making special provisions, such as segregating the data in question 
from view by [CONTACT_473], clinical team, or others as appropriate until the time of DBL and 
unblinding.
Under normal circumstances, the blind should not be broken until all subjects have completed 
the study  and the database is finalized. Otherwise, the blind will be broken only if specific 
emergency  treatment/course of action would be dictated by [CONTACT_35496]. In such cases, the investigator may in an emergency  determine the identity  of the 
treatment by  [CONTACT_23793].It is recommended that the investigator contact [CONTACT_402544], to discuss the particular situation, before breaking the blind. Telephone 
contact [CONTACT_97500] 24hours per day, 7days per week. In 
the event the blind is broken, the sponsor must be informed as soon as possible. The date and 
reason for the unblinding must be documented by [CONTACT_8784], in the appropriate section of the 
CRF, and in the source document. The documentation received from the IWRS indicating the 
code break must be retained with the subject's source documents in a secure manner.
Subjects who have had their treatment assignment unblinded for a SAE will not continue to 
receive study  agent but should continue to return for scheduled evaluations .
Summary  level unblinded data will be made available to the sponsor at the Week 52 DBL 
(DBL 1). Subject level data will be unblin ded to selected members of the sponsor’s data 
management, programming, pharmacology , clinical and biostatistics teams for analysis and 
reporting, while the subjects are still being followed in the study . Identification of sponsor 
personnel who will have access to the unblinded subject level data will be documented prior to 
unblindin g.The Study Responsible Physician will remain blinded throughout the double -blind 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
52
Approved , Date: [ADDRESS_507365] level treatment assignment and dosing regimen . Site investigators and 
personnel, and the subjects /caregivers will remain blinded until after the Week 104 DBL 
(DBL 2) has occurred. An exception to this rule will be made for those subjects who are meeting 
the responder criteria at Week 52of the double -blind period . These will be unblinded to
determine eligibility  for re-starting active treatment during the open -label extension period.
Subject level data will be unblinded to Data Monitoring Committee (DMC )and Interim Anal ysis 
Committee (IAC). Please refer to Section 11.10 andSection11.11 for details.
6. DOSA GE A ND A DMINISTR ATION
6.1. Dosage
All study agent (golimumab or placebo) will be administered SCusing a sponsor -supplied , 
single-use administration device. This will be either thecommerciall y available prefilled syringe 
with a needle guard (the PFS-Ultrasafe [PFS-U]), designed to deliver a single, fixed dose of 
50mg, or theinvestigational VarioJect injection device (“VarioJect) ”which deliv ersa single, 
variable dose of 10to 45mgin 5 mg increments . Identical devices containing placebo will be 
used to deliver a volume equival ent to that of active treatment for subjects randomized to the 
placebo arm.
Body surface area will be calculated at Week 0 for the induction and maintenance dose of 
golimumab (and will be adjusted as needed) based on weight cut-off according to Table 1. 
Detailed charts using height and weight for induction and maintenanc e doses according to weight 
cut-off are presented in Attachment 2-Aand 2-B, respectivel y. Body surface area will be 
calculated using the Mosteller equation: BSA (m2) = ([height (cm) x weight (kg)]/3600)1/2.The 
dosage form (PFS -U or VarioJect) and volumes required for administration are presented in 
Attachment 2-C.For certain induction doses, 2 injections may be required for administration of 
1induction dose.
Table 1: Golimumab SC Dosing Regimens by [CONTACT_402545] -Off For Subjects Who Are Randomized 
to the Golimumab Treatm ent Group
Body  weight* Week 0 and 2 Week 4 through Week 52 
(Double -Blind) PeriodWeek 0 through Week 
50 (Open -Label 
Extension) Period
<45 kg 60 mg/m230 mg/m2q2w 30 mg/m2q2w
≥45 kg 100 mg 50 mg q2w 50 mg q2w
Number of injections/dose 1 or 2** 1** 1**
*Body weight to be evaluated approximately every  3 months w ith dose adjustment if necessary (below  and see Time 
and Event sTable) .
**Refer to Attachment 2
During the 52-week dosing period, subjects may experience changes in their weight and/or 
height necessitating a change in thedose of the study  agent. There will be 4opportunities to
calculate thestudy  agent dose during the 52-week dosing period. Study agent dose for the first 
12weeks will be based on height and weight obtained at the Week 0 visit. At the Week 12visit, 
height and weight will be obtained andthe dose for the next 14weeks (until the Week 26visit) 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
53
Approved , Date: [ADDRESS_507366] 2019will be calculated. Similarly ,at the Week26 and 38 visits, the dose for the subsequent 12 and 
14-week intervals, respectively ,will be calculated (see Time and Events Schedule ).
The same procedure will be applied for the responders during the open -label extension period. 
Study  agent dose will be calculated at the OLWeek 0, 12, 28, 44, and 50visits. The last dose of 
study  agent is tobe administered at Week 50.Detailed charts using height and weight for 
open -label extension period according to weight cut -off ispresented in Attachment 2-B.
Responders being restarted on active drug will not undergo an induction regimen but will 
immediately  be started on the maintenance dose. A new induction dose may entail an increased 
risk for immunogenicit y and/or hypersensitivity reactions and there is no clear rationale for 
reaching stead y state as quickly as possible given the longer delay after diagnosis of T1D.
Detai ls on dose preparation and administration can be found in the Study  Site Investigational 
Product and Procedures Manual (SI PPM).
For the most comprehensive information regarding the VarioJect , refer to thecurrent version of 
the VarioJec tIB.
6.2. Dose Administration
Study  agent dosing will be administered using the PFS-U or VarioJect. It will be injected 
subcutaneousl y by [CONTACT_402546] -site staff and for some dosings ,subject s/caregivers will be given 
the option of "self-administration" after appropriat e training (described below) .For purposes of 
this study , the term “self -administration” is defined as study  agent administered either by [CONTACT_402547]/or at study  sites. In cases where subjects/caregivers do 
not want or are unable to participate in self-administration ofstudy  agent, subjects will receive 
all doses of study  agent at study  sites .
For responders in the open -label extension period, study  agent administration will be performed 
by [CONTACT_402548] . In-between visit doses will be administered either by [CONTACT_402549] .In cases where subjects/caregivers do not want or are unable to 
participate in self-administration of study  agent, subjects will receive all doses of study  agent at 
study  sites .
Study  staff and those subjects /caregivers who will participate in self-administration will receive 
training on study  agent administration at the investigative site under the supervision of a trained 
health care professional, which must be documented. This will include education regarding 
instructions for use (IFU), proper handling and storage of devices, guidance on study  agent 
injection ,and proper handing and accounting for used devices. Required storage conditions and 
expi[INVESTIGATOR_402497].
Injection sites include the front of thighs (which is recommended), the lower abdomen (avoiding 
the 2-inch area around the navel), or the back of the upper arms. Different sites should be used 
for consecutive injection s. Sites that are tender for any reason should be avoided. Study  agent 
and insulin injections should be given at different anatomic sites.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
54
Approved , Date: [ADDRESS_507367] does not meet 
any criteria in Section 10.2, that dose may still be administered as long as it is in the current 
dosing window (See Section 7.1) otherwise dosing should resume with the next planned dose. 
Refer to Section 10.2 for dose holding and dosing resumption for other conditions. If 
subjects/caregivers have a question about the subject status and their ability  to be dosed, they  are 
to consult with the study -site investigational team. If subjects/ caregiver s have a question about 
the subject status and their ability to be dosed, they are to consult with the study -site 
investigational team.
Administration of the first 3 doses will occur during study  visits (Week 0, 2, and 4). For 
subjects/caregivers who will be participating in self-administration, training will take place at 
these visits .It is possible that the device required for induction doses differs from the device 
required for maintenance doses. Training should be provided on the device intended for 
maintenance dosing. Prior to allowing at home self-administrat ion, at least [ADDRESS_507368]/caregiver using the device to be used for at home self-administration ,must be 
witnessed by [CONTACT_464].At the Week 8, 12, 18, 26, 38, and 52 study  visits of the double -blind 
period and Week 12, 20, 28, 36, 44 , and 50 study  visits of the open -label extension period where 
study  agent will be administered, either subjects/caregivers or study  staff may administer the 
injection.
Following dosing ,subjects are to be monitored for at least 30 minutes as detaile d in Section 9.1.3
and Section 9.1.5 . All data regarding study  agent administration including date, time, and 
anatomic location of injection, study agent dosing device and if there are AEs, reactions or 
device complications will be recorded . During self-administration, subjects/caregivers are to 
contact [CONTACT_1758] -site team in the event of problems or complication including but not limited to 
signs of immediate or delay ed local or s ystemic reaction (Section 9.9).
At any time, if subjects /caregivers are uncertain about how to administer the study  agent or has 
questions regarding self-administration , the sponsor recommends a review of the IFU with the 
study  staff along with practice inje ctions with a training device if necessary . If at an y time during 
one of the [ADDRESS_507369]/caregiver must return to the study  site for training and the subject/caregiver 
using the device must be witnessed by [CONTACT_402550]-administering a successful injection prior 
to performing at home self -administration.
Forsubject s/caregiver sunwilling or unable to self-administer the study  agent outside of the 
study  site, subsequent doses will be administered atthestudy  site by [CONTACT_402551] . During the dosing period these 
subjects/caregivers can be trained for self-administration of subsequent dosing per the above 
guidelines.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
55
Approved , Date: [ADDRESS_507370] [ZIP_CODE]. TREA TMENT COMPLIA NCE
7.1. STUDY AGENT DOSING COMPLIA NCE : RECORDING AND WINDOWS
7.1.1. Dosing Recording
Details on the specifics of the study  agent including study  agent dosing device type,date, time, 
anatomic location of injection ,and person administering the dose, will be documented in the 
CRF or recorded in the electronic diary  (eDiary ).Study -site person nel will record this 
information for study  agent administration sconducted at the study  visits (see Time and Events 
schedule ). For subjects/caregivers participating in self-administration, this data will be entered
into an eDiary unless self-administra tion is done on-sitewhere this information will be recorded 
in the study  site’s documents, not in the eDiary .All information related to self-administration 
will be reviewed and verified with subjects/caregivers at subsequent stud y visits.
Subjects are toreceive dosing with study  agent every  2 weeks following randomization through 
Week 52, for a total of 27 doses (Table 2).The “target dosing day”for the study  will be at 
14-day intervals and calculated based on the day of randomization. The target dosing day 
schedule will not be readjusted due to missed or of f schedule dosing.
The investigator or designated study -site personnel will maintain a log of all study  agent 
dispensed and returned both from and to the study site and the sponsor and, in cases of subject 
self-administration, to and from the study  site and subject/caregiver. Drug supplies for each 
subject will be inventoried and accounted for throughout the stud y.
Study  sites are expected to keep in close contact [CONTACT_108804]/caregivers and encourage dosing 
and study  visit compliance, whether or not they  are participating in self -administration. This may 
occur proactively  via telephone or electronic communication, sending automated dosing 
reminders, and through monitoring eDiaries whic h will be obtaining regular (ie,daily ) subject 
data entry  updates.
[IP_ADDRESS]. Dosi ng Recording –Open -Label Extension Period
Details on the specifics of the study  agent including study  agent dosing device type, date, time, 
anatomic location of injection, and person administering the dose, will be documented in the 
CRF or recorded in the or paper diary . Study -site personnel will record this information for study  
agent administrations conducted at the study  visits (see Time and Events schedule ). For 
subjects/caregivers participating in self-administ ration, this data will be entered into the paper 
diary  unless self-administration is done on-site where this information will be recorded in the 
study  site’s documents, not in the paper diary . All information related to self-administration will 
be reviewed and verified with subjects/caregivers at subsequent study  visits.
Subjects are to receive dosing with study  agent every  2 weeks based on Week 0 of the open -label 
extension period, for a total of 27 doses (Table 3). The “target dosing day” for the study  will be 
at 14-day intervals and calculated based on the day of randomization. The target dosing day 
schedule will not be readjusted due to missed or off schedule dosing.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
56
Approved , Date: [ADDRESS_507371]/caregiver. Drug supplies for each 
subject will be inventoried and accounted for throughout the stud y.
Study  sites are expected to keep in close contact [CONTACT_108804]/caregivers and encourage dosing 
and study  visit compliance, whether or not they  are participating in self -administration. This may 
occur proactively  via telephone or electronic communication, sending automated dosing 
reminders, and through or paper diaries during the open -label extension period which will be 
obtaining regular (ie, dail y) subject data entry  updates.
7.1.2. Dosing Windows
All attempts should be made to dose on the scheduled target dosing day , yet it is recognized 
that due to schedules and other events thismay not be possible.
Weeks 2 and 4:Study  agent dosing for Week 2 and 4 is to occur ±1 day of the target-dosing
day.
Weeks 6 through 52:For study  agent dosed from Weeks [ADDRESS_507372] should be given ±3days 
of the target day, regardless of whether subjects are participating in self-administration or being 
dosed at stud y sites. In situations where subjects cannot dose within this window, the dose can be 
administered up to 7 days after the targeted dosing day . If the dose cannot be administered within 
this period, that dose should not be given, and subjects should resume dosing at the next 
scheduled dosing interval.
Entire study :Throughout the study , administration of sequential study  agent dosing’s must 
occur no less than 7 day sapart.
Table 2: Study Agent Dosing Window Table
Time Dose Administration Window A round Target Dosing Day*
Required Administration at theStudy Site
Randomization Visit Week 0 N/A
Visits Week 2 and 4 ±1 day
Visits and Dosing Weeks 6 through 52 ±3 days
*Calculated based on 14 -day intervals from randomization day. Subjects/caregivers will schedule dosing -only visits 
to comply with dosing schedule.
[IP_ADDRESS]. Dosing Windows -Open -Label Extension Period
Week 2: Study  agent dosing for Week 2is to occur ± 1 day  of the target -dosing day .
Weeks 4 through 50:For study  agent dosed from Weeks [ADDRESS_507373] should be given ±3days 
of the target day, regardless of whether subjects are participating in self-administration or being 
dosed at study  sites .
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
57
Approved , Date: [ADDRESS_507374] 2019Entire study: Throughout the study , administration of sequential study  agent dosing’s must 
occur no less than 3days apart.
Table 3: Study Agent Dosing Window Table –Open -Label Extension Period
Time Dose Administration Window Around Target Dosing Day*
Required Administration at the Study Site
Visit Week 2 ± 1day
Visits and Dosing Weeks 4through 50 ± 3 days
*Calculated based on Week 0 of open -label extension period. Subjects/caregivers will schedule dosing -only visits to 
comply with dosing schedule.
8. PRESTUDY AND CONCOMITA NT THERAPY
During the double -blind period, prestudy therapi[INVESTIGATOR_43710] 28days before screening 
and between screening and randomi zation must be recorded in the CRF .
Concomitant therapi[INVESTIGATOR_402498].
All therapie s (prescription or over-the-counter medications, including vaccines, vitamins, herbal 
supplements) different from the study  agent must be recorded in the CRF. Recorded information 
will include a description of thetype of the drug, treatment period, dosing regimen, route of 
administration, and its indication.
8.1. Required Medications
Insulin preparations as advised by [CONTACT_458] [INVESTIGATOR_1238]/or the subject’s primary  
physician or endocrinologist to target current glycemic control recommendations by [CONTACT_402552] y with a HbA1c target of <7.5% in children 17 years old and younger and <7% in 
those [ADDRESS_507375] 
3injections of insulin daily , including short -and long-acting insulin preparations, or will utilize 
a continuous subcutaneous insulin infusion/pump. Glucose levels should be checked at least 
4times daily . HbA1c will be recorded regularl y as part of the study  and subjects may have 
HbA1c conducted b y their physician who is managing their diabetes.
During the double -blind period, subjects will record insulin use for the 7-days preceding each 
study  visit and hypoglycemic events occurring at any time during the study  will be captured 
using an eDiary .Subjects will also be loading daily  glucometer readings into their eDiary . This 
information will be reviewed at each study  visit and recorded using CRFs. Please also refer to 
Section 9.8.
During the open -label extension period, subjects will record insulin use for the 10-days 
preceding each study  visit and hypoglycemic events occurring at any time during the study  will 
be captured using the paper diary .
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
58
Approved , Date: [ADDRESS_507376]’s primary 
clinical -care team about possible adjustments in the insulin regimen, referral to a registered 
dietitian, or other approaches that the diabetes management team believes would improve the 
glucose control if necessary .
8.2. Permitted Medications
There are no medications specificall y contraindicated for use with golimumab, so subjects may 
continue to receive medications as needed for existing medical conditions .Please see Section 8.[ADDRESS_507377] of medications that should not be taken in conjunction with the study  agent during the 
study . Specific permitted medications that subjects may need during the study  include, but are 
not limited to:
Low-dose estrogen oral contraception.
Acetaminophen and NSAIDs (eg, ibuprofen and naproxen).
Diphenhy dramine (or equivalent antihistamines).
Non-infectious (ie, recombinant, inactivated or otherwise “non -live”) vaccines 
recommended b y the CDC in individuals 6 y ears old and above (including the HPV vaccine) 
and those recommended for immunosuppressed individuals or those with chronic diseases 
(diabetes mellitus). For these immunizations, if required and applicable, subjects should 
receive recommended one-time vaccinations prior to first study  agent administration. If a 
subject has started a recommended vaccination series, the next administration in the series 
should be given before first dosing of study  agent, if consistent with recommended 
administration schedule . If needed , the series may be completed during the study  according 
to the recommenced schedule. If a subject has not received the first dose of a required 
vaccination series, they should receive this before the first study  agent administration and 
continue to receive vaccinations in this series during the study  as recommended. Subjects 
are to receive non-infectious vaccines during the recommended time frame if they meet 
specific criterion during the study , ie, becoming age-eligible, while participating in the 
study . Documentation of all vaccines given during screening and post-randomization
participation in the study  must be provided to the study  site.
8.3. Prohibited Medications
The concomitant use of the following drugs is not permitted during the study :
Live vaccines (eg, varicella, measles, mumps, rubella, cold-attenuated intranasal influenza 
vaccine, and smal lpox) in the 90 daysbefore enrollment, during the treatment period s,and 
for 120 daysafter completing study  treatment. In addition, household contacts should be 
encouraged nottoreceive small pox or oral polio vaccine due to the risk of viral shedding.
BCG vaccination during the study  or for [ADDRESS_507378] administration of study 
agent.
Agents that influence insulin sensitivity  or secretion, which include but are not limited to 
MTX , sulfony lureas , metformin, dipheny lhydantoin, thiazide, or other potassium -depleting 
diuretics, beta-adrenergic blockers, or niacin through Week 104 including the open -label 
extension period .
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
59
Approved , Date: [ADDRESS_507379] 2019Agents that may  result in immunosuppression or immunomodulation through Week 104and 
the open -label extension period .This includes initiation of long-or chronic -dosing of 
high-dose inhaled, extensive topi[INVESTIGATOR_402499]. This also includes biologic 
immune modulators including but not limited to abatacept and anakin ra. Note: A short 
course of cortico steroids may  be used for treatment of a transient condition.
If a subject receives, or if the principal investigator [INVESTIGATOR_402500] a subject needs a prohibited 
medication, the case must be immediately  discussed with spons orStudy Responsible Physician 
todetermine whether study  treatment should continue or be discontinued.
9. STUDY EVA LUATIONS
9.1. Study Procedures
9.1.1. Overview
The Time and Events Schedule summarizes the frequency  and timing of efficacy ,PK,
immunogenicit y,Pharmacody namics ,biomarker, pharmacogenomic, andsafet yassessments 
applicable to this study .
During the double -blind period, a4-hour MMTT will be performed during screening, and at 
Weeks12, 26, 38, 52, 78,and [ZIP_CODE].During the open -label extension period, a 4-hour 
MMTT will be performed to establish eligibility  criteria unless the previous MMTT was 
<3months ago and will also be performed at OL Screenin g and OL Weeks [ADDRESS_507380]. Subjects are to follow the dietary 
and insulin use guidelines as described in Attachment 3 to perform the MMTT.
Subjects/caregivers will collect data related to diabetes management ,hypoglycemic events, 
and study  agent dosingusing sponsor -supplied eDiary and glucometer (for the double -blind 
period) and paper diary (for the open -label extension period) .
PK and Immunogenicity samples must be collected before stud y agent administration.
Additional serum or urine pregnancy  tests may be performed, as determined necessary  by 
[CONTACT_31837], to establish the absence of pregnancy  at any 
time during the subject's participation in the study .
Blood collection:
The total blood volume to be collected from each subject, including during screening, 
the 52-week treatment period and 52-week off-therapy  follow -up period is 
approximately  436mL for subjects <35 kg and 505 mL in subjects ≥35 kg.During the 
open -label extension period, approximately  210 mL for subjects <35 kg and 234 mL for 
subjects ≥35 kg will be drawn.
It is recognized that the amount of blood that may be drawn for research purposes in 
adults and children may not exceed certain limits , both at a single visit and over aset 
amount of time. Guidance for blood drawing in this study is:
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
60
Approved , Date: [ADDRESS_507381] s (18 years of age and older)
The amount of blood that may be drawn for research purposes shall not exceed 10.5 mL/kg or 
550mL, whichever is smaller, over any  8-week period.
Pediatric Subjects (6 Through 17 Years of Age):
The amount of blood that may be drawn for research purposes shall not exceed more than 
5mL/kg in a single day and shall not exceed more than 9.5 mL/kg over any 8-week period .
Inany subject whose clinical condition might be adversel y affected by [CONTACT_402553], for example, a subject with significant anemia or compromised cardiac 
output, investigators should consider further limiting the volume of blood withdrawn f or research 
purposes.
In instances of medical need, it is the responsibility  of the site investigator and/or subject ’s 
healthcare providers to determine ifblood draws in excess of the above limits should occur .
Because blood sampl ingin excess of those mandated by [CONTACT_402554] , sites must ensure that all instances of blood collection 
in excess of permitted volumes are recorded and justified in the subject ’s record.
9.1.2. Screening Period
For all subjects participating in this study , the screening visit must occur within 28daysof study 
agent administration and may  occur over more than 1 day . Prior to screening, the investigator (or 
designee) will explain the study ’s rationale, procedures, and risks, and ask each potential 
subject /care giver to consent /assent to participate. The start of the screening period of the study 
will be defined as the day written informed consent /assent is obtained . Subjects may participate 
in optional pharmacogenom ic assessments which will require a separate consent/assent. 
Subject swill be assigned a unique subject number and evaluation for inclusion/exclusion criteria 
(Section 4)will be performed, which will include clinical and laboratory  evaluations and the
4-hour MMTT .
An eDiary  and glucometer will be issued to subjects during screening for training on how 
subjec ts/caregivers are to collect data between study  visits related to: including insulin use, BG
levels, hypoglycemic events, and study  agent administration. Subject data collected using 
eDiaries will be reviewed and verified at subsequent study  visits, includ ing the randomization 
visit (see Time and Events Schedule ). In cases where subjects are not enrolled in the study , they 
will be directed on how to return the device s.
The measurements collected and procedures perfor med during the screening visit for all subjects 
are identified in the Time and Events Schedule . In anticipation of successful screening and 
continued interest in the study , study  personnel should discuss the optimal timing for and even 
tentatively  schedule study  randomization at the screening visit. This is due to the limited window 
between screening and randomization and recognizing that all futur e dosing and study  visits for 
2years will be based on that randomizat ion date.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
61
Approved , Date: [ADDRESS_507382] undergo testing for TB (see Attachment 1) and their medical history  assessment 
must include specific questions about a history  of TB or known occupational or other personal 
exposure to individuals with active or suspected TB. The subject should be asked about past 
testing for TB, including responses to tuberculin skin or other TB testing .
Subjects with a negative QuantiFERON -TB Gold test result are eligible to continue with 
randomization procedures. Subjects with a positive QuantiFERON -TB Gold test result must be 
excluded from the study .
A subject whose first QuantiFERON -TB Gold test result is indeterminate should have the test 
repeated. In the event that the second QuantiFERON -TB Gold test result is also indeterminate, 
the subject should be excluded from the study .
Retesting
If subjects screen but do not meet all study participation criteria (See Section 4.1and 
Section 4.2.1 ), they may be eligible for retesting that may lead to randomization. Retesting of 
laboratory  testswill be allowed once and will take place during an unscheduled visit within 
28days of initia l screening phase.
Rescreening
If subjects are eligible to participate in the study  but do not randomize within 28days of signing 
the consent /assent form or donot meet specific enrollment criteria that may change to allow 
enrollment (ie, development of T1D autoantibodies), subjects may be rescreened and be 
randomized as long as inclusion and exclusion criteria are met and the subject is able to be 
randomized within 100days of T1D diagnosis. Rescreening is allowed only once. Subjects who 
are rescreened will receive a new subject number, repeat the informed consent process, and then 
restart a new screening phase.
[IP_ADDRESS]. Screening Period -Open -Label Extension Period
For the open -label extension period, the optional screening visit should occur within [ADDRESS_507383] occur within 14 days prior to Week 104. Prior to screening, the investigator (or 
designee) will explain the study ’s rationale, procedures, and risks, and ask each potential 
subject/caregiver to consent/assent to participate. The start of the screening period of the study 
will be defined as the day written informed consent/assent is obtained. Rules for MMTT have 
been described in Attachment [ADDRESS_507384] number and evaluation for inclusion/exclusion criteria 
(Section 4) will be perfor med, which will include clinical and laboratory  evaluations and the 
4-hour MMTT.
Apaper diary  will be issued to subjects during screening for training on how subjects/caregivers
are to collect data between study  visits related to: including insulin use, hypogl ycemic events, 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
62
Approved , Date: [ADDRESS_507385] data collected using paper diaries will be reviewed and 
verified at subsequent study  visits (see Time and Events Schedule ).
Subjects must undergo testing for TB (see Attachment 1) and their medical history  assessment 
must include specific questions about a history  of TB or known occupational or other personal 
exposure to individuals with active or suspected TB. The subject should be asked about past 
testing for TB, including responses to tuberculin skin or other TB testing.
Subjects with a negative QuantiFERON -TB Gold test result are eligible to continue with 
randomization procedures. Subjects with a positive QuantiFERON -TB Gold test result must be 
excluded from the study .
A subject whose first QuantiFERON -TB Gold test result is indeterminate should have the test 
repeated. In the event that the second QuantiFERON -TB Gold test result is also indeterminate, 
the subject should be excluded from the study .
9.1.3. Randomization, Treatment Period , and Follow -up Period
[IP_ADDRESS]. Active Treatment Period: Weeks 0 To 52
Randomization : Week [ADDRESS_507386] 5days of daily  insulin use recorded
within the 7 days immediately  preceding randomization. If not, subjects/caregivers should be 
instructed to reschedule this visit to have atleast 5 days of daily insulin usage recorded prior to 
the rescheduled randomization visit. Subjects will be randoml y assigned as described in 
Section 3.1to receive study  agent (golimumab or placebo) .Subject weight and height will be 
obtained to determine dose and device.
After the predose PK/immunogenicit y sample is drawn, the dose of study agent (golimumab or 
placebo) will be administered at thestudy  site.Subjects should be monitored for at least 30 
minutes following injection and be observed for any adverse reactions, including injection site 
reactions (See Section 9.9). Subjects /caregivers who want to participate in study  agent 
administration “self -administration” outside of some study  visits begintraining onusing the 
sponsor -supplied single -use injection devices (See details S ection 6.2).Additional training on t he 
eDiary  and glucometer will b e given as needed.
Future target dosing and study  visit days will be calculated based on the day of initia l dosing at 
randomization (Week 0) and will not be redefined later during the study. Therefore, the study  
staff are encouraged to discuss the study  visit dayswith subjects/caregivers and consider this 
schedule to determine what might be the anticipa ted (ie, day of the week) for future dosing and 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
63
Approved , Date: [ADDRESS_507387] on study 
compliance is detailed in Section 7.
At this visit,subjects/caregivers will be supplied with a calendar with target dosing daysand 
target study  visit day s that show dosing and visit windows (See S ection 7.1.2 ).
Study Visits: Week s2 and [ADDRESS_507388] 30 minutes following injection and be observed for any adverse reactions, including 
injection site reaction (Section 9.9).In addition ,for those wh o will be administering the injection
outside of study  visits (“self -administration”), subjects and/or caregivers should continue and 
complete administration training, includi ng conducting a successful injection by [CONTACT_402555]-injection . If the training was considered successful 
and the site staff considers that the subject or caregiver cansuccessfully  self-administer, the 
subject will be sent home with study  agent injection devices at Week 4, with instructions for 
handling and storage of drug and used devices. The visit window for these visits is±1day from 
the target dosing day .
Study Visits Including Study Agent Dosing: Weeks 8, 12, 18, 26, 38, and [ADDRESS_507389] pre dose
PK/immunogenicity sample drawn , have safet y and/or efficacy  assessments performed ,and 
receive study  agent dosing by [CONTACT_402556] . All subject 
required data, including that recorded via eDiary  data, will be reviewed . During these visits, 
subjects/caregivers who areadministering injections are to return used devices and receive 
additional devices and supplies per the Time and Events Schedule since the last visit. At these 
visits, subjects/ caregiver s will also receive additional device training as needed . During 
Week s12, 26, and 38, subjects are to have their weight and height reassessed to determine if 
dosing adjustments need to be made for the next interval as described in Section 6.1, with 
additional training as needed. The visit window s for these study  visits are ± 3days from the 
target dosing day .
Study Visits for PKSampling and Clinical Review Only: Weeks 33 and 45
Visits on Weeks 33 and 45 are not dosing visits however in addition to clinical review and 
assessments, a random PK sample will be drawn . Subjects/caregivers who are participating in 
administering injections are toreturn used devices and receiv e additional injection devices and 
supplies ,if needed, at these visits .The visit windows for these study  visits are ±7days from the 
target dosing (visit) day.
[IP_ADDRESS]. Study Agent Self -Administration or Dosing -Only  Visits : Study Weeks 
6, 10, 14, 16, 20, 22, 24, 28, 30, 32, 34, 36, 40, 42, 44, 46, 48, and 50
After Week 4, subjects/ caregivers who have met the training requirement, are given the option to 
self-administer majorit yof the study  agent doses off-sitethat do not coincide with study  visits. 
As detailed in Section 6.2 and the IFU, subjects/caregiver s will receive training on 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
64
Approved , Date: [ADDRESS_507390] 3 dosing visits, and at study  visits preceding off-site
administration subjects will receive the appropriate study  agent devices for dosing until the next 
dosing visit as well as supplies and instructions on handling and storage before and after usage. 
Subjects/caregivers will enter information including dateand time of dosing, device used, 
anatomic site injected, and person administering dose into their eDiary . Subjects/ caregiver s will 
be asked to closel y monitor the study  agent injection site for at least 30minutes and 
intermittently  thereafter. During self-administration, subjects/care givers are to contact [CONTACT_10748] -site team in the event of problems or complication including but not limited to signs of 
immediate or delay ed local or sy stemic reaction (Section 9.9). These dose administrations should 
occur ± 3day of target dosing day  as detailed above.
For subjects/caregiver s unwilling or unable to administer the injection , subjects/care giver s are to 
work with the site team to develop a visit schedule to meet the dosing criteria in Section 9.1.[ADDRESS_507391] 
±3days of the target dosing day .
[IP_ADDRESS]. Off-Therapy Follow -up Period –Weeks 52to [ADDRESS_507392] dose of study  agent is to be administered at the Week 52 study  visit. Subjects will 
remain in the study  until Week 104, continue recording data in their eDiary  and followed for 
evaluations of safet y, PK/anti -drug antibodies ,and durability  of response. Subjects will have 
assessments only at Week 78 and Week 104. All safet y and efficacy assessments will be 
performed at these visits according to the Time and Events Schedule . The visit windows for 
these 2 visits are ± [ADDRESS_507393] occur within 14 days prior to Week 104 .
9.1.5. Open -Label Extension Period
Subjects meeting the inclusion criteria applicable for responders and who are willing to 
participate will restart active study  treatment in the open -label extension period.
[IP_ADDRESS]. Active Treatment Period: OL Weeks 0 To 5 2
Restart : OL Week [ADDRESS_507394] remains 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
65
Approved , Date: [ADDRESS_507395] weight and height will be obtained to determine dose and device.
The dose of study  agent (golimumab )will be administered at the study  site. Subjects should be 
monitored for at least 30 minutes following injection and be observed for any adverse reactions, 
including injection site reactions (See Section 9.9). Subjects/caregivers who want to participate 
in study  agent “self -administration” outside of some study  visits begin training on using the 
sponsor -supplied single -use injection devices (See details Section 6.2). Additional training on the 
paper diary  and glucomet er will be given as needed.
Future target dosing and study  visit days will be calculated based on the day of initial dosing 
(Week 0) and will not be redefined later during the study . Therefore, the study  staff are 
encouraged to discuss the study  visit dayswith subjects/caregivers and consider this schedule to 
determine what might be the anticipated (ie, day of the week) for future dosing and study  visits. 
Specific study  visits and study  agent treatment windows and impact on study  compliance is 
detailed in Section 7.
At this visit, subjects/caregivers will be supplied with a calendar with target dosing days and 
target study  visit day s that show dosing and visit windows (See Section [IP_ADDRESS] ).
Study Visits: OL Weeks [ADDRESS_507396] 30 minutes following injection and be observed for any adverse reactions, 
including injection site reaction (Section 9.9). In addition, for those who will be administering 
the injection outside of study  visits (“self -administration”), subjects and/or caregivers should 
continue and complete administration training, including conducting a successful injection by  [CONTACT_402557]-injection. If the training was considered
successful and the site staff considers that the subject or caregiver can successfully 
self-administer, the subject will be sent home with study  agent injection devices at OL Week 4, 
with instructions for handling and storage of drug and used devices. The visit window for OL 
Week 2 and Week 4 visitsis±1day and ±3 days, respectivel y from the target dosing day .
Study Visits Including Study Agent Dosing: OL Weeks 12, 20, 28, 36, [ADDRESS_507397] 
predose PK/immunogenicity  sample drawn, have safet y and/or efficacy  assessments performed, 
and receive study  agent dosing by [CONTACT_402556] . All 
subje ct required data, including that recorded via paper diary  data, will be reviewed. During 
these visits, subjects/caregivers who are administering injections are to return used devices and 
receive additional devices and supplies per the Time and Events Schedule since the last visit. At 
these visits, subjects/caregivers will also receive additional device training as needed. During OL 
Weeks 12, 28, and 44, subjects are to have their weight and height reassessed to deter mine if 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
66
Approved , Date: [ADDRESS_507398] 2019dosing adjustments need to be made for the next interval as described in Section 6.1, with 
additional training as needed. The visit windows for these study  visits are ± 3days from the 
target dosing day .
Study Visits for PK Sampling and Clinical Review Only: OL Weeks 0, 4, 12, 28, and 5 2
A PK sample will be drawn at visits in OL Weeks 0, 4, 12, 28, and 52. Subjects/caregivers who 
are participa ting in administering injections are to return used devices and receive additional 
injection devices and supplies, if needed, at these visits. The visit windows for these study  visits 
are ± 3 days from the target dosing (visit) day except for OL Week 0 .
[IP_ADDRESS]. Study Agent Self -Administration or Dosing -Only  Visits: OL Weeks 0, 
2, 4, 12, 20, 28, 36, 44 , and 5 0
After OL Week 4, subjects/caregivers who have met the training requirement, are given the 
option to self-administer majority  of the study  agent doses off-site that do not coincide with 
study  visits. As detailed in Section 6.2and the IFU, subjects/caregivers will receive training on 
administration during the first 3 dosing visits, and at study  visits preceding off-site 
administration subjects will receive the appropriate study  agent devices for dosing until the next 
dosing visit as well as supplies and instructions on handling and storage before and after usage. 
Subjects/caregivers will enter information including date and time of dosing, device used, 
anatomic site injected, and person administering dose into their paper diary . Subjects/caregivers 
will be asked to closely monitor the study  agent injectio n site for at least 30minutes and 
intermittently  thereafter. During self-administration, subjects/caregivers are to contact [CONTACT_10748] -site team in the event of problems or complication including but not limited to signs of 
immediate or delay ed local or sy stemic reaction (Section 9.9). These dose administrations should 
occur ± 3 day  of target dosing day  as detailed above.
For subjects/caregivers unwil ling or unable to administer the injection, subjects/caregivers are to 
work with the site team to develop a visit schedule to meet the dosing criteria in Section 9.1.[ADDRESS_507399] 
±3days of the target dosing day except for OL Weeks 0 and 2 .
[IP_ADDRESS]. Post -Treatment Visit
The last dose of study agent is to be administered at the Week 50. A post-treatment visit will be 
conducted for all subjects at OL Week 60or10weeks after the last dose of study  agent to collect 
SAEs and AEs of interest since the last visit unless the subject has died, has been lost to 
follow -up, or has withdrawn consent. If astudy  visit is not possible, follow -up information may 
be collected via email or other electronic means.
9.1.6. All Study Visits -Early Dete ction o f Active Tuberculosis
To aid in the early  detection of TB reactivation or new TB infection during study  participation, 
subjects must be evaluated for signs and symptoms of active TB at scheduled visits (refer tothe
Time and Events Schedule ). The following series of questions is suggested for use during the 
evaluation and should be addressed at all study  visits:
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
67
Approved , Date: [ADDRESS_507400] 2019“Have you/Has your child had a new cough of >14 days’ duration or a change in a chronic 
cough?”
“Have you/Hasyour child had an y of the following s ymptoms:
Persistent fever?
Unintentional weight loss?
Night sweats?”
“Have you/Has your child had close contact [CONTACT_41022]?” (If there is 
uncertaint y as to whether a contact [CONTACT_41023] “close,” a physician specializing in 
TB should be consulted.)
If the evaluation raises suspi[INVESTIGATOR_40958] a subject may have TB reactivation or new TB infection, 
an immediate and thorough investigation should be undertaken, including, where possible, 
consultation with a phy sician specializing in TB.
Investigators should be aware that TB reactivation in immunocompromised subjects ma y present 
as disseminated disease or with extrapulmonary  features. Subjects with evidence of active TB 
should be referred for appropriate treatment.
Subjects who experience close contact [CONTACT_402558] a chest radiograph, a repeat QuantiFERON -TB Gold testand, if possible, 
referral to a physician specializing in TB to determine the subject’s risk of developi[INVESTIGATOR_402501] . Study  agent administration should be 
interrupted during the investigation . If the QuantiFERON -TB Gold test result is indeterminate, 
the test should be repeated as outlined in Section 9.1.2 and Section [IP_ADDRESS] . Subjects should be 
encouraged to return for all subsequent scheduled study  visits according to the protocol .
9.2. Study Endpoints and Evaluations
9.2.1. Efficacy  Evaluations
The following efficacy  evaluations will be assessed:
A 4-hour MMTT will be performed to assess C-peptide levels and the C-peptide AUC at 
screening andWeeks 12, 26, 38, 52, 78, and 104. For additional details, see the Time and 
Events Schedule .
Blood glucose levels between visits will be obtained by [CONTACT_402531] -glucometer 
readings.
Hemoglobin A1c (as % HbA1c) and insulin as U/kg body  weight/day . An HbA1c 
measurement will be done at each study  visit and subjects should record the type and 
amount of insulin they  have used during the 7-day period immediatel y preceding each study  
visit.
Hypoglycemic events, define d as a BG level of ≤70 mg/dL  or clinical sequelae consistent 
with hy poglycemia without a BG reading, will be documented throughout the study.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
68
Approved , Date: [ADDRESS_507401] 2019Records of glucose measurements, insulin use and hy poglycemic events and communication 
with the subject will be kept in source documentation, on the appropriate CRF, or in the 
patient diary .
[IP_ADDRESS]. Efficacy  Evaluations -Open -Label Extension Period
A 4-hour MMTT will be performed to assess C -peptide levels and the C -peptide AUC at OL  
screening (unless performed <3 months ago), OL Week 28,and OL Week 52. For 
C-responders who are lacking thenecessary  information to calculate IDAA1c score, an 
HbA1 cwill be performed and 10 days of insulin dose information will be required. For 
additional details, see the Time and Events Schedule .
During the open -label extension period, subjects may use either fingersticks or continuous 
glucose monitoring (CGM) at thediscretion of the investigator and/or according to local 
practice. The subjects will no t be required to download BG values from the eDiary .
Hemoglobin A1c (as % HbA1c) and insulin as U/kg body  weight/day . An HbA1c 
measurement will be done at each study  visit and subjects should record the type and 
amount of insulin they  have used during the 10-day perio d.
Hypoglycemic events, defined as a BGlevel of ≤70 mg/dL  or clinical sequelae consistent 
with hy poglycemia without a BG reading, will be documented throughout the study.
Records of glucose measurements , insulin use and hy poglycemic events and communication 
with the subject will be kept in source documentation, on the appropriate CRF, or in the 
patient diary . 
9.2.2. Efficacy  Endpoints
[IP_ADDRESS]. Primary
The primary  endpoint is the MMTT -stimulated 4 -hour C -peptide AUC at Week52.
[IP_ADDRESS]. Major S econdary
Change from baseline in insulin use in units per k ilogram bod y weight per day  at Week 52.
Change from baseline in HbA1c at Week 52.
Hypoglycemic event rates (defined as BG levels of ≤70, 55, and 35mg/dL or clinical 
sequelae consistent with severe hypoglycemia in the absence of a BG reading) through 
Week 52.
[IP_ADDRESS]. Other Endpoints
Change from baseline in MMTT -stimulated 4 -hour C -peptide AUC over time.
Change from baseline in comparative MMTT -stimulated 2 -hour C -peptide AUC over time.
Change from baseline in MMTT -stimulated C-peptide over time.
Change from baseline in insulin use in units per kilogram bod y weight per day  over time.
The proportion sof subjects with hypoglycemia from baseline to Week 104, from baseline to 
Week 52 and from Week 52to Week 104.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
69
Approved , Date: [ADDRESS_507402] 2019The event ratesof hypoglycemia from baseline to Week 104 and from Week52 through 
Week 104.
Change from baseline in HbA1c levels over time.
Proportion of subjects with peak MMTT -stimulated C -peptide ≥0.2 pmol/mL over time.
Time to peak MMTT -stimulated C -peptide < 0.2 pmol/mL .
[IP_ADDRESS]. Exploratory  Efficacy  Endpoints – Open -Label Extension Period
All the efficacy  endpoints defined for the double -blind period will be exploratory  for the open -
label extension period and will be summarized descriptively . Disease progression will be 
compared between the double -blind period and the extension period in subjects who attended the 
open -label extension period if deemed reasonable.
9.2.3. Safety  Endpoints
Proportion of subjects with treatment -emergent AEs and severe AEs through Weeks 52and 
104.
Proportion of subjects with study  agent inject ionsite reactions through Week 52.
Proportion of subjects with severe infections through Week s 52 and 104.
[IP_ADDRESS]. Safety  Endpoints –Open -Label Extension Period
Proportion ofsubjects with treatment -emergent AEs and severe AEs through OL Weeks 52
and 60.
Proportion of subjects with study  agent injection site reactions through OL Week 52.
Proportion of subjects with severe infections through OL Weeks 52 and 60.
9.2.4. Exploratory Endpoints
[IP_ADDRESS]. Mechanistic


[IP_ADDRESS]. Metabolic



SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
70
Approved , Date: [ADDRESS_507403] [ZIP_CODE].3. Clinical P harmacology
9.3.1. Evaluations
Serum sample s will be used to evaluate the PK ,the immunogenicit y of golimumab (antibodies to 
golimumab) , and pharmacod ynamics (PD; free/t otal TNF α). Sera collected may additionall y be 
used to evaluate biomarkers for safety  or efficacy  aspects to address concerns that may arise 
during or after the study . Subject confidentiality  will be maintained . Sera for the measurement of 
golimumab concentration ,antibodies to golimumab , and free/total TNF αwill be derived from 
the same blood draw.
Instructions for the collection, handling , and shipment of these samples are found in the 
Laboratory  Reference Manual provided b y the s ponsor.
9.3.2. Analytical Procedures
Pharmacokinetics
Serum samples will be analyzed to determine concentrations of golimumab using a validated, 
specific, and sensitive method by  [CONTACT_43754].
Immunogenicity
The detection and characterization of antibodies to golimumab will be performed using a 
validated assay  method by [CONTACT_43754]. All samples collected for 
detecti on of antibodies to golimumab will also be evaluated for golimumab serum concentration 
to enable interpretation of the antibody  data.
Pharmacodynamics
Serum samples will be analyzed to determine concentrations of free and total TNFα (sample 
volume perm itting) using a qualified method by  [CONTACT_43754].
9.3.3. Pharmacokinetic Parameters
Serum golimumab concentrations will beevaluated and summarized over time for the specified 
visits as indicated in the Time and Events Schedule .
A population PK analysis with data through Week 52 may beperformed to characterize the PK 
of golimumab as well as to identify  and quantify important covariates of PK (eg, body  weight, 
sexand immunogenicity ) in subjects with T1D, if necessary . Apparent clearance (CL/F) and 
volume of distribution (Vd/F) will be estimated using a nonlinear mixed effects modeling 
(NONMEM) approach.
9.3.4. Immunogenicity  Assessments (Antibodies to Golimumab)
Antibodies to golimumab will be evaluated in serum samples collected from all subjects 
according to the Time and Events Schedule . Additionally , serum samples should also be 
collected at the final visit from subjec ts who are discontinued from treatment or withdrawn from 
the study . These samples will be tested by  [CONTACT_4209]'s designee.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
71
Approved , Date: [ADDRESS_507404] 2019Serum samples will be screened for antibodies binding to golimumab and the titer of confirmed 
positive samples will be reported. For subjects positive for antibodies to golimumab, the positive 
samples will be evaluated for neutralizing antibodies. Other analysesmay be performed to more 
fully  characterize the immunogenicit y of golimumab in this population .
The incidence of antibodies to golimumab during the study  will be determined.
9.3.5. Clinical Pharmacology –Open -Label Extension Period
The same procedures explained inSections 9.3.[ADDRESS_507405] general and T1D-specific immune and 
metabolic responses. Specificall y, serum and cell-based biomarkers will be evaluated for 
inflammation -associ ated proteins, changes in immune cell subsets, and will be used to better 
understand the biology  of T1D, to provide a biological assessment of the response of subjects to 
treatment with golimumab, to analy ze differences between responders and nonresponders , and to 
determine if the markers can be used to classify  patients as potential responders prior to 
treatment. It is important to note that these evaluations will be exploratory in nature as there are 
no validated measures to interrogate these areas .These studies may help to explain 
inter-individual variability in clinical outcomes or may help to identify  population subgroups in 
this study  that respond preferentiall y togolimumab (see Section 9.2), and thus characteristics of 
those with T1D who might benefit the most from golimumab therap y in the future.
Immune assess ments may include but are not limited tomonitoring T-cell profiles (including 
changes in specific subty pes such as activa ted, effector, and regulatory  T cells) and Bcell 
profiles by [CONTACT_4133] .61In addition ,serum levels of circulating pro-and anti-inflammatory 
cytokines, non-specific markers of inflammation (ie, C-reactive protein), and changes in T1D 
autoantibody  profiles may be assessed .
Metabolic assessments may include innovative assessments of β-cell stress and death, which are 
anticipated to include pro-insulin: C-peptide ratios and serum levels of circulating 
methy lated -insulin DNA, (see Section 9.5, Pharmacogenomic [DNA] Evaluations ).1,63,[ADDRESS_507406] a number of these assessments ,samples will be obtained 
and banked for later batch anal ysis.
9.4.1. Biomarkers –Open -Label Extension Period
The same procedure as explained in Section 9.4will be followed for the open -label extension 
period.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
72
Approved , Date: [ADDRESS_507407] [ZIP_CODE].5. Pharmacogenomic (DNA ) Evaluations
In addition to immune and metabolic factors that may  be affected by [CONTACT_402559], as discussed above it is recogniz ed that genetic variation can be an 
important contributory  factor to inter -individual differences in drug distribution and response and 
can also serve as a marker for disease susceptibility, prognosis, and response to therap y.
Required Pharmacogenomic (DNA) Assessments : An individual’s MHC haploty pe gives insight 
to interactions of distinct types of lymphocy testhat may cause T1D and may help to identify  
those who are at risk of developi[INVESTIGATOR_007] T1D.6,8Genetic assessments of MHC haploty pes, may help 
to explain inter-individual variability  in clinical outcomes and may help to identify  subgroups 
that respond preferentially  to golimumab . Agreeing to participate in this assessment is required
for this study .
Optional Exploratory Pharmacogenomic (DNA) Assessments : Pharmacogenomic research may 
consist of the analysis of one or more genetic markers throughout the genome in relation to 
golimumab or T1D clinical endpoints. One goal of this study  to use genetic markers, such as but 
not limited to the methy lation status of insulin DNA, obtained from serum to assist in the 
identification of individuals with T1D who may preferentiall y respond to golimumab and better 
understand the magnitude and mechanism of this response. DNA samples will be used for 
research related to golimumab or T1D. They  may also be used to develop tests/assay s related to 
golimumab and or other immune modulators and improved understanding of T1D or other 
immune -mediated diseases. Subjects participating in this portion of the study  must sign a 
separate pharmacogenetics informed consent /assent and opt-in for exploratory  pharmacogenetics 
research . Further, a subject may  withdraw such consent /asse ntat any time without affecting their 
participation in other aspects of the study , or their future participation in the study .
9.5.1. Pharmacogenomic (DNA ) Evaluations –Open -Label Extension Period
Pharmacogenomic assessment of molecular MHC haploty pe and insuli n DNA methy lation will 
not be performed for the open -label extension period. The open -label extension period will 
include PBMC sample collection and serum biomarker sample collection.
9.6. Safety  Evaluations
There will be thorough monitoring and evaluation of subjects in this study focusing onstudy 
agent , device -related, and disease -related safet y issues.
Study Agent Related:
Safety  evaluation will include regular monitoring for clinicall y-related AEs, and in addition, 
monitoring of clinical laboratory  changes (ie, hematological and serum chemistry  panel), and
active monitoring of early  detection of active tuberculosis Monitoring of CMV and EBV viral 
load will be done to detect if there is any  study  agent effect on primary  immune response to these 
infections that often take place during childhood and adolescence or impact reactivation of these 
virus in those who have been infected previously .
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
73
Approved , Date: [ADDRESS_507408] 2019Device -related:
Device -related AEs, for the PFS-Uand theVarioJect, will be collected. Device -related issues 
may include those that lead to a missed dose, overdose, underdose, application -site bruise, 
injection site pain, accidental exposure to product, or needle -stick injury  issue, for example.
Disease -related: Hypoglycemia
As indicated elsewhere, subjects , and when applicable their caregiver s, must agree to follow the 
current recommendations of tight glycemic control as defined by [CONTACT_30158] . In order to achieve 
these goals, this may require enhanced BGmonitoring and greater amounts and frequency  of 
insulin administration and may  have the unintended side effects of h ypoglycemia.
Hypoglycemia may have severe sequela eincluding loss of consciousness, coma or death. 
Subjects and their caregiver s must work with local PIs and their primary  care physicians to 
determine an approach that is best, and most safel y, allows subjects to target their specific 
HbA1c goal.
Any BG levels ≤70mg/dL from the glucometer captured in the eDiary  will prompt 
subjects/ caregiver sdocument signs and symptoms consistent with hypoglycemia at the time of 
(possible) hypoglycemic epi[INVESTIGATOR_1841], interventions administered ,and levels of assistance required 
by [CONTACT_423]. In addition, subjects/caregivers are to document any instances of suspe cted 
(clinical) h ypogl ycemia in the eDiary  even in the absence of a confirmatory  BGreading .
Serious adverse event reports will be provided to the DMC members on an ongoing basis. The 
DMC will have access to unblinded data and review tabulated safet y summa ries (if appropriate) 
and any additional data that the DMC may request during the conduct of the study . No formal 
statistical hypothesis testing is planned. In additi on, during the study , the sponsor's Study 
Responsible Physician (or designee) will regularl y review blinded safet y data from the sites and 
notify  the DMC and appropriate sponsor personnel of any issues. The remit of the DMC and the 
roles and responsibilities of the members will be described in a separate DMC c harter.
Details regarding the Independent DMC are provided in Section 11.[ADDRESS_507409] be 
recorded on the Adverse Event section of the CRF.
Any clinically  significant abnormalities persisting at the end of the study/earl y withdrawal will 
be followed b y the investigator until resolution or until a clinically  stable endpo int is reached.
The study  will include the following evaluations of safet y and tolerability  according to the 
timepoints provided in the Time and Events Schedule :
Adverse Events
Adverse events will be reported by [CONTACT_24362] (or, when appropriate, by a caregiver, surrogate, 
or the subject's legall yacceptable representative) for the duration of the study . Adverse events 
will be followed by  [CONTACT_23803] 12, Adverse Event Reporting.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
74
Approved , Date: [ADDRESS_507410] 
be filed with the source documents.
The following tests will be performed by a Central L aboratory :
Hematology  Panel
-hemoglobin -white blood cell (WBC) count with differential
-hematocrit -platelet count
Serum Chemistry Panel
-sodium -calcium
-potassium -phosphate
-chloride -albumin
-bicarbonate -total protein
-blood urea nitrogen (BUN) -total and direct bilirubin
-creatinine -aspartate aminotransferase (AST)
-glucose -alanine aminotransferase (ALT)
-alkaline phosphatase
Additional Laboratory Tests
-HbA1c
-Type 1 diabetes antibodies (anti-insulin, anti -GAD -65, ICA, anti -ZnT8, anti -IA2)
-C-peptide
-insulin
-pro-insulin
-C-reactive protein
-CD4 T -cell count
-CD8 T -cell count
-HIV antibod y-only at screening
-hepatitis B antibod y/antigen panel -only at screening
-hepatitis C virus antibody -only at screening
-CMV and EBV DNA PCR
-MHC haploty pe–only atWeek 0 (randomization)
-Lipi[INVESTIGATOR_805] (cholesterol, HDL, LDL, Trigl ycerides) –Only  done at fasting visits: screening, 
Week 12, 26, 38, 52, 78 and 104 .
-Coagulation pane l(PT/PTT/ INR)-only at screening
-Serum pregnancy  testing -only at screening (for females of childbearing potential)
The following test will be performed at the study site:
Urine pregnancy  testing (for females of childbearing potential)
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
75
Approved , Date: [ADDRESS_507411] 2019During the study , all abnormal laboratory  values will require further explanation from the 
investigator. Clinically  significant abnormal laboratory  values should be repeated until they 
return to normal or are otherwise explained b y the investigator.
Clinical Assessments:
Vital Signs (oral ortympanic temperature, pulse/heart rate, respi [INVESTIGATOR_697], blood 
pressure )
Blood pressure and pulse/ heart rate measurements canbe assessed with a completely  automated 
device. Manual techniques will be used if an automated device is not available. Blood pressure 
and pulse/heart rate measurements should be preceded by [CONTACT_2669] [ADDRESS_507412] in a quiet 
setting without distractions (eg, television, cell phones).
Physical Examination
Physical examinations (PE; full orbrief) sometimes including height and body  weight will be 
conducted at times ind icated in the Time and Events Schedule .
A full physical exam includes an evaluation of general appearance, head, eyes, ears,nose,and 
throat evaluation, neck palpation for thyroid, lymphadenopathy and tenderness, auscultation of 
the heart, lungs and abdomen, palpation of abdomen, external evaluation of genitalia with Tanner 
Staging , evaluation of extremities and skin, and gross neurologic evaluation of strength, 
sensation and balance.
A brief physical examination includes general appearance, head, eyes, and throat evaluation, 
neck palpation for thy roid, ly mphadenopathy  and tenderness, auscultation of the heart, lungs and 
abdomen, palpation of abdomen, evaluation of extremities and skin.
Any clinical ly relevant finding or change in physical exam occurring during the study  must be 
recorded on the Adverse Event section of the CRF.
Weight will be measured using a calibrated scale at each weight measurement and subjects will 
be instructed to remove shoes and outdoor apparel and gear.
9.6.1. Safety  Evaluations –Open -Label Extension Period
There will be thorough monitoring and evaluation of subjects in this study  focusing on study 
agent, device -related, and disease -related safet y issues.
Study Agent Related (Open -Label Extension Period) :
Safety  evaluation will include regular monitoring for clinicall y-related AEs, and in addition, 
monitoring of clinical laboratory  changes (ie, hematological and serum chemistry  panel), and 
active monitoring of early  detection of active tuberculosis Monitoring of CMV and EBV viral 
load will be done to detect if there is any  study  agent effect on primary  immune response to these 
infections that often take place during childhood and adolescence or impact reactivation of these 
virus in t hose who have been infected previously .
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
76
Approved , Date: [ADDRESS_507413] 2019Device -related (Open -Label Extension Period) :
Device -related AEs, for the PFS-U and the VarioJect, will be collected. Device -related issues 
may include those that lead to a missed dose, overdose, underdose, applicati on-site bruise, 
injection site pain, accidental exposure to product, or needle -stick injury  issue, for example.
Disease -related: Hypoglycemia (Open -Label Extension Period)
As indicated elsewhere, subjects , and when applicable their caregiver s, must agree to follow the 
current recommendations of tight glycemic control as define dby [CONTACT_402560]. In order to achieve 
these goals, this may require enhanced BGmonitoring and greater amounts and frequency  of 
insulin administration and may  have the unint ended side effects of h ypoglycemia.
Hypoglycemia may have severe sequela eincluding loss of consciousness, coma or death. 
Subjects and their caregiver s must work with local PIs and their primary  care physicians to 
determine an approach that is best, and most safel y, allows subjects to target their specific 
HbA1c goal.
Any BGlevels ≤70mg/dL from the glucometer will prompt subjects/caregivers document signs 
and symptoms consistent with hypoglycemia at the time of (possible) hypogl ycemic epi[INVESTIGATOR_1841], 
interventi ons administered, and levels of assistance required by [CONTACT_423]. In addition, 
subjects/caregivers are to document any instances of suspected (clinical) hypoglycemia in the 
paper diary  even in the absence of a confirmatory  BGreading.
Serious adverse eventreports will be provided to the DMC members on an ongoing basis. The 
DMC will have access to unblinded data and review tabulated safet y summaries (if appropriate) 
and any additional data that the DMC may request during the conduct of the study . No forma l 
statistical hypothesis testing is planned. In additi on, during the study , the sponsor's Study 
Responsible Physician (or designee) will regularl y review blinded safet y data from the sites and 
notify  the DMC and appropriate sponsor personnel of any issues. The remit of the DMC and the 
roles and responsibilities of the members will be described in a separate DMC charter.
Details regarding the Independent DMC are provided in Section 11.[ADDRESS_507414] be 
recorded on the Adverse Event section of the CRF.
Any clinically  significant abnormalities persisting at the end of the study/earl y withdrawal will 
be followed b y the investigator until resolution or until a clinically  stable endpoint is reached.
The study  will include the following evaluations of safet y and tolerability  according to the 
timepoints provided in the Time and Events Schedule :
Adverse Events (Open -Label Extension Period)
Adverse events will be reported by [CONTACT_423] (or, when appropriate, by a caregiver, surrogate, 
or the subject's legall y acceptable representative) for the duration of the study . Adverse events 
will be followed by  [CONTACT_23803] 12, Adverse Event Reporting.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
77
Approved , Date: [ADDRESS_507415] 2019Clinical Labora tory Tests (Open -Label Extension Period)
Blood samples for serum chemistry  and hematology  will be collected. The investigator must 
review the laboratory  results, document this review, and record any clinically  relevant changes 
occurring during the study  inthe adverse event section of the CRF. The laboratory  reports must 
be filed with the source documents.
The following tests will be performed by a Central L aboratory:
Hematology  Panel
-hemoglobin -white blood cell (WBC) count with differential
-hematocrit -platelet count
Serum Chemistry Panel
-sodium -calcium
-potassium -phosphate
-chloride -albumin
-bicarbonate -total protein
-blood urea nitrogen (BUN) -total and direct bilirubin
-creatinine -aspartate aminotransferase (AST)
-glucose -alanine aminotransferase (ALT)
-alkaline phosphatase
Additional Laboratory Tests (Open -Label Extension Period)
-HbA1c
-C-peptide
-insulin
-pro-insulin
-C-reactive protein
-CD4 T -cell count
-CD8 T -cell count
-HIV antibod y -only at screening
-hepatitis B antibody /antigen panel -only at screening
-hepatitis C virus antibody  -only at screening
-CMV and EBV DNA PCR
-Lipi[INVESTIGATOR_805] (cholesterol, HDL, LDL, Trigl ycerides) will not be measured during the open -label 
extension period.
-Coagulation panel (PT/PTT/I NR) -only at screening
-Serum pregnancy  testing -only at screening (for females of childbearing potential)
The following test will be performed at the study site:
Urine pregnancy  testing (for females of childbearing potential)
During the study , all abnormal laboratory  values will require further explanation from the 
investigator. Clinically  significant abnormal laboratory  values should be repeated until they 
return to normal or are otherwise explained b y the investigator.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
78
Approved , Date: [ADDRESS_507416] 2019Clinical Assessments (Open -Label Extension Period) :
Vital Signs (oral or tympanic temperature, pulse/heart rate, respi[INVESTIGATOR_697], blood 
pressure)
Blood pressure and pulse/heart rate measurements can be assessed with a completely  automated 
device. Manual techniques will be used if an automated device is not available. Blood pressure 
and pulse/heart rate measurements should be preceded by [CONTACT_2669] [ADDRESS_507417] in a quiet 
setting without distractions (eg, television, cell phones).
Physical Examination (Open -Label Extension Period)
Physical examinations (PE; full or brief) sometimes including height and body  weight will be 
conducted at times indicated in the Time and Events Schedule .
A full physical exam includes an evaluation of general appearance, head, eyes, ears,nose,and 
throat evaluation, neck palpation for thyroid, lymphadenopathy  and tenderness, auscultation of 
the heart, lungs and abdomen, palpation of abdomen, external evaluation of genitalia w ith Tanner 
Staging, evaluation of extremities and skin, and gross neurologic evaluation of strength, 
sensation and balance.
A brief physical examination includes general appearance, head, eyes, and throat evaluation, 
neck palpation for thy roid, ly mphadenop athy and tenderness, auscultation of the heart, lungs and 
abdomen, palpation of abdomen, evaluation of extremities and skin.
Any clinicall y relevant finding or change in physical exam occurring during the study  must be 
recorded on the Adverse Event section of the CRF.
Weight will be measured using a calibrated scale at each weight measurement and subjects will 
be instructed to remove shoes and outdoor apparel and gear.
9.7. Sample Collection and Handling
The actual dates and times of sample collection must be recorded in the CRF or laboratory 
requisition form.
Refer to the Time and Events Schedule for the timing and frequency  of all sample collections.
For visits with study  agent administration, all blood samples for asses sing golimumab 
concentration and antibodies to golimumab must be collected before the administration of the 
study  agent.
Instructions for the collection, handling, storage, and shipment of samples are found in the 
laboratory  manual that will be provided. Collection, handling, storage, and shipment of samples 
must be under the specified, and where applicable, controlled temperature conditions as indicated 
in the laboratory  manual.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
79
Approved , Date: [ADDRESS_507418] [ZIP_CODE].8. Data to be Collected by  [CONTACT_402561]/caregivers will obtain and record a number of pi[INVESTIGATOR_402502]. The data will be collected using an eDiary  that will be 
supplied by [CONTACT_402562]/caregiver during the screening visit. Training on devices 
and what data is to be collected will be conducted by [CONTACT_3449]-site staff at that visit, and at 
subsequent visits as needed. All data recorded in the eDiaries will be reviewed by [CONTACT_402563]. For the open -label extension period, paper diaries instead of eDiaries will be 
provided.
Exogenous insulin administration .Subjects/caregiver are to record the type and amount of 
insulin they have used during the 7-day period immediately  preceding each study  visit (see 
the Time and Events Schedule ). This data will be used to calculate exogenous insulin use in 
units/kg/day .During the open -label extension period, subjects will be required to record 
10days of insulin use prior to each visit.
Hypoglycemic events. Subjects/caregiver s are to record information surrounding all BG
measure measurement that are ≤70mg/mL or of suspected hypoglycemia due to clinical 
symptomatology . Data including BGlevel, clinical symptoms (including but not limited to 
change in mental status or loss of consciousness ), length of the event, therapi[INVESTIGATOR_402503], and if assistance or medical care (including clinic, emergency  room or 
hospi[INVESTIGATOR_059]) was required for the event.
Study agent dosing . For subjects/caregivers participating in self-administration they are to 
record study  agent administration date, time,and anatomic location of the injection, person 
administering study  agent, and if there are any complications associated with study  agent 
administration .
Glucometer readings .
Screening –Double -blind Week 104: Subjects/caregivers will be given a 
sponso r-supplied glucometer and supplies to self-monitor BGlevels during the study . 
Subjects/caregivers may notuse their own glucometers. Blood glucose readings should 
take place at least 4 times a day, ie, premeal and at bedtime, as needed and at any time 
of suspected hypoglycemia. Blood glucose readings from the provided glucometers will 
be electronical ly transmitted to the eDiaries provided or when BGlevels ≤70mg/mL 
during the double -blind pe riod (Weeks 0 to 104).
Open -label Week s0to 52: During this phase, subjects may use either fingersticks or 
continuous glucose monitoring (CGM ) at the discretion of the investigator and/or 
according to local practice .The subjects will not be required to download BG values 
from the eDiary .
9.9. Injection Site Reaction Monitoring
Injection reactions or allergic reactions have been observed with administration of monoclonal 
antibodies. Mild to serious local and systemic reactions (including anaph ylaxis) may  occur at any  
time during the administration of study  agent.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
80
Approved , Date: [ADDRESS_507419] should be treated at the 
investigator’s discretion. Any adverse reaction (eg, swelling, induration, redness/ery thema, 
pain/tenderness, warmth, bruising or bleeding) should be recorded on the AE page of the CRF. 
The ty pe of reaction should also be indicated.
Delayed Injection Site, Allergic, and Hypersensitivity Reactions
Reactions following study  agent administrati on may occur 1 to 21 days after study  agent
injection and presentation can be variable , and can, for example include myalgia and/or 
arthralgia with fever and/or rash. In some cases, these may be accompanied by [CONTACT_402564], localized or systemic edema, dysphagia, urticari a, sore throat, and/or 
headache . Any and all such adverse reaction sshould be recorded on the AE page of the CRF. 
The ty pe of reaction should also be indicated.
Self-Assessment
In addition to recording the details of the study  agent dosing day, time, anatomic site and if there 
were any complications of the injection, subjects and/or caregivers should be instructed to
monitor the injection site for any reactions, including, but not limited to swelling, 
rednes s/ery thema, pain, tenderness, warmth, bruising , or bleeding . For severe injection site 
reactions or changes at the injection site hours to days following injection, the subject/caregiver 
should contact [CONTACT_402565].
10. SUBJECT COMPLETION/ DISCONTINUA TION OF STU DY TREATMENT/ 
WITHDRA WALFROM THE STUDY
10.1. Completion
A subject will be considered to have completed the study  if he or she has completed assessments 
at Week 104of the off-therapy  follow -up period or Week [ADDRESS_507420] completed the study .Subjects are able to initiate the 
prohibited medicines and ac tivities per the guidance provided in Section 4.3and Section 8.3.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
81
Approved , Date: [ADDRESS_507421] 201910.2. Discontinuation of Study Treatment /Withdrawal from the Study
Discontinuation of Study Treatment
A subject will notbe automatically  withdrawn from the study  if they have to temporarily  or 
permanentl y discontinue treatment before the end of the treatment regimen.
If a subject permanently  discontinues study  treatment for any reason before the end of the 
treatment phase (Week 52), they should be encouraged to continue with all scheduled visitsto 
and including the final study  visit (Week 104), but without receiving study agent administration. 
If unwilling or unable to participate in all visits, subjects should be encourag ed to participate in 
as many  of the planned study  visits as possible for continued assessment, but without receiving 
study  agent administration. If the subject is not able to participate in the next 2sequential study  
visits that include an MMTT, they  shou ld be encouraged to return fo r the End of Study  visits (per 
the Time and Events Tables) approximately  [ADDRESS_507422] withdraws following the treatment period (after Week 52) they should be 
encourage d to participate in the Week [ADDRESS_507423] is 
unwilling or unable to complete any of the remaining scheduled study  visits, they should be 
encouraged to return for the End of Study visit (per Time and Events Schedule )approximately 
[ADDRESS_507424] dose administration, as applicable.
Following randomization (ie, between Week 0 and Week 104), consecutive MMTT sshould not 
be repeated if the time interval between them is less than 10weeks. The MMTT can be repeated 
in less than [ADDRESS_507425] study  agent dose (Section 12.4.1 ).
Subjects who permanently  discontinue active treatment during the open -label extension period 
will have their end -of-study  visit followed b y the post-treatment visit 10weeks later .
Study treatment may be temporarily or permanently discontinued due to events described 
below.
Events That Result in Permanen t Discontinuation of Study  Treatment .
The investigator believes that for safet y reasons or tolerability  reasons it is in the best 
interest of the subject to discontinue study  treatment .
The subject becomes pregnant .
The subject has asevere infection requiring inpatient hospi[INVESTIGATOR_402504].
The subject has a severe hypersensitivity  reaction, such as anaphy laxis or angioedema, 
to the study  agent.
The subject has a clinically  significant cardiovascular event.
The subject is deemed ineligible according to the following TB screening criteria:
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
82
Approved , Date: [ADDRESS_507426] has symptoms suggestive of active TB based on follow -up assessment 
questions and/or physical examination, or has had recent close contact [CONTACT_4490] a 
person with active TB, and cannot or will not continue to undergo additional 
evaluation.
oA subject undergoing evaluation has a chest radiograph with evidence of current 
active TB and/or a positive QuantiFERON -TB Gold test result and/or an 
indeterminate QuantiFERON -TB Gold test result on repeat testing (see
Section 9.1.2 and Section [IP_ADDRESS] ).
The subject misses 3 consecutive study  agent administrations .
A general lack of compliance with study  visits and procedures per study  team or 
sponsor.
One confirmed epi[INVESTIGATOR_402505]/or AST >3x upper limit of normal (ULN) as 
defined in Attachment 5. If a subject has an ALT or AST value of >3x ULN, the next 
dose of study  agent administration should be held pending repeat confirmatory  testing 
which is to take place as soon as possible and preferably  within 72 hours. If the value is 
still >3xULN then the subject is to permanently discontinue study treatment. If the 
repeat value is <2xULN then dosing may proceed . If the repeat value is ≥2xULN) and 
≤3xULN, follow guidelines in the next section.
The subject meets criteria for permanent study  agent discontinuatio n based on 
AST/AL T elevations , AEs, or infections in the next subsection below (Events Resulting 
In Temporary  and Potentially  Permanent Discontinuation of Study  Agent) .
Events Resulting in Temporary and Potentially  Permanent Discontinuation of Study  
Treatment .
An ALTand/or AST elevation ≥2 x the upper limit of normal (ULN) and ≤3x ULN (as
defined in exclusion criteria in Section 4.2.1 andAttachment 5 ).
Repeat AST and ALT as soon as possible but prefe rably within 72hours of receipt of the 
confirmed results. If one or both are ≥[ADDRESS_507427] and ≤3x UL N then:
Suspend administration of study  treatment and recheck the subject within 72hours and at 
least w eekly as needed thereafter.
If AST and ALT are <2x ULN on repeat testing, resume dosing at the next expected 
interval.
If AST and ALT are not <2x UL N by 4 weeks, permanently discontinue study treatment.
Note: Three independent temporary  suspensions from study treatment due to transient 
elevations in ALT and/or AST ≥2x but ≤3x ULN is allowed during the entire treatment 
period. If a third elevation occurs that requires a dose to be held, permanently  discontinue 
study  treatment.
A Significant Infection.
Define d as:
1.Any severe infection meeting SAE criteria as defined in Section 12, or
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
83
Approved , Date: [ADDRESS_507428] [ZIP_CODE].Any infection not meeting SAE criteria but otherwise clinically  significant per 
investigator’s judgment, or
3.Infection or reactivation of EBV or CMV as defined by [CONTACT_402566]; 
or if the EBV viral load is ≥10,000 copi[INVESTIGATOR_402506] 
≥10,000 copi[INVESTIGATOR_402507].
Suspend administration of study  treatment and recheck any abnormal laboratory  values as 
soon as possible and preferabl y within 72 hours.
Mon itor the subject and abnormal labs at least weekly .
If the AE resolves or reduces to mild or less, dosing may resume at the next expected 
interval.
If the AE does not resolve in 4 weeks, permanently  discontinue study  treatment.
A Serious Adverse Event or S tudy Agent -related Severe Adverse Event.
Defined as:
1.Any SAE (as defined in Section 12.1.1 ) or
2.Any severe AE that is considered related (possibly , probably , or very  likely  related) 
to study  agent (as defined in Section 12.1.2 ).
With theexception of:
When clinical and laboratory  abnormalities are considered related to T1D disease activity  
(ie, hypogly cemia and hypergl ycemia) and study  treatment is not considered a 
contributin g factor, administration may not need to be modified. The site investigator 
should consult with the sponsor if this is encountered.
Suspend administration of study  treatm ent and recheck the subject at least weekl y; if based 
on abnormal laboratory  values, r epeat abnormal laboratory  values as soon as possible within 
72hours.
If the AE resolves or reduces to a moderate AE (Section 12.1.2 ) or less, dosin g may resume 
at the next expected interval.
If the AE does not resolve to a moderate AE or less (Section 12.1.2 ) in 4weeks, discontinue 
study treatment permanently .
Note: If there are more than [ADDRESS_507429] will be withdrawn from the stud y for any of the following reasons:
Lost to follow -up.
Withdrawal of consent /assent .
Death .
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
84
Approved , Date: [ADDRESS_507430] 2019The study investigator or sponsor, for any reason, decides the subject should be withdrawn 
from the study .
If a subject is lost to follow -up, every  reasonable effort must be made by  [CONTACT_1758] -site personnel 
to contact [CONTACT_23814]/withdrawal. The measures 
taken to follow -up must be documented.
When a subject withdraws before completing the study , the sponsor and the DMC chair is to be 
notified and the reason for withdrawal is to be documented in the CRF and in the source 
document. Study  agent assigned to the withdrawn subject may  not be assigned to another subject. 
Subjects who withdraw will notbe replaced. If a subject withdraws fro m the study  before the end 
of study, all attempts should be made to obtain End of Study assessments .
In addition to the above withdrawal criteria, C+R and R responders will be withdrawn if on 2 
consecutive occasions 2 months apart, the remission score is >9. The C responders will be 
discontinued if their remission score is increasing on [ADDRESS_507431] the following options regarding the optional
research sample s:
The collected sample swill be retained and used in accordance with the subject's original separate
informed consent /assent for optional research samples .
The subject may withdraw consent /assent for optional research samples , in which case the 
sample swill be destroyed ,and no further testing will take place. To initiate the sample 
destruction process, the investigator must notify  the sponsor study -site contact [CONTACT_67794] /assent for the optional research samples and to request sample destruction. The sponsor 
study -site contact [INVESTIGATOR_1318], in turn, contact [CONTACT_363129]. If requested, the investigator will receive written confirmation from the sponsor that 
the sample shave been destroy ed.
Withdrawal From the Optional Research Samples While Remaining In The Main Study
The subject may withdraw consent /assent for optional research samples while remaining in the 
study . In such a case, the optional research sample swill be destroy ed. The sample destruction 
process will proceed as described above.
Withdrawal From The Use Of Samples In Future Research
The subject may  withdraw consent /assent for use of samples for research (refer to Se ction 16.2.5 , 
Long -Term Retention of Samples for Additional Future Research). In such a case, samples will 
be destro yed after they are no longer needed for the clinical study . Details of the sample 
retention for researc h are presented in the main ICF .
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
85
Approved , Date: [ADDRESS_507432] 201911. STATISTICA L METHODS
Statistical analy sis will be done by [CONTACT_43758]. A general 
description of the statistical met hods to be used to anal yze the efficacy  and safet y data is outlined 
below. Specific details will be provided in the Statistical Analy sis Plan (SAP) .
Descriptive statistics (eg, mean, median, standard deviation [SD], minimum, and maximum) will 
be used to summarize continuous variables. Counts and percentages will be used to summarize 
categorical variables. Graphic data display s may  also be used to summarize the data.
Efficacy  analyses will be based on the modified intent -to-treat (mITT) population (ie, all 
randomized subjects who have received at least 1 dose of study  agent ). Subjects included in the 
efficacy  analyses will be summarized according to their assigned treatment group regardless of 
whether or not they  receive the assigned treatment.
Safet y analyses will include all subjects who received at least [ADDRESS_507433] baseline data, demographic, and baseline clinical disease characteristics will be 
summarized for all m ITT subjects.
11.2. Sample Size Determination
The sample size calculation is based on the primary  endpoint, an MMTT 4-hour C-peptide AUC 
at Week 52. Due to skewed C -peptide AUC data, normalizing transformation of log (AUC +1) is 
applied for sample size assessment. The method has been well accepted and used in numerous 
clinical studies25,26,42,57,60Based on published data, a common SD of log (AUC+1) of 0.215 is 
assumed, and the back -transformed means for 4-hour C-peptide AUC are assumed to be 
0.385 and 0.635 for the placebo and golimumab groups respectivel y, ie the expected treatment 
differ ence (back -transformed) is 0.25. With 81subjects (54 on golimumab and 27 on placebo) 
and an alpha of 0.05 (2-sided), there is 90% power to detect the treatment difference through a 
2-sample t -test.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
86
Approved , Date: [ADDRESS_507434] 1 dose of study  
agent. The primary  efficacy  endpoint will be analy zed by [CONTACT_402567] (MMRM ).
Primary Endpoi nts
The primary  endpoint is the MMTT -stimulat ed 4-hour C-peptide AUC at Week 52. To address 
the primary  objective of the study , the primary  endpoint will be analy zed by [CONTACT_2329] a MMRM 
based on restri cted maximum likelihood. The model will be based on a normalizing 
transformation of log(AUC+ 1). The analysis will use post-baseline log(AUC+1) data as the 
response variable and will include the fixed, categorical effects of gender, treatment, time, and
treatment -by-time interaction, as well as the continuous, fixed covariates of baseline and 
baseline -by-time interaction. An unstructured covariance will be used to model the within -patient 
errors. The treatment comparison at Week [ADDRESS_507435] square mean difference and 
the 2-sided 95% confidence interval will be estimated based on this model. Descriptive statistics 
and estimates from the above model will be presented on the back -transformed scale. 
Specificall y, the back -transformed mean is the geometric -like mean derived through exp(y )-1, 
where y = log(AUC+1). For transparency  and completeness, descriptive statistics on the raw 
scale will be presented as well. Additional details will be presented in the SAP.
To assess the robustness of the prima ry analysis result, some sensitivity  analyses will be 
conducted. Such anal yses include but are not limited to the following:
1.Similar repeated measure analy sis with some data imputed. If a subject’s last observed AUC 
value prior to Week 52 is 0, then all missing values through Week 52 will be imputed with 
zero. Repeated measure analy sis will be conducted on the partially  imputed data.
2.An analysis of covariance (ANCOVA ) model with log(AUC+1) at Week 52 as the response 
variable, baseline log(AUC+1) and age as covariates, and treatment and gender as fixed 
factors. D ifferent missing data handling strategies such as completers’ analy sis, and multiple 
imputation will be explored.
3.Similar ANCOVA model by  [CONTACT_402568].
4.Comparing change fro m baseline in [ADDRESS_507436] in these endpoints will be estimated by [CONTACT_402569]®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
87
Approved , Date: [ADDRESS_507437] 2019groups along with their associated 95% confidence intervals. The hypoglycemia event rate 
(number of hy pogly cemia epi[INVESTIGATOR_302054] -year exposure) at Week 52will be anal yzed using 
a Poisson regression model. Change from baseline in insulin use and change from baseline in 
HbA1c will be analyzed by [CONTACT_402570]. Additional details will be provided in the 
SAP.
1.Change from baseline in insulin use in units per kilog ram bod y weight per day  at Week 52.
2.Change from baseline in HbA1c at Week 52.
3.Hypoglycemic event rates (defined as BGlevels of ≤70, 55, and 35mg/dL or clinical 
sequelae consistent with severe hypoglycemia in the absence of a BG reading) through 
Week 52.
11.3.1. Exploratory  Efficacy  Analyses –Open -Label Extension Period
All the efficacy  endpoints defined for the double -blind period will be exploratory  for the 
open -label extension period and will be summarized descriptivel y.Disease progression will be 
compared between the double -blind period and the extension period in subjects who attende d the 
open -label extension period if deemed reasonable.
11.4. Pharmacokinetic A nalyses
Data will be listed for all subjects with available serum concentrations per treatment. All 
concentrations below the lowest quantifiable concentration (LQC) in a sample or missing data 
will be labeled as such in theconcentration data listings. Concentrations below the LQC in a 
sample will be treated as 0in the summary  statistics and for the calculation ofPKparameters. 
All subjects and samples excluded from the analy sis will be clearl y documented in the study  
report.
For each dose group, descriptive statistics, including arithmetic mean, SD, coefficient of 
variation, median, minimum, and maximum will be calculated for the golimumab serum 
concentrations at each sampling time of golimumab.
Serum golimumab concentrations will be summarized over time. In addition, ifnecessary , a 
population PK analysis will be performed to characterize the PK of golimumab as well as to 
identify  and quantify  important covariates of PK in the T1D population . The apparent total 
systemic clearance (CL/F) and apparent volume of distribution (V/F) will be estimated using a 
NONMEM approach and will be presented in a se parate technical report.
The same anal yses will be performed for the open -label extension period.
11.5. Immunogenicity  Analyses (Antibodies to Golimumab)
The occurrence and titers of antibodies to golimumab during the study  will be summarized over 
time for all subjects who receive an administration of golimumab and have appropriate samples 
collected for detection of antibodies to golimumab (ie, subjects with at least [ADDRESS_507438] golimumab administration).
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
88
Approved , Date: [ADDRESS_507439] 2019The incidence of neutralizing antibodies (NAbs) to golimumab will be summarized for subjects 
who are positive for antibodies togolimumab and have samples evaluable for NAbs to 
golimumab .
Other immunogenicit y analy ses may be performed to further characterize the immune responses 
that are generated.
The same anal yses will be performed for the open -label extension period.
11.6. Biomarker A nalyses
Results from exploratory anal yseswill be presented in a separate biomarker technical report.
The same anal yses will be performed for the open -label extension period.
11.7. Pharmacokinetic/Pharmacody namic A nalyses
If data permits, the relationships between serum golimumab concentration and efficacy  may be 
analyzed graphicall y. If a visual trend is observed, a suitable PK/PD model may be developed to 
descri be the exposure -response relationship and will be presented in a separate technical report .
The same anal yses will be performed for the open -label extension period.
11.8. Pharmacogenomic A nalyses
For the double -blind period, r esults from exploratory  and haploty pe analyses will be presented in 
a separate biomarker technical report.
For the open -label extension period, results from the exploratory  analyses will be presented in a 
separate biomarker technical report.
11.9. Safety  Endpoints and Analyses
Safety  assessments will include the examination of the incidence rates of AEs, vital signs, 
laboratory  parameters, and physical examinations. Safety  analyses will be conducted on the 
safet y analysis set, which is defined as all subjects who have received at least a 1 dose of study 
agent.
Adverse Events
The verbatim terms used in the CRF by [CONTACT_43760] (MedDRA). Treatment -emergent AEs are AEs 
with onset during the treatment period orthat are a consequence of a pre-existing condition that 
hasworsened since baseline .All reported treatment -emergent AEs will be included in the 
analysis. For each AE, the percentage of subjects who experience at least 1occurrence of the 
given event will be summarized by[CONTACT_402571]. 
Treatment -emergent AEs will also be summarized by a maximum severity  and relationship to 
study  agent. Separate summaries will be provided for SAEs and AEs leading to study  agent 
discontinuation.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
89
Approved , Date: [ADDRESS_507440] 2019In addition, summary  tables will be presented by [CONTACT_402572] s
within each specified period:
Double -Blind Period :
a.Proportion of subjects with treatment -emergent AEs and severe AEs through Weeks [ADDRESS_507441] ion site reactions through Week 52.
c.Proportion of subjects with severe infections through Weeks 52 and 104 .
d.Open -Label Extension Period : 
1.Continue to evaluate safety  and exploratory  efficacy  endpoints as per the Time and 
Events Schedule (open -label extension period) and no new efficacy  hypotheses will be 
tested compared to the double -blind period.
Listings, datasets, or subject narratives may be provided, as appropriate, for those subjects who 
die, who discontinue treatment due to an AE, or who experience a severe or an SAE .
Clinical Laboratory Tests
Laboratory  data will be summarized by [CONTACT_23821]. Reference ranges and markedl y 
abnormal results (specified in the SAP) will be used in the summary of laboratory  data. 
Descriptive statistics will be calculated for each laboratory  analyte at baseline and for observed 
values and changes from baseline at each scheduled timepoint. Frequency tabulatio ns of the 
changes from baseline will be presented in pre-versus post-treatment cross -tabulations (with 
classes for below, within, and above normal ranges). Frequency  tabulations of the abnormalities 
will be made. A listing of subjects with any markedl y abnormal laboratory  results will be 
provided.
Vital Signs
Descriptive statistics of temperature, pulse/heart rate, respi[INVESTIGATOR_2842], and blood pressure 
(systolic and diastolic) values and changes from baseline will be summarized at each scheduled 
timepoint. The percentage of subjects with values beyond clinically  important limits will be 
summa rized and a corresponding listing will be provided.
Physical Examination
Proportion of subjects with abnormal physical examination findings will be summarized at each 
scheduled timepoint. Subjects with any  post -treatment abnormalities will be listed.
Open -Label Extension Period
Clinical laboratory  tests, vital signs, and physical examination for the open -label extension 
period will be assessed as similar to the double -blind period.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
90
Approved , Date: [ADDRESS_507442] 60% of subjects complete their Week 264-hour,MMTT 
assessment . All available 4-hour,C-peptide AUC data at interim analysis will be incorporated in 
this analy sis. No formal DBL is planned for this interim anal ysis.
An IAC will be established to review the interim data and formulate recommendations in 
accordance with the objectives of the interim analy sis. The IAC will consist of at least a clinician 
and a statistician (neither of whom are involved in the conduct of the study  or compound 
development), one of whom will chair the committee, and other members as required based on 
the results of the interim analy sis. Details will be provided in the IAC charter. The DMC serves 
the IAC function. The disclosure of unblinded results will be limit ed to specific sponsor 
personnel not involved in the study . Interim analyses results will not be disseminated to 
investigators or individuals associated with the conduct of the study .The interim analy ses will 
not have an y statistical impact on the anal yses of any  other endpoints.
11.11. Data Monitoring Committee
An Independent DMC consisting of external experts and internal experts not associated with this 
study will be established to monito r data on an ongoing basis to ensure the continuing safet y of 
the subjects enrolled in this study .The committee will meet periodically  to review interim data. 
After the review, the DMC will make recommendations regarding the continuation of the study . 
Thedetails will be provided in a separate DMC charter.
The DMC will consist of at least one medical expert [INVESTIGATOR_154991]. The DMC responsibilities, authorities, and procedures will be documented in its 
charter .
12. ADVERSE EVENT REPORT ING
Timely , accurate, and complete reporting and analy sis of safety  information from clinical studies 
are crucial for the protection of subjects, investigators, and the sponsor, and are mandated by 
[CONTACT_23824]. The sponsor has established Standard Operating Procedures in 
conformity  with regulatory  requirements worldwide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by [CONTACT_402573] e with those procedures.
12.1. Definitions
12.1.1. Adverse Event Definitions and Classifications
Adverse Event
An AEis any untoward medical occurrence in a clinical study  subject administered a medicinal 
(investigational or non-investigational) product. An AEdoes not necessarily  have a causal 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
91
Approved , Date: [ADDRESS_507443] 2019relationship with the treatment. An AEcan therefore be any unfavorable and unintended sign 
(including an abnormal finding), symptom, ordisease temporally  associated with the use of a 
medicinal (investigational or non-investigati onal) product, whether or not related to that 
medicinal (investigational or non-investigational) product. (Definition per International 
Conference on Harmonisation [I CH])
This includes any  occurrence that is new in onset or aggravated in severit y or freque ncy from the 
baseline condition, or abnormal results of diagnostic procedures, including laboratory  test 
abnormalities.
Note: The sponsor collects AEs starting with the signing of the ICF(refer to Section 12.4.[ADDRESS_507444] AErecording).
Serious Adverse Event
AnSAE based on ICH and European Guidelines on Pharmacovigilance for Medicinal Products 
for Human Use is an y untoward medical occurrence that at an y dose:
Results in death .
Is life -threatening (The subject was at risk of death at the time of the event. It does not refer 
to an event that h ypothetically might have caused death if it were more severe.)
Requires inpatient hospi[INVESTIGATOR_1081] .
Results in persistent or significant disability /incapacity .
Is a congenital anomal y/birth defect .
Is a suspected transmission of an y infectious agent via a medicinal product .
Is Medicall y Important .*
*Medical and scientific judgment should be exercised in deciding whether expedited 
reporting is also appropriate in other situations, such as important medical events that may 
not be immediately  life-threatening or result in death or hospi[INVESTIGATOR_402508]. These should usually  be considered serious.
Unlisted (Unexpected) Adverse Event/Reference Safety Information .
An AEis considered unlisted if the nature or severity  is not consistent with the applicable 
product reference safet y information. For golimumab , the expectedness of an AEwill be 
determined by [CONTACT_83408]'s Brochure. For exogenou s 
insulin with a marketing authorization, the expectedness of an AEwill be determined by 
[CONTACT_118553]/sum mary  of product characteristics .
Adverse Event Attribution Definitions .
The following provides guidance on how the study  team is to assess and categorize the 
relationship of AEs in relation to study  agent:
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
92
Approved , Date: [ADDRESS_507445] 2019Adverse Event Association With The Study Agent
Not Related :AnAEthat is not related to the use of the drug.
Doubtful: AnAEfor which an alternative explanation is more likely, eg,concomitant 
drug(s), concomitant disease(s), or the relationship in time suggests that a causal relationship 
is unlikely .
Possible :An AEthat might be due to the use of the drug. An alternative explanation, 
eg,concomitant drug(s), concomitant disease(s), is inconclusive. The relationship in time is 
reasonable; therefore, the causal relationship cannot be excluded.
Probable :An AEthat might be due to the use of the drug. The relationship in time is 
suggestive (eg,confirmed by [CONTACT_23827]). An alternative explanation is less likely , 
eg,concomitant drug(s), concomitant disease(s).
Very Likely :An AEthat islisted as a possible adverse reaction and cannot be reasonabl y 
explained by [CONTACT_4867], eg,concomitant drug(s), concomitant disease(s). 
The relationship in time is very suggestive (eg,it is confirmed by [CONTACT_213008]).
This study  will utilize sponsor -suppl ied study agent dosing devices, the PFS-U and VarioJect as 
detailed inthe SIPPM . The following provides guidance on how the study  team is to assess and 
categorize the relationship of AEs in relation to these devices.
Adverse Event Association With The Study Device
Not related :There is another obvious cause of the AE other than the study device .
Unlikely :There is anot her more likel y cause of the AE other than the study device.
Possibly :The AE could be due to the study  device.
Probably :The A E is probably  attributable to the study  device.
Definitely :The AE is most likely  or definitel y attributable to the study  device.
12.1.2. Severity Criteria
An assessment of severity  grade will be made using the following general categorical 
descriptors:
Mild : Awar eness of sy mptoms that are easily  tolerated, causing minimal discomfort and not 
interfering with every day activities.
Moderate : Sufficient discomfort is present to cause interference with normal activity .
Severe : Extreme distress, causing significant impai rment of functioning or incapacitation. 
Prevents normal every day activities.
The investigator should use clinical judgment in assessing the severit y of events not directly  
experienced b y the subject (eg, laboratory  abnormalities).
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
93
Approved , Date: [ADDRESS_507446] 201912.2. Hypogl ycemia Definitions, Recording and Interpretation
This study  will usethe ADA suggested classification of hypoglycemia to guide the collection of 
epi[INVESTIGATOR_402509]/or symptomatic hypogl ycemia.65A hypoglycemic BG reading will 
be classified as an y confirmed BGreading of ≤70mg/dL.
In clinical practice, severe hypoglycemia is considered an event requiring assistance of another 
person for support which may include administration of carboh ydrates or glucagon. Individual s 
with severe hypoglycemia may, experience events such as a seizure, altered/loss of 
consciousness, or coma. Such events do not need to have a documented BG reading to be 
classified clinicall y as a severe hypoglycemic event . This study  will collect this "clinical 
practice" definition of severe hy poglycemia, whether or not the sy mptoms areassociated with an 
abnormal/ low BG reading. Data on all hy poglycemic events as describ ed above will be collected 
as part of the efficacy  analy ses.
In terms of AE reporting in this study , the severity  of a hypoglycemia AEshould be classified as 
mild, moderate, or severe, or as anSAE according to the definitions in Section 12.1.1 , Section 
12.1.2 , and Section 12.4.1 .Because there may be difference in terminology  used in clinical 
practice and AErecording in clinical trials, a hypoglycemic epi[INVESTIGATOR_402510] “severe” 
using clinical definitions may not necessarily  be classified as a “severe” (or serious) AE, and 
conversel y an epi[INVESTIGATOR_402511] a severe AE. Again, itis the investigator’s responsibility  to categorize the 
severit y of a h ypogl ycemic event in terms of AEreporting .
12.3. Special Reporting Situations
Safety  events of interest on a sponsor study  agent that may require expedited reporting and/or 
safet y evaluation include, but are not limited to:
Overdose of a spon sor study  agent
Suspected abuse/misuse of a sponsor study  agent
Accidental or occupational exposure to a sponsor study  agent
Medication error involving a sponsor product (with or without subject/patient exposure to 
the sponsor study  agent , eg, name [CONTACT_402586])
Special reporting situations should be recorded in the CRF. Any special reporting situation 
that meets the criteria of an SAE should be recorded on the SAE page of the CRF.
12.4. Procedures
12.4.1. All Adverse Events
All AEs and special reporting situations, whether serious or non-serious, will be reported from 
the time a signed and dated ICFis obtained until completion of the subject's last study -related 
procedure ,which may include contact [CONTACT_20687] -up of safet y. Serious adverse events, including 
those spontaneousl y reported to the investigator within [ADDRESS_507447] dose of study  
agent (which is the end of the study ), must be reported using the Serious Adverse Event Form. In 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
94
Approved , Date: [ADDRESS_507448] be recorded using medical terminology  in the source document and the CRF. Whenever 
possible, diagnoses should be given when signs and symptoms are due to a common etiolo gy 
(eg,cough, runny nose, sneezing, sore throat, and head congestion should be reported as "upper 
respi[INVESTIGATOR_23739]"). Investigators must record in the CRF their opi[INVESTIGATOR_402512] y. All measures required forAEmanagement must be 
recorded in the source document and reported according to sponsor instructions.
All devices associated with device -related AEs will be investigated including the return of the 
device to the sponsor for inspection.
The sponsor assumes responsibility  for appropriate reporting of AEs to the regulatory authorities. 
The sponsor will also report to the investigator (and the head of the investigational institute 
where required) all suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) . Theinvestigator 
(or sponsor where required) must report S[LOCATION_003]R s to the appropriate Independent Ethics 
Committee/I nstitutional Review Board (IEC/I RB) that approved the protocol unless otherwise 
required and documented by [CONTACT_6179]/IRB .A S[LOCATION_003]R will be reported to regulatory  authorities 
unblinded. Participating investigators and IEC/IRB will receive a blinded S[LOCATION_003]R summary , 
unless otherwise specified.
For all studies with an outpatient period , the subject must be provided with a "wallet (study )
card" and instructed to carry this card with them for the duration of the study  indicating the 
following:
Study number
Statement, in the local language(s), that the subject is participating in a clinical study
Investigator's name [INVESTIGATOR_1238] [ADDRESS_507449] teleph one number
Local sponsor's name [INVESTIGATOR_1238] [ADDRESS_507450] telephone number (for medical staff only )
Site number
Subject number
Any other information that is required to do an emergency  breaking of the blind
12.4.2. Serious A dverse Events
All SAEs occurring during thestudymust be reported to the appropriate sponsor contact [CONTACT_184932] -site personnel within 24 hours of their knowledge of the event.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
95
Approved , Date: [ADDRESS_507451] be com pleted and signed by a physician from the study site and transmitted to 
the sponsor within 24 hours. The initial and follow -up reports of an SAE should be made by 
[CONTACT_6972] (fax) .
All SAEs that have not resolved by [CONTACT_2054] , or that have not resolved upon 
discontinuation of the subject's participation in the study , must be followed until any of the 
following occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can beattributed to agents other than the study  agent or to factors unrelated to 
study  conduct
It becomes unlikely  that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration 
of due diligence with follow -up efforts)
Suspected transmission of an infectious agent by  a medicinal product will be reported as an SAE . 
Any event requiring hospi[INVESTIGATOR_059] (or prolongation of hospi[INVESTIGATOR_059]) that occurs during the 
course of a subject's participation in a study  must be reported as an SAE , except hospi[INVESTIGATOR_111074]:
Hospi[INVESTIGATOR_43717](eg, social reasons such as 
pending placement in long -term care facility ).
Surgery or procedure planned before entry  into the study  (must be documented in the CRF ).
The cause of death of a subject in a study  within [ADDRESS_507452] dose of study  agent , 
whether or not the event is expected or associated with the study  agent , is consi dered an SAE .
Disease progression should not be recorded as an AEor SAE term; instead, signs and symptoms 
of clinical sequelae resulting from disease progression/lack of efficacy  will be reported if they 
fulfill the SAE definition (refer toSection 12.1.1 , Adverse Event Definitions and 
Classifications).
12.4.3. Pregnancy
All initial reports of pregnancy  in female subjects or partners of male subjects must bereported 
to the sponsor by [CONTACT_1758] -site personnel within 24 hours of their knowledge of the event using 
the appropriate pregnancy  notification form. Abnormal pregnancy  outcomes (eg, spontaneous 
abortion, fetal death, stillbirth, congenital anomal ies, ectopic pregnancy ) are considered SAEs 
and must be reported using the Serious Adverse Event Form. Any subject who becomes pregnant 
during the study  must be promptly  withdrawn from the studyand discontinue further study 
treatment .
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
96
Approved , Date: [ADDRESS_507453] 
administration of study  agent(s) in subjects participating in this clinical study  must be reported 
by [CONTACT_402574] 9.1.[ADDRESS_507454] countries. These events are to be 
considered serious only  if they  meet the definition of an SAE .
12.5. Contact[CONTACT_23830] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23831] y issues or questions regarding the study  are listed in the Contact [CONTACT_23832](s), which will be provided as a separate document.
13. PRODUCT QUA LITY COMP LAINT HA NDLING
A product qualit y complaint (PQC) is defined as any suspi[INVESTIGATOR_1884] a product defect related to 
manufacturing, labeling, device, or packaging, ie, any dissatisfaction relative to the identity , 
quality , durability , or reliability  of a product, including its labeling or package integrity . A PQC 
may have an impact on the safet y and efficacy  of the product. Timely , accurate, and complet e 
reporting and analysis of PQC information from studies are crucial for the protection of subjects, 
investigators, and the sponsor , and are mandated by [CONTACT_23824]. The sponsor 
has established procedures in conformit y with regulatory  requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by [CONTACT_111168].
All VarioJect devices associated with device -related PQCs will be investig ated including the 
return of the device to the sponsor for inspection .PFS-U should be retained for further 
investigation if requested by  [CONTACT_456] .
13.1. Procedures
All initial PQCs must be reported to the sponsor by  [CONTACT_1758] -site personnel within [ADDRESS_507455] report the PQC to the 
sponsor according to the SAE reporting timelines (refer to Section 12.4.2 , Serious Adverse 
Events). A sample of the suspected product should be maintained for further investigation if 
requested b y the sponsor .
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
97
Approved , Date: [ADDRESS_507456] Quality
The names (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23835](s), which will be 
provided as a separate document.
14. STUDY DRUG INFORMA TION
14.1. Physical Descri ption of Study Drug( s)
Golimumab will be supplied as a sterile ,clear to slightly  opalescent, colorless to light yellow 
liquid for SC injection in single -use prefilled syringes. Each prefil led syringe contains 50mg 
(0.5mL of liquid) of golimumab, histidi ne, sorbitol and polysorbate [ADDRESS_507457] kits in tamper resistant packaging.
Ultrasafe Passive Delivery System With Prefilled Syringe ( PFS-U)
The UltraSafe Passive Delivery  System (UltraSafe) is a manuall y-operated, single -use, 
disposable needle guard system that is an accessory  to a PFS. Each 50 mg-single dose prefilled 
glass s yringe ( 27-gauge ½ inch needle) contains 50mgof golimumab p er 0.[ADDRESS_507458] be stored at controlled temperatures ranging from 36°F to 46°F (2°C to 
8°C). Study  agent must be handled in strict accordance with the protocol and the container label 
and will be stored in a limited access area or in a locked cabinet under appropriate environmental 
conditions.
Refer to the pharmacy  manual/study  SIPPM for additional guidance on study  agent preparation, 
handling, and storage.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
98
Approved , Date: [ADDRESS_507459] be documented on the drug 
accountability  form. All study  agent will be stored and disposed of according to the sponsor's 
instructions. Study -site personnel must not combine contents of the stud y agent containers.
The dispensing of study  agent to the subject, and the return of study  agent from the subject (if 
applicable), must be documented on the drug accountability  form. Subjects, or their legall y 
acceptable representatives where applicable, must be instructed to return all original containers, 
whether empt y or containing stud y agent .
Study  agent must be handled in strict accordance with the protocol and the container label, and 
must be stored at the study  site in a limited access area or in a locked cabinet under appropriate 
environmental conditions. Unused study  agent , and study  agent returned by [CONTACT_423], must be 
available for verification by  [CONTACT_456]'s study  site monitor during on -site monitoring visits. The 
return to the sponsor of unused study  agent , or used returned study  agent for destruction, will be 
documented on the drug return form. When the study  site is an authorized destruction unit and 
study  agent supplies are destroy ed on -site, this must also be documented on the drug return form.
Potentially  hazardous materials such as used ampules, needles, syringes and vials containing 
hazardous liquids, should be disposed of immediately  in a safe manner and therefore will not be 
retained for drug accountability  purposes.
Study agent should be dispensed under the supervision of the investigator or a qualified member 
of the study -site personnel , or by a hospi[INVESTIGATOR_307]/clinic pharmacist. Study  agent will be supplied only 
to subjects participating in the study . Returned study  agent must not be dispensed again, even to 
the same subject. Study  agent may not be relabeled or reassigned for use by [CONTACT_23837]. The 
investigator agrees neither to dispense the study  agent from, nor store it at, any  site other than the 
study  sites agreed upon w ith the sponsor.
15. STUDY -SPECIFIC MATERIA LS
The investigator will be provided with the following:
Investigator 'sBrochure s
SIPPM Laboratory manual
Sponsor -approved Informed Consent/Assent Form
Dose assignment system manual
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
99
Approved , Date: [ADDRESS_507460] 2019Investigator site file
Electronic data capture (eDC)Manual
IWRS Manual
Subject eDiaries and manuals
Subject glucometers and manuals
Study -specific Patient Participation Cards
Materials for off-siteadministration
16. ETHICA L ASPECTS
16.1. Study -Specific Design Considerations
Potential subjects willbe fully informed of the risks and requirements of the study  and, during the 
study , subjects will be given any new information that may affect their decision to continue 
participation. They  will be told that their consent /assent to participate in the study is voluntary  and 
may be withdrawn at any time with no reason given and without penalt y or loss of benefits to 
which they would otherwise be entitled. Only subjects who are fully able to understand the risks, 
benefits, and potential AEs of thestudy , and provide their consent /assent voluntaril y will be 
enrolled.
When referring to the signing of the ICF, the terms legal guardian and legall y acceptable 
representative refer to the legall y appointed guardian of the child with authorit y to authorize 
participati on in research. For each subject, his or her parent(s) (preferabl y both parents, if 
available) or legally  acceptable representative(s), as required by [CONTACT_427], must give 
written consent /assent (permission) according to local requirements after the nature of the study 
has been full y explained and before the performance of any  study -related assessments. Assent must 
be obtained from children (minors) capable of understanding the nature of the study, typi[INVESTIGATOR_402513] [ADDRESS_507461] provided consent /assent (and assent as applicable) refers 
to the subjects and his or her parent(s) or the subject's legal guardian(s) or legall y acceptable 
representative(s) who have provided consent /assent according to this process. Minors who assent 
to a study  and later withdraw that assent should not be maintained in the study  against their will, 
even if their parents still want them to participate.
The total blood volume to be collected from each subject , including during screening, the 
52-week treatment period and 52-week off-therapy  follow -up period is approximately  436mL
for subjects <35kg and 505mLin subjects 35 kg.During the open -label extension period,
approximately  210 mL for subjects <35 kg and 234 mL  for subjects ≥35 kg will be drawn.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
100
Approved , Date: [ADDRESS_507462] 201916.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
country -specific requirements.
Good Clinical Practice is an international ethical and scientific quality standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provides public assurance that the rights, safety , and well -being of 
study  subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki ,and that the study  data are credible.
16.2.2. Independent Ethics Committee or Institutional Review  Board
Before the start of the study , the investigator (or sponsor where required) will provide the 
IEC/IRB with current and complete copi[INVESTIGATOR_23747] (as required by [CONTACT_13125]) :
Final protocol and, if applicable, amendments .
Sponsor -approved ICF(and any  other written materials to be provided to the subjects) .
Investig ator's Brochure (or equivalent information) and amendments/addenda .
Sponsor -approved subject recruiting materials .
Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable .
Investigator's curriculum vitae or equivalent information (unless not required, as 
documented b y the IEC/IRB) .
Information regarding funding, name [CONTACT_8152], institutional affiliations, other potential 
conflicts of interest, and incentives for subjects .
Any other doc uments that the I EC/IRB requests to fulfill its obligation .
This study will be undertaken only after the IEC/I RB has given full approval of the final 
protocol, amendments (if any, excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct , unless required locall y), the ICF, applicable 
recruiting materials, and subject compensation programs, and the sponsor has received a copy of 
this approval. This approval letter must be dated and must clearl y identify the IEC/IRB and the 
documents being approved.
Approval for the collection of optional samples for research and for the corresponding ICFmust 
be obtained from the IEC/IRB. Approval for the protocol can be obtained independent of this 
optional research component .
During the study  the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropriate:
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
101
Approved , Date: [ADDRESS_507463] 2019Protocol amendments (excluding the ones that are purel y administrative, with no
consequences for subjects, data or study  conduct) .
Revision(s) to ICFand any  other written materials to be provided to subjects .
If applicable, new or revised subject recruiting materials approved b y the sponsor .
Revisions to compensation for study -related injuries or payment to subjects for participation 
in the study , if applicable .
New edition(s) of the Investigator's Brochure and amendments/addenda .
Summaries of the status of the study  at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y).
Reports of AEs that are serious, unlisted/unexpected, and associated with the study  agent .
New information that may adversel y affect the safet y of the subjects or the conduct of the 
study .
Deviations from or changes to the protocol to eliminate immediate hazards to the subjects .
Report of deaths of subjects under the investigator's care .
Notification if a new investigator is responsible for the study  at the site .
Development Safet y Update Report and Line Listings, where applicable .
Any other requirements of the IEC/I RB.
For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study conduct) , the amendment and applicable ICFrevisions 
must be submitted promptly  to the IEC/I RB forreview and approval before implementation of 
the change(s).
At least once a year, the IEC/I RB will be asked to review and reapprove this study , where 
required.
At the end of the study , the investigator (or sponsor where required) will notify  the IEC/I RB 
about the study  completion.
16.2.3. Informed Consent and A ssent Form
Each subject or a legally acceptable representative must give written consent /assent according to 
local requirements after the nature of the study  has been fully explained. The ICF(s) must be 
signed before performance of any study -related activity . The ICF(s) and assent form that is/are
used must be approved by [CONTACT_8135]/I RB and be in a language 
that the subject can read and understand. The informed consent /assent should be in accordance 
with principles that originated in the Declaration of Helsinki, current ICH and GCP guidelines, 
applicable regulatory  requirements, and sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the study-site 
personnel must explain to potential subjects or their legally acceptable representatives the aims, 
methods, reasonabl y anticipated benefits, and potential hazards of the study ,and any discomfort 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
102
Approved , Date: [ADDRESS_507464] 2019participation in the study  may entail. Subjects will be informed that their participation is 
voluntary  and that they may withdraw consent /assent to participate at any time. They  will be 
informed that choosing not to participate ,will not affect the care the subject will receive for the 
treatment of his or her disease . Subjects will be told that alternative treatments are available if 
they refuse to take part and that such refusal will not prejudice future treatment. Finally , they  will 
be told that the investigator will maintain a subject identification register for the purposes of 
long-term follow -up if needed and that their records may be accessed by [CONTACT_402575], to the extent 
permitted by [CONTACT_6983](s) or regulations. By [CONTACT_402576] /assent for 
additional safet y evaluations, and subsequent disease -related treatments , if needed.
The subject or legally  acceptable representative will be given sufficient time to read the ICF and 
the opportunity  to ask questions. After this explanation and before entry into the study , 
consent /assent should be appropriatel y recorded by [CONTACT_41040]'s or his or her 
legally acceptable representative's personally  dated signature. After having obtained the 
consent /assent , a cop y of the ICFmust be given to the subject.
Subjects will be asked for consent /assent to provide optional samples for research . After 
informed consent /assent for the study  is appropriately  obtained, the subject or his or her legally 
acceptable representative will be asked to sign and personall y date a separate ICF indicating 
agreement to participate in the optional research component . Refusal to participate in the 
optional research will not result in ineligibility  for the study .A copy of this signed ICF will be 
given to the subject.
If the subject or legally  acceptable representative is unable to read or write, an impartial witness 
should be present for the entire informed consent /assent process (which includes reading and 
explaining all written information) and should personall y date and sign the ICFafter the oral 
consent of the subject or le gally  acceptable representative is obtained.
Children (minors) or subjects who are unable to comprehend the information provided can be 
enrolled only after obtaining consent of a legally  acceptable representative. Assent must be 
obtained from children (minors) capable of understanding the nature of the study , typi[INVESTIGATOR_1306] y 
subjects 7years of age and older , depending on the institutional policies. Written assent should 
be obtained from subjects who are able to write. A  separate assent form written in language the 
subject can understand should be developed for adolescents. After having obtained the assent, a 
copy  of the assent form must be given to the subject and to the subjec t's parent or if applicable to 
the subject's legally  acceptable representative. If subjects meet "responder" definition and are 
interested in participating in open-label extension phase of study , subjects and parents /legal 
guardians will have to sign new I CF/assent forms .
16.2.4. Privacy of Personal Data
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary  to fulfill the objectives of the study .
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
103
Approved , Date: [ADDRESS_507465] or his or her legally acceptable representative
includes explicit consent /assent for the processing of personal data and for the 
investigator /institution to allow direct access to his or her original medical records (source 
data/documents) for study -related monitoring, audit, IEC/IRB review, and regulatory  inspection. 
This consent /assent also addresses the transfer of the data to other entities and to other countries.
The subject has the right to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study , and the applicable laws and regulations.
16.2.5. Long -Term Retention of Samples for Additional Future Research
Samples collected in this study  may be stored for up to 15 years (or according to local 
regulations) for additional research. Samples will only be used to under stand golimumab , to 
understand T1D autoimmunity and/or immune modulation, to understand differential drug 
responders, and to develop tests/assay s related to golimumab . The research may begin at any 
time during the stud y or the post -study  storage period .
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may  withdraw their consent /assent for their samples to 
be stored for research ( seeSection 10.3, Withdrawal From the Use of Research Samples)
17. ADMINISTRA TIVE REQUI REMENTS
17.1. Protocol A mendments
Neither the investigator nor the sponsor will modify  this protocol without a formal amendment 
by [CONTACT_456]. All protocol amendments must be issued by  [CONTACT_356353] b y 
the investigator. Protocol amendments must not be implemented withou t prior IEC/IRB 
approval, or when the relevant competent authority  has raised any grounds for non-acceptance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
amendment must be promptly  submitted to the IEC/I RB and relevant competent authority . 
Documentation of amendment approval by  [CONTACT_23846]/IRB must be provided to the 
sponsor. When the change(s) involves only logistic or administrative aspects of the study ,the 
IEC/IRB ( where required) only  needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable, 
the investigator or other physician in attendance will contact [CONTACT_307510] (s), which will beprovided as a separate
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
104
Approved , Date: [ADDRESS_507466] any departure from the protocol, and the source 
documents will describe this departure and the circumstances requiring it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory 
requirements are met.
17.2.2. Require d Prestudy  Documentation
The following documents must be provided to the sponsor before shipment of study  agent to the 
study site:
Protocol and amendment(s), if any, signed and dated by  [CONTACT_458] .
A copy of the dated and signed (or sealed, where appropriate per local regulations), written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly  identify  the specific 
protocol by [CONTACT_23850] (or sealed, where appropriate per local 
regulations) b y the chairman or authorized designee.
Name [CONTACT_23875]/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, 
from the IEC/I RB, a general statement may be substituted for this list. I f an investigator or a 
member of the study -site personnel is a member of the IEC/IRB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opi[INVESTIGATOR_23748].
Regulatory  authority  approval or notification, if applicable .
Signed and dated statement of in vestigator (eg, Form FDA 1572), if applicable .
Documentation of investigator qualifications (eg, curriculum vitae) .
Completed investigator financial disclosure form from the principal investigator, where 
required .
Signed and dated Clinical Trial Agreement, which includes the financial agreement .
Any other documentation required by  [CONTACT_427] .
The following documents must be provided to the sponsor before enrollment of the first subject:
Completed investigator financial disclosure forms from all subin vestigators .
Documentation of subinvestigator qualifications (eg, curriculum vitae) .
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
105
Approved , Date: [ADDRESS_507467] 2019Name [CONTACT_23876] , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable .
Local laborat ory documentation demonstrating competence and test reliability 
(eg,accreditation/license), if applicable .
17.3. Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study . This document will be reviewed by [CONTACT_66886] -site contact [CONTACT_23853].
The subject identification and enrollment log will be treated as confidential and will be filed by 
[CONTACT_402577]. To ensure subject confidentiality , no copy  will be made. All 
reports and communications relating to the study  will identify  subjects by [CONTACT_23855]. In cases where the subject is not randomized into the study, the date seen and 
date of birth will be used.
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility  for inclusion in the study .
17.4. Source Documentation
At a minimum, source docu ment s consistent in the type and level of detail with that commonly  
recorded at the study  site as a basis for standard medical care must be available for the following: 
subject identification, eligibility , and study  identification; study  discussion and date of signed 
informed consent /assent ; dates of visits; results of safet y and efficacy  parameters as required by 
[CONTACT_760]; record of all AEs and follow -up of AEs; concomitant medication; drug 
receipt/dispensing/return records; study  agent administration information ; and date of study 
completion and reason for early discontinuation of study  agent or withdrawal from the study , if 
applicable.
The author of an entry  in the source documents should be identifiable.
Specific details required as source data for the study  and source data collection methods will be 
reviewed with the investigator before the study  and will be described in the monitoring 
guidelines (or other equivalent document).
The minimum source document ation requirements for Section 4.1,Inclusion Criteria and 
Section 4.1.2 ,Exclusion Criteria that specify  a need for documented medica l history  are as 
follows:
Referral letter from treating ph ysician or
Complete history  of medical notes at the site
Discharge summaries
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
106
Approved , Date: [ADDRESS_507468] interv iew or other protocol required assessment (eg, physical examination, 
laboratory  assessment) and documented in the source documents.
An electronic source system may be utilized, which contains data traditionally  maintained in a 
hospi[INVESTIGATOR_23749] (eg, electronic source documents) as well as 
the clinical study -specific data fields as determined by [CONTACT_760]. This data is electronicall y 
extracted for use by [CONTACT_456]. If the electronic source system is utilized, references made to 
the CRF in the protocol include the electronic source system but information collected through 
the electronic source system may not be limited to that found in the CRF. Data in this system 
may be considered source documentation.
17.5. Case Report Form Co mpletion
Case report forms are prepared and provided by [CONTACT_66888].
All data relating to the study  must be recorded in CRF. All CRF entries, corrections, and 
alterations must be made by [CONTACT_70464] -site personnel. The investigator 
must verify  that all data entries in the CRF are accurate and correct.
The study  data will be transcribed by [CONTACT_3449]-sitepersonnel from the source documents onto an 
electronic CRF, if applicable. Study -specific data will betransmitted in a secure manner to the 
sponsor.
Worksheets may be used for the capture of some data to facilitate completion of the CRF. Any 
such worksheets will become part of the subject's source document s. Data must be entered into 
CRF in English. The CRF must be completed as soon as possible after a subject visit and the 
forms should be available for review at the next scheduled monitoring visit.
All subjective measurements (eg, pain scale information or other questionnaires) will be 
completed by [CONTACT_23856].
If necessary , queries will be generated in the eDC tool. If corrections to a CRF are needed after 
the initial entry  into the CRF , this can be done in either of the following ways:
Investigator and study-site personnel can make corrections in the eDC tool at their own 
initiative or as a response to an auto query  (generated by  [CONTACT_66832]) .
Sponsor or sponsor delegate can generate a query  for resolution by [CONTACT_277485] -site personnel.
17.6. Data Quality  Assurance/Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study -sitepersonnel before the study , andperiodic monitoring visits by [CONTACT_456], and direct 
transmission of clinical laboratory  data from a Central Laboratory  into the sponsor's data base. 
Written instructions will be provided for collection, handling, storage, and shipment of samples.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
107
Approved , Date: [ADDRESS_507469] 2019Guidelines for CRF completion will be provided and reviewed with study -sitepersonnel before 
the start of the stud y.
The sponsor will review CRF for accuracy  and completeness during on -site monitoring visits and 
after transmission to the sponsor; any discrepancies will be resolved with the investigator or 
designee, as appropriate. After upload of the data into the study database they  will be verified for 
accuracy  and consistency with the data sources.
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all CRF 
and all source documents that support the data collected from each subject, as well as all study  
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study  documents as specified by [CONTACT_23859](s). 
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents.
Essential documents must be retained until at least 2years after the last approval of a marketing 
application in an ICH region and until there are no pending or contemplated marketing 
applications in an ICH region or until at least 2years have elapsed since the formal 
discontinuation of clinical development of the investigational product. These documents will be 
retained for a longer period if required by [CONTACT_402578]. It is the responsibility  of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibility  of keepi[INVESTIGATOR_13274], custody  must be transferred to a person who will 
accept the responsibility . The sponsor must be notified in writing of the name [CONTACT_23877]. Under no circumstance shall the investigator relocate or dispose of any study  
documents before having obtained written approval from the sponsor .
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator /institution must permit access to such 
reports.
17.8. Monitoring
The sponsor will use a combination of monitoring techniques central, remote, or on-site 
monitoring to monitor this study .
The sponsor will perform on-site monitoring visits as frequ ently as necessary . The monitor will 
record dates of the visits in a study  site visit log that will be kept at the study site. The first post-
initiation visit will be made as soon as possible after enrollment has begun. At these visits, the 
monitor will compar e the data entered into the CRF with the source documents
(eg,hospi[INVESTIGATOR_307]/clinic/phy sician’s office medical records) . The nature and location of all source 
documents will be identified to ensure that all sources of original data required to complete the 
CRF are known to the sponsor and study -site personnel and are accessible for verification by  [CONTACT_402579]®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
108
Approved , Date: [ADDRESS_507470] access to source document s(medical records) must be allowed for the purpose of 
verify ing that the recorded data are consistent with the original source data. Findings from this 
review will be discussed with the study -site personnel . The sponsor expects that, during 
monitoring visits, the relevant study -site personnel will be available, the source document swill 
be accessible, and a suitable environment will be provided for review of study -related 
documents. The monitor will meet with the investigat or on a regular basis during the study to 
provide feedback on the study conduct.
In addition to on-site monitoring visits, remote contacts can occur. It is expected that during 
these remote contacts, study -site personnel will be available to provide an upd ate on the progress 
of the study  at the site .
Central monitoring will take place for data identified by  [CONTACT_70467].
17.9. Study Completion/Termination
17.9.1. Study Completion /End of Study
The study  is considered completed with the last visitfor the last subject participating in the 
study . The final data from the study site will be sent to the sponsor (or designee) after completion 
of the final subject visit at that study  site, in the time frame specified in the Clinical Trial 
Agreement.
17.9.2. Study Termination
The sponsor reserves the right to close the study site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor .Study sites will be closed upon study  completion. A
study site is considered closed when all required documents and study  supplies have been 
collected and a study -site closure visit has been performed.
The investigator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the earlyclosure of astudy site by [CONTACT_11004]:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of subjects by  [CONTACT_093]
Discontinuation of further study  agent development
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
109
Approved , Date: [ADDRESS_507471] 201917.10. On-Site A udits
Representatives of the sponsor's clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and company  policy . These audits will require access to all study 
records, including source documents, for inspection. Subject privacy  must, however, be 
respected. The investigator and study -site personnel are responsible for being present and 
available for consultation during routinely  scheduled study -site audit visits conducted by [CONTACT_170192].
Similar auditing procedures may also be conducted by [CONTACT_23865], either as 
part of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immediately  notify the sponsor if he or shehas
been contact[INVESTIGATOR_530] b y a regulatory agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding golimumab or the sponsor's 
operations (eg,paten t application, formulas, manufacturing processes, basic scientific data, prior 
clinical data, formulation information) supplied by [CONTACT_43787], and any data, including pharmacogenomic and/or exploratory biom arker 
research data, generated as a result of this study , areconsidered confidential and remain the sole 
propert y of the sponsor. The investigator agrees to maintain this information in confidence and 
use this information only to accomplish this study  andwill not use it for other purposes without 
the sponsor's prior written consent.
The investigator understands that the information developed in the study will be used by [CONTACT_402580] , and thus may  be disclosed 
as required to other clinical investigators or regulatory  agencies. To permit the information 
derived from the clinical studies to be used, the investigator is obligated to provide the sponsor 
with all data obtained in the study .
The results of the study  will be reported in a Clinical Study  Report generated by [CONTACT_170195] . Recruitment 
performance or specific expertise related to the nature and the key assessment parameters of the 
study  will be used to determine a coordinating investigator . Results of pharmacogenomic and/or
exploratory  biomarker analy ses performed after the Clinical Study  Report has been issued will 
be reported in a separate report and will not require a revision of the Clinical Study  Report. 
Study  subject identifiers will not be used in publication of results. Any work created in 
connection with performance of the study  and contained in the data that can benefit from 
copy right protection (except any publication by [CONTACT_40999]) shall be 
the propert y of the sponsor as author and owner of cop yright in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines , the sponsor shall have the right to publish such primary  (multicenter) data 
and information without approval from the investigator. The investigator has the right to publish 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
110
Approved , Date: [ADDRESS_507472] been submitted for publication, within 12 months of the availability  of the final data (tables, 
listings, graphs), or the sponsor confirms there will be no multicenter study  publication. 
Author ship of publications resulting from this study  will be based on the guidelines on 
authorship, such as those described in the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals, which state that the named authors must have made a signific ant 
contribution to the design of the study  or analy sis and interpretation of the data, provided critical 
review of the paper, and given final approval of the final version.
Registration of Clinical Studies and Disclosure of Results
The sponsor will register and disclose the existence of and the results of clinical studies as 
required b y law.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
111
Approved , Date: [ADDRESS_507473] recent amendment.
Amendment 2 (09 May 2017)
The overall reason for the amendment: The overall reason for the amendment is to update testing parameters, to 
address clarifications needed for severe hypoglycemia definition and to correct inconsistencies within the protocol.
Applicable Section(s) Description of Change(s)
Rationale: To provide clarity and consistency, the units of laboratory tests for viral load measurements cited in the 
protocol are being updated to match the units actually used by [CONTACT_15622].
4.2. Exclusion Criteria; 
criterion 11 and criterion 12,
and
10.2. Discontinuation of 
Study 
Treatment/Withdrawal from 
the StudyCMV and EBV viral load units updated to match the Covance laboratory units used by 
[CONTACT_15622]. Updated to: EBV viral load ≥10,000 copi[INVESTIGATOR_402514] ≥10,000 copi[INVESTIGATOR_402515]. 
Rationale: Text describing events resulting in temporary and potentially permanent discontinuation of study agent 
was updated to provide clarity.
10.2. Discontinuation of 
Study 
Treatment/Withdrawal from 
the Study; Discontinuation 
of study treatment;
Study treatment may be 
temporarily or permanently 
discontinued due to events 
described below  Text w as updated/rearranged. Instructions were updated to clarify that the subject 
should be rechecked w ithin [ADDRESS_507474] and ALT on repeat dosing.
Definitions and instructions updated.
Section rearranged with minor edits to provide clarity.
The follow ing bullet was removed from the protocol:
Theoverall course of study treatment will not be extended and missed doses will 
not be administered.
10.2. Discontinuation of 
Study 
Treatment/Withdrawal from 
the Study; Discontinuation 
of study treatmentText added to clarify intervals betw een sequential Mixed -Meal Tolerance Tests 
(MMTT). 
Rationale: Definitions of terms and examples were updated or added to the protocol to provide clarity. 
12.2. “Severe” 
HypoglycemiaSection title updated to “Hypoglycemia Definitions, Recording and Interpretation”.
Hypoglycemia definitions clarified to assist identification, recording, and interpreting 
these events. Seaquist ER, Anderson J, Childs B, et al reference added. 
4.2. Exclusion Criteria; 
criterion 4Celiac disease was added to the list of examples.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
112
Approved , Date: [ADDRESS_507475] 2019Applicable Section(s) Description of Change(s)
Rationale: Removal of a full physical exam at Week 0 so that the Tanner Staging at Screening does not need to be 
repeated at Week 0. 
Time And Events Schedule The full physical exam at Week 0 w as changed to a brief physical exam at Week 0.
Rationale: Analysis of TNFα levels added to the protocol in response to Food and Drug Administration (FDA) 
Investigational New Drug (IND) request for pharmacokinetic ( PK)/pharmacodynamics (PD) modeling
Time And Events Schedule Free/total TNFα row  added under the Cl inical Pharmacology section.
Time And Events Schedule Subheading row  Pharmacokinetics/Immunogenicity changed to Clinical 
Pharm acology to encompass all procedures in this subcategory.
Time And Events Schedule, 
footnote nFootnote updated to include further instructions on timing and bioanalysis of the 
samples.
SYNOPSIS, 
Pharm acokinetic and 
Immunogenicity 
Evaluations and
9.3. Pharm acokinetics 
and ImmunogenicityThe synopsis subsection title updated w as updated to Clinical Pharmacology 
Evaluations.
Section title updated to 9.3. Clinical Pharmacology. 
SYNOPSIS, 
Pharm acokinetic and 
Immunogenicity 
Evaluations and
9.3. Pharm acokinetics 
and ImmunogenicityThe synopsis subsection Clinical Pharmacology and the first paragraph of the protocol 
body section Ph armacokinetics and Immunogenicity was updated to include 
Total/F ree TNFα. 
9.3.2. Analytical 
ProceduresPharm acody namic subsection added to include analysis of serum samples to 
determine concentrations of free and total TNFα.
Rationale: Text w as updated to match sample names to what is reflected in the laboratory manual and to clarify that 
optional pharmacogenomics serum collection and optional DNA collections are to be collected prior to dosing.
Time And Events Schedule Serum sample collection renamed serum biomarker sample.
Time And Events Schedule Optional pharmacogenomics serum collection was renamed DNA Methylation 
(Optional).
9.5. Pharmacogenomic 
(DNA) EvaluationsOptional added to the Subsection title: Exploratory Pharmacogenomic (DNA) 
Assessments. Subsection now called: Optional Exploratory Pharmacogenomic (DNA) 
Assessments :
Time And Events Schedule New  footnote “s” added to state biomarker and pharmacogenomics s ample must be 
collected prior to study agent administration. 
Rationale: Blood volumes were updated to align with the Central Laboratory blood volumes.
9.Study Evaluations;
9.1. Study Procedures; 
9.1.1. Overvie w
and
16.1. Study -Specific 
Design ConsiderationsBlood volumes were updated to reflect the Central Laboratory blood volume table.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
113
Approved , Date: [ADDRESS_507476] 2019Applicable Section(s) Description of Change(s)
Rationale: Additional text was added to provide clarity around rounding rules for body w eight.
Attachment 2: Dose And 
Device Charts For Study 
CNTO148DML2001 In 
Subjects With Type 1 
Diabetes; Attachment 2 -A:
Dosing Chart for 
Induction Doses at Week 0 
and Week 2Text added to provide additional information around rounding rules for body weight 
and an example was provided.
Rationale: Approximately was added to the length of the enrollment period to allow  for flexibility. 
3.1. Overvie w of Study 
DesignThe enrollment period of 12 to 18 months was updated to approximately 12 to 
18months. 
Rationale: Change in description of the packaging of the devices used to match the description in the device 
packaging.
14.2. Packaging The term child resistant was changed to tamper resistant.
Rationale: Correction of terminology used in the protocol
Attachment 3:
Procedures for 
Performing the Mixed -Meal 
Tolerance TestThe term Boost High Protein was changed to Boost original.
The term central operations manual was changed to Central Laboratory manual. 
Rationale: Text w as added in order for local laboratory testing of Quantiferon -TB samples to be allow ed in the study. 
Attachment 1:
Quantiferon -TB Gold 
TestingSentence added to allow  for local laboratory to perform the QuantiFERON test in 
select circumstances approved by [CONTACT_456]. 
Rationale: Text describing type of data used for efficacy analyses was updated to provide clarity and the timepoint at 
Week 52 w as removed.
11.3. Efficacy Analyses; 
Primary EndpointsThe text w as updated to include the fact that the analysis will use post -baseline 
log(AUC+1) data and the Week 52 ti mepoint was removed. 
Rationale: Text w as updated to provide clarity on 2 MMTT -stimulated C -peptide endpoints.
[IP_ADDRESS]. Other Endpoints The description of peak w as added to the MMTT -simulated C -peptide endpoint.
Rationale : The timepoints for the distribution of study agent injection devices was corrected in the Time and Events 
Schedule. 
Time And Events Schedule Distribute study agent injection devices was updated to include Week 33 and Week 45
Footnote g was updated with detailed instructions around study agent administration 
and PK sampling for clarity.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
114
Approved , Date: [ADDRESS_507477] 2019Applicable Section(s) Description of Change(s)
Rationale: Minor errors w ere noted
Throughout the protocol Minor grammatical, formatting, or spelling changes were made.
References VarioJect Injection Pen Investigator’s Brochure and Seaquist ER, Anderson J, Childs 
B, et al references were added to the list of references.
10.2. Discontinuation of 
Study 
Treatment/Withdrawal from 
the StudyEncouraged to participate in the Week 104 and Week 52 v isits was changed to 
encouraged to participate in the Week 52 and Week 104 visits.
Amendment 1 (02 Jun e2016 )
The overall reason for the amendment: The overall reason for the amendment is to incorporate feedback from 
health authorities into the protocol.
Applicable Section(s) Description of Change(s)
Rationale: An additional inclusion criterion was needed to confirm current or future immunization status.
4.1. Inclusion Criteria; 
inclusion criterion 11New  criterion added to confirm current or future immunization status.
Rationale: Clarification of the definition and timing for immunizations that can be received w as needed in the 
protocol. 
8.2. Perm itted 
MedicationsDetails were added around vaccines permitted in the study and their schedule. 
Rationale: The handling of laboratory samples from the Mixed -Meal Tolerance Test ( MMTT) needed clarification 
for storage and shippi[INVESTIGATOR_402516].
Attachment 3: 
Procedures for 
Performing the Mixed -
Meal Tolerance TestInstructions were added for processing, storage, and shippi[INVESTIGATOR_402517].
Rationale: Recognition that those with clinically stable autoimmune thyroiditis may be able to participate in this 
study needed to be added to the protocol.
4.2. Exclusion Criteria; 
criterion 4Criterion updated to provide an exception for subjects with clinically stable autoimmune 
thyroiditis. 
Rationale: Clarity needed around the number of injections in Table 1. 
6.1. Dosage; Table 1 Number of injections updated to number of injections/dose in Table 1. 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
115
Approved , Date: [ADDRESS_507478] 2019Applicable Section(s) Description of Change(s)
Rationale: Consistency needed in the protocol in relation to neutralizing antibodies.
9.3.4. Immunogenicity 
Assessments 
(Antibodies to 
golimumab)Text added describing evaluation of positive samples for neutralizing antibodies.
Rationale: The title of the study was decided after issuing of the protocol.
Title page The study title was added to the cover page of the protocol.
Rationale: Where to record self -administration done at the study site needed clarification. 
TIME AND EVENTS 
SCHEDULE; 
Screening through Off -
therapy Follow -up; 
Footnote bFootnote updated to include instructions for recording self -administration done at the 
study site.
7.1.1. Dosing 
RecordingText added to clarify self -administration done at the study site should not be recorded 
into an eDiary.
Rationale: Clarification was needed on subject/caregiver data collection using the sponsor -supplied eDiary and 
glucometer. 
9.1.1. Overview Collection of hypoglycemic events was added to list of data that subject/caregivers are to 
collect using the sponsor -supplied eDiary and glucometer.
Rationale: Clarification was needed around length of time subject/caregivers need to record data in their eDiary.
[IP_ADDRESS]. Off-Therapy 
Follow -up Period –
Weeks [ADDRESS_507479]/caregivers to record data in their eDiary until 
Week 104.
Rationale: Members of the Independent DMC needed to be defined in the protocol.
11.11. Data Monitoring 
CommitteeText w as added to define associations of individuals who can be members of the 
Independent DMC for this study. 
Rationale: The IAC may consist of individuals external to the sponsor.
11.10. Interim Analysis Removed “internal” in reference to the IAC.
Rationale: Clarification regarding timing of administration of study agent needed in the dosing charts.
Attachment 2 -A;
Attachment 2 -ATitle of the tables were updated w ith range of weeks for study agent administration. 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
116
Approved , Date: [ADDRESS_507480] 2019Applicable Section(s) Description of Change(s)
Rationale: Minor errors w ere noted.
1. INTRODUCTION; 
Type 1 DiabetesShots changed to injections.
4.2. Exclusion Criteria; 
criterion 14Current of prior corrected to: current or prior.
ABBREVIATIONS Abbreviations for CDC and HPV w ere added to the list of abbreviations.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
117
Approved , Date: [ADDRESS_507481] 2019REFERENCES
1. Akirav EM1, Lebastchi J, Galvan EM, Henegariu O, Akirav M, Ablamunits V, Lizardi PM, Herold KC. 
Detection of β cell death in diabetes using differentially methylated circulating DNA Proc Natl Acad Sci U S 
A. 2011;108(47):[ZIP_CODE] -[ZIP_CODE].
2. Argiles JM, Lopez -Soriano J, Lopez -Soriano FJ. Cytokines and diabetes: the final step? Involvement of TNF -
alpha in both type I and II diabetes mellitus. Horm Metab Res. Oct 1994;26(10):447 -449.
3. Arif S, Cox P, Afzali B, et al. Anti-TNFalpha therapy --killing two birds w ith one stone? Lancet. 
2010;375(9733):2278.
4. Asvold BO, Sand T, Hestad K, Bjorgaas MR. Cognitive function in type 1 diabetic adults with early exposure 
to severe hypoglycemia: a 16 -year follow -up study. Diabetes Care. 2010;33:1945 -1947.
5. Atkinson MA, Bluestone JA, Eisenbarth GS, et al. How  does type 1 diabetes develop?: the notion of homicide 
or beta -cell suicide revisited. Diabetes. 2011;60(5):1370 -1379.
6. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014;383:69 -82.
7. Bjorg aas MR. Cerebral effects of severe hypoglycemia in young people w ith type 1 diabetes. Pediatr Diabetes. 
2012;13:100 -107.
8. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. 
Nature. 2010;464(7293):1293 -1300.
9. Bougneres PF, Carel JC, Castano L, et al. Factors associated w ith early remission of type I diabetes in children 
treated w ith cyclosporine. N Engl J Med. 17 1988;318(11): 663-670.
10. Bougneres PF, Landais P, Boisson C, et al. Limited duration of remission of insulin dependency in children 
with recent overt type I diabetes treated w ith low -dose cyclosporin. Diabetes. 1990;39(10):1264 -1272.
11. Boulton JG, Bourne JT. Unstable diabetes in a patient receiving anti -TNF -alpha for rheumatoid arthritis. 
Rheum atology (Oxford). 2007;46(1):178 -179.
12. Boyle KD. Keyes -Elstein L, Ehlers MR, et al. Tw o-and four -hour tests differ in capture of C -peptide 
responses to a mixed meal in type 1 diabetes. Diabetes Care. 2016:e1 -e3. DOI: 10.2337/dc15 -2077. 
http://care.diabetes journals.org/content/early/2016/04/12/dc15 -2077.short?rss=1. Accessed on April 21, 2016.
13. Cavallo MG, Pozzilli P, Bird C, et al. Cytokines in sera from insulin -dependent diabetic patients at diagnosis. 
Clin Exp Immunol. 1991;86(2):256 -259.
14. Chiang JL, Kirkman MS, Laffel LMB, Peters AL. Type 1 diabetes through the life span: a position statement 
of the American Diabetes Association. Diabetes Care. 2014;37:2034 –2054.
15. Clark AL, Best CJ, Fisher SJ. Even silent hypoglycemia induces cardiac arrhyth mias. Diabetes. 2014;63:1457 -
1459.
16. Cook JJ, Hudson I, Harrison LC, et al. Double -blind controlled trial of azathioprine in children w ith newly 
diagnosed type I diabetes. Diabetes. 1989;38(6):779 -783.
17. Daneman D. T ype 1 diabetes. Lancet . 2006;367(9513):847 -858.
18. Department of Health and Human Safety. 2000 CDC growth charts for the [LOCATION_002]: methods and 
development. Data from the national health examination surveys and the national health and nutrition 
examination surveys. Vital Health and Statistics. 2002 ; 11(246): [ADDRESS_507482] of intensive therapy on residual beta -cell 
function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, 
controlled trial. Ann Inte rn Med. 1998;128:[ADDRESS_507483] of metabolic activity of beta cells on cytokine -induced 
damage and recovery of rat pancreatic islets. Acta Diabetol. 1995;32(4):217 -224.
21. Eisenbarth GS. Type 1 diabetes: molecular, ce llular and clinical immunology. Adv Exp Med Biol. 
2004;552:306 -310.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
118
Approved , Date: [ADDRESS_507484] 201922. ENBREL® [package insert]. Thousand Oaks, CA: Immunex Corporation; March 2015. 
http://pi.amgen.com/united_states/enbrel/derm/enbrel_pi.pdf Accessed on April 14, 2016.
23. Estrada CL, Danielson KK, Drum ML, Lipton RB. Hospi[INVESTIGATOR_402518], Illinois. Pediatrics. 2009;124:926 -934.
24. Fonolleda M , Murillo M, Vazquez F, Bel J, Vives -Pi M . Remission Phase in Paediatric Type 1 Diabetes: Ne w 
Understanding and Emerging Biomarkers. Horm Res Paediatr 2017 ;88:307 –315.
25. Gitelman SE, Gottlieb PA, Rigby [CONTACT_66243], et al. Antithymocyte globulin treatment for patients w ith recent -onset 
type 1 diabetes: 12 -month results of a randomised, placebo -controlled, phase 2 trial. Lancet Diabetes & 
Endocrinology. 2013. http://dx.doi.org/10.1016/S2213 -8587(13)[ZIP_CODE] -2. Accessed March 18, 2016.
26. Gottlieb PA, Quinlan S, Krause -Steinrauf H, et al. Failure to preserve β -cell function with mycophenolate 
mofetil and daclizumab combin ed therapy in patients with new -onset type 1 diabetes. Diabetes Care. 
2010;33(4):[ADDRESS_507485] phases from composite type 1 diabetes trialnet data. Diabetes. 
2012;61 (8):2066 -2073.
28. Guidance for Industry. Diabetes Mellitus: Developi[INVESTIGATOR_402519]: DRAFT GUIDANCE. U.S. Department of Health and Human Services, Food and Drug 
Administration, Center for Drug Evaluation and Research (CDER), February 2008.
29. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. 
(CPMP/EWP/1080/00 Rev. 1. European Medicines Agency Committee for Medici nal Products for Human Use 
(CHMP). May 2012.
30. Han S, Donelan W, Wang H, Reeves W, Yang LJ. Novel autoantigens in type 1 diabetes. Am J Transl Res. 
2013;5(4):379 -392.
31. Herold KC, Gitelman SE, Ehlers MR, et al. Teplizumab (anti -CD3 mAb) treatment preserves C -peptide 
responses in patients with new -onset type 1 diabetes in a randomized controlled trial: metabolic and 
immunologic features at baseline identify a subgroup of responders. Diabetes. 2013;62:3766 -3774.
32. HUMIRA® [package insert]. N orth Chicago, IL: [COMPANY_013] , Inc; March 2016. 
http://www.rxabbvie.com/pdf/humira.pdf Accessed on April 14, 2016.
33. Icks A, Rosenbauer J, Haastert B, Giani G. Hospi[INVESTIGATOR_402520] -
diabetic control subjects: a prospective population -based study . Diabetologia. 2001;[ADDRESS_507486] 3:B87 -92.
34. Incidence and trends of childhood Type [ADDRESS_507487] Group. Diabet 
Med. 2006;23(8):857 -866.
35. Investigator's Brochure: SIMPONI® (golimumab) Edition 15. Janssen Research & Development, LLC
(May 2014).
36. Investigator’s Brochure: VarioJec Injection Pen. Edition 1. Janssen Research & Development, LLC 
(March 2016).
37. Kaw ahara DJ, Kenney JS. Species differences in human and rat islet sensitivity to human cytokines. 
Monoclonal anti -interleukin -1 (IL-1) influences on direct and indirect IL -1-mediated islet effects. Cytokine. 
1991;3(2):117 -124.
38. Kleijw egt FS, Laban S, Duinkerken G, et al. Critical role for TNF in the induction of human antigen -specific 
regulatory T cells by [CONTACT_402581] s. J Immunol. 2010;185(3):1412 -1418.
39. Koulmanda M, Bhasin M, Awdeh Z, et al. The role of TNF -alpha in mice with type 1 -and 2 -diabetes. PLoS 
One. 2012;7(5):e33254
40. Kodama S, Davis M, Faustman DL. The therapeutic potential of tumor necrosis factor for autoimmune disease: 
a mechanistically based hypothesis. Cell Mol Life Sci. 2005;62(16):[ADDRESS_507488] ablished 
type 1 diabetes. Diabet Med. 2015;32:1346 -1353.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
119
Approved , Date: [ADDRESS_507489], Carla J. Greenbaum CJ, et al. Sample Size Requirements for Studies of Treatment 
Effects on Beta -Cell Function in Newly Diagnosed T ype 1 Diabetes. PLoS ONE. 2011;6(11):[ADDRESS_507490] of C -peptide preservation on metabolic and clinical 
outcomes in the Diabetes Control and Complications Trial. Diabetes. 2014;63:739 -748.
44. Lin A, Northam EA, Werther GA, Cameron FJ. Risk factors for decline in IQ i n youth with type 1 diabetes 
over the 12 years from diagnosis/illness onset. Diabetes Care. 2015;38:236 -242.
45. Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J 
Med. 2014;371:[ADDRESS_507491] NA et al. Epi[INVESTIGATOR_402521] 1 diabetes. Endocrino Meta Clin North America. 2010;39 
(3):481 -497.
47. Mandrup -Poulsen T, Bendtzen K, Dinarello CA, Nerup J. Human tumor necrosis factor potentiates human 
interleukin 1 -mediated rat pancreatic beta -cell cytotoxi city. J Immunol. Dec 15 1987;139(12):4077 -4082.
48. Mastrandrea L, Yu J, Behrens T, Buchlis J, Albini C, Fourtner S, Quattrin T. Etanercept treatment in children 
with new -onset type 1 diabetes: pi[INVESTIGATOR_47669], placebo -controlled, double -blind study. Diabetes Care. 
2009;32(7):1244 -1249.
49. Mauras N, Mazaika P, Buckingham B, et al. Longitudinal assessment of neuroanatomical and cognitive 
differences in young children with type 1 diabetes: association with hyperglycemia. Diabetes. 2015;64:1770 -
1779.
50. Max Andersen MLCet al. Partial remission definition: Validation based on the insulin dose -adjusted HbA1c 
(IDAA1C) in 129 Danish children w ith new -onset type 1 diabetes. Pediatr Diabetes. 2014;15(7):469 –476.
51. Molbak AG, Christau B, Marner B, Borch -Johnsen K, Nerup J. Inci dence of insulin -dependent diabetes 
mellitus in age groups over 30 years in Denmark. Diabet Med . 1994;11(7):650 -655.
52. Moran A, Bundy B, Becker DJ, et al. Interleukin -1 antagonism in type 1 diabetes of recent onset: two 
multicentre, randomised, double -blind, placebo -controlled trials. Lancet. 2013;381(9881):[ADDRESS_507492] P., Sw ift P., et al. New  definition for the partial remission period in children and 
adolescents with type 1 diabetes. Diabetes Care. 2009;32(8):1384 –1390.
54. Nagl K, Hermann JM, Plamper M, et al. Factors contributing to partial remission in type 1 diabetes: analysis 
based on the insulin dose -adjusted HbA1c in 3657 children and adolescents from [LOCATION_013] and Austria. Pediatr 
Diabetes 2017;18:428 -434.
55. Orban T, Bund y B, Becker DJ, et al. Co-stimulation modulation with abatacept in patients with recent -onset 
type 1 diabetes: a randomised, double -blind, placebo -controlled trial. Lancet. 2011;378(9789):412 -419.
56. Palta M, LeCaire T, Daniels K, Shen G, Allen C, D'Alessio D . Risk factors for hospi[INVESTIGATOR_51531] a cohort with 
type 1 diabetes. Wisconsin Diabetes Registry. Am J Epi[INVESTIGATOR_5541]. 1997;146:627 -636.
57. Pescovitz MD, Greenbaum CJ Heidi Krause -Steinrauf, H, et al. Rituximab, B -Lymphocyte Depletion, and 
Preservation of Beta -Cell Function. N Engl J Med. 2009;361(22):2143 -2152.
58. Rabinovitch A. An update on cytokines in the pathogenesis of insulin -dependent diabetes mellitus. Diabetes 
Metab Rev. 1998;14(2):129 -151.
59. REMICADE®[package insert]. Horsham, PA: Janssen B iotech, Inc; Janua ry 2016. 
https://www.remicade.com/shared/product/remicade/prescribing -information.pdf. Accessed on April 14, 2016.
60. Rigby [CONTACT_66243], DiMeglio LA, Rendell MS, et al. Targeting of memory T cells w ith alefacept in new -onset type 1 
diabetes (T1DAL study): 12 month res ults of a randomised, double -blind, placebo -controlled phase 2 trial. 
Lancet Diabetes & Endocrinology. 2013;1(4):284 -292, http://dx.doi.org/10.1016/S2213 -8587(13)[ADDRESS_507493] . 2015;125:3285 -3296.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
120
Approved , Date: [ADDRESS_507494] 201962. Sayers A, Thayer D, Harvey JN, et al. Evidence for a persistent, major excess in all cause admissions to 
hospi[INVESTIGATOR_402522]-1 diabetes: results from a large Welsh national matched community cohort study. 
BMJ Open. 2015;5:e005644.
63. Schölin A1, Nyström L, Arnqvist H, Bolinder J, Björk E, Berne C, Karlsson FA; Diabetes Incidence Study 
Group in Sweden (DISS). Proinsulin/C -pepti de ratio, glucagon and remission in new -onset Type 1 diabetes 
mellitus in yo ung adults. Diabet Med. 2011 ;28(2):[ADDRESS_507495] ER, Anderson J, Childs B, et al. Hypoglycemia and diabetes: a report of a w orkgroup of the American 
Diabetes Association and the Endocrine Society.Diabetes Care. 2013 May;36(5):1384 -1395. doi: 
10.2337/dc12 -2480. Epub.
65. Secrest AM, Becker DJ, Kelsey SF, Lap orte RE, Orchard TJ. Characterizing sudden death and dead -in-bed 
syndrome in T ype 1 diabetes: analysis from tw o childhood -onset T ype 1 diabetes registries. Diabet Med. 
2011;28:293 -300.
66. Sherry NA1, Tsai EB, Herold KC. Natural history of beta -cell function i n type 1 diabetes. Diabetes. 2005;[ADDRESS_507496] 2:S32 -S39.
67. Siminerio LM1, Albanese -O'Neill A2, Chiang JL3, Hathaway K4, Jackson CC4, Weissberg -Benchell J5, 
Wright JL6, Yatvin AL7, Deeb LC8; American Diabetes Association. Care of young children with diabetes in 
the child care setting: a position statement of the American Diabetes Association. Diabetes Care. 
2014;37(10):2834 -2842.
68. SIMPONI®[package insert]. Horsham, PA: Janssen B iotech, Inc; January 2016. 
http://www.simponi.com/shared/product/simponi/prescribing -information.pdf. Accessed on April 14, 2016.
69. Sosenko JM, Palmer JP, Rafkin -Mervis L, Krischer JP. Glucose and C -peptide changes in the perionset period 
of type 1 diabetes in the diabetes prevention trial –type 1. Diabetes Care. 2008;31(11): 2188 –2192.
70. Standa rds of Medical Care in Diabetes —2011. Diabetes C are. 2011 ; 34(Suppl 1): S11 -S61.
71. Stanescu DE, Lord K, Lipman TH. The epi[INVESTIGATOR_402521] 1 diabetes in children. Endocrinol Metab Clin 
North Am. 2012;41(4):679 -694.
72. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes -related 
complications in the diabetes control and complications trial. Diabetes Care. 2003;26:832 -836.
73. van Belle TL, Coppi[INVESTIGATOR_146838], von Herrath MG. T ype 1 diabetes: etiology, immunology, and therapeutic 
strategies. Physiol Rev. 2011;91(1):79 -118.
74. van Eijk IC, Peters MJ, Nurmohamed MT, van Deutekom AW, Dijkmans BA, Simsek S. Decrease of 
fructosamine levels during treatment with adalimumab in patients with both diabetes and rheumatoid arthritis. 
Eur J Endocr inol. Mar 2007;156(3):291 -293.
75. Wherrett DK, Chiang JL, Delamater AM, et al. Defining pathways for development of disease -modifying 
therapi[INVESTIGATOR_67734] 1 diabetes: a consensus report. Diabetes Care. 2015;38:[ADDRESS_507497]. Sep 
2004;34(9):[ADDRESS_507498] of Concomitant 
Methotrexate: An Open -Label, Randomized Study. Clin Ther. 2012;34:77 -90.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
121
Approved , Date: [ADDRESS_507499] 2019Attachment 1: Quantiferon -TBGold Testing
QuantiFERON -TB Gold Testing
The QuantiFERON -TB Gold test is one of the interferon -(IFN -) based blood assay s for TB 
screening (Cellestis, 2009). It utilizes the recently  identified M. tuberculosis -specific antigens 
ESAT -[ADDRESS_507500] form at, as well as TB7.7 (p4) in the In-Tube format, to 
detect in vitro cell-mediated immune responses in infected individuals. The QuantiFERON -TB 
Gold assay  measures the amount of IFN-produced by [CONTACT_41056] T-cells when stimulated with 
the synthetic M. tuberculosis -specific antigens. In M.tuberculosis -infected persons, sensitized 
Tlymphocy tes will secrete IFN-in response to stimulation with the M. tuberculosis -specific 
antigens and, thus, the QuantiFERON -TB Gold test should be positive. Because the antig ens 
used in the test are specific to M.tuberculosis and not found in BCG, the test is not confounded 
by [CONTACT_14400], unlike the tuberculin skin test. However, there is some cross -reactivity  with 
the 3Mycobacterium species, M. kansasii , M. marinum , and M. szulgai . Thus, a positive test 
could be the result of infection with one of these [ADDRESS_507501] (standard format) in subjects with active TB, 
sensiti vity has been shown to be approximately  89% (Mori et al, 2004). Specificity  of the test in 
healthy  BCG -vaccinated individuals has been demonstrated to be more than 98%. In contrast, the 
sensitivity  and specificity  of the tuberculin skin test was noted to be only about 66% and 35% in 
a study  of Japanese patients with active TB and healthy  BCG-vaccinated young adults, 
respectivel y. However, sensitivity  and specificity  of the tuberculin skin test depend on the 
population being studied, and the tuberculin skin test performs best in healthy  young adults who 
have not been BCG -vaccinated.
Data from a limited number of published studies examining the performance of the 
QuantiFERON -TB Gold assay  in immunosuppressed populations suggest that the sensitivity  of 
the Quan tiFERON -TB Gold test is better than the tuberculin skin test even in immunosuppressed 
patients (Ferrara et al, 2005; Kobashi et al, 2007; Matulis et al, 2008). The ability  of IFN --based 
tests to detect latent infection has been more difficult to study  dueto the lack of a gold standard 
diagnostic test; however, several TB outbreak studies have demonstrated that the tests correlated 
better than the tuberculin skin test with the degree of exposure that contacts had to the index TB 
case (Brock et al, 2004; Ewer et al, 2003). In addition, TB contact [CONTACT_402582] a positive QuantiFERON -TB Gold test result and were not treated for 
latent TB infection were much more likely to develop active TB during longitudinal follow -up 
than those who had a positive tuberculin skin test and a negative QuantiFERON -TB Gold test 
result (Higuchi et al, 2007; Diel et al, 2008).
Although the performance of the new IFN --based blood tests for active or latent M. tuberculosis
infection have not been well validated in the immunosuppressed population, experts believe 
these new tests will be at least as, if not more, sensitive, and definitel y more specific, than the 
tuberculin skin test (Barnes, 2004; personal communication, Apri l, [ADDRESS_507502]).
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
122
Approved , Date: [ADDRESS_507503] In-Tube format will be provided for this study . The In-Tube 
format contains 1 additional M. tuberculosis -specific antigen, TB7.7 (p4), which is thought to 
increase the specificity  of the test.
To perform the test using the In-Tube format, blood is drawn through standard venipuncture into 
supplied tubes that already  contain the M. tuberculosis -specific antigens. Approximately  [ADDRESS_507504], each requiring 1 mL  of blood. One tube contains the M. tuberculosis -
specific antigens, while the remaining tubes contain positive and negative control reagents. 
Thorough mixing of the blood with the antigens is necessary  prior to incubation. The blood is 
then incubated for 16 to 24-hours at 37°C, after which tubes are centrifuged for approximately 
15minutes at 2000 to 3000g. Following centrifugation, plasma is harvested from each tube, 
frozen, and shipped on dry  ice to the Central L aboratory . The Central Laboratory  will perform an 
ELISA to quantify  the amount of IFN-present in the plasma using spectrophotometry  and 
computer software anal ysis.
The Central Laboratory will analyze and report results for each subject, and sites will be 
informed of the results. Subjects who have an indeterminate result should have the test repeated.
In select circumstances as approved by [CONTACT_456], a local laboratory  may be used to perform 
the QuantiFERON® -TB Gold test.
Adherence to Local Guidelines
Local country  guidelines for immunocompromised patients should be consulted for acceptable 
antituberculous treatment regimens for latent TB. If no local country  guidelines for 
immunocompromised patients exist, US guidelines must be followed.
References
Barnes PF. Diagnosing latent tuberculosis infection: Turning glitter to gold [editorial]. Amer J 
Respir Crit Care Med. 2004;170:[ADDRESS_507505] in tuberculosis contacts. Am J Respir Crit Care Med. 2004;170:65 -69.
Cellestis. QuantiFERON -TB Gold clinicians guide and QuantiFERON -TB Gold I n-Tube Method 
package insert. Downloaded from www.cellestis.com, February  2009.
Diel R, Lodd enkemper R, Meywald -Walter K, Niemann S, Nienhaus A. Predictive value of a 
whole blood IFN -assay for the development of active tuberculosis disease after recent infection 
with my cobacterium tuberculosis. Am J Respir Crit Care Med. 2008;177:[ADDRESS_507506] for 
diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet. 
2003;361:1168 -1173.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
123
Approved , Date: [ADDRESS_507507] 2019Ferrara G, Losi M, Meacci M, et al. Routine hosp ital use of a new commercial whole blood 
interferon -assay  for the diagnosis of tuberculosis infection. Am J Respir Crit Care Med. 2005; 
172:631 -635.
Higuchi K, Nobu yuki H, Mori T, Sekiya Y. Use of QuantiFERON -TB Gold to investigate 
tuberculosis contacts in a high school. Respi[INVESTIGATOR_16921] . 2007;12:[ADDRESS_507508] for 
immunocompromised patients. Eur Respir J. 2007; 30:945 -950.
Matulis G, Jüni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in 
immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium 
tuberculosis antigen -specific interferon assay . Ann Rheum Dis. 2008;67:84 -90
Mori T, Sakatani M, Yamagishi F, et al. Specific detection of tuberculosis infection: An 
interferon --based assay  using new antigens. Am J Respir Crit Care Med. 2004;170:59 -64.
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
124
Approved , Date: [ADDRESS_507509] 2019Attachment 2 :Dose and Device Charts for Study CNTO 148DML 2001 in Subjects With Type 1 
Diabetes
DOSE AND DEVICE CHARTS FOR STUDY CNTO148DML2001 IN SUBJECTS WITH 
TYPE 1 DIABETES
Attachment 2 -A: Dosing Chart for Induction Doses at Week 0 and Week 2
Volume (mL) from VarioJect ( shaded white) and/or 50 mg PFS -U (shaded light gray )
Body weight rounded to the nearest [ADDRESS_507510] 10 cm. (Example: weight of 27.6 kg and height of 114.9 cmround 
weight up to 30 kg, and height down to 110 cm,resulting in an induction dose volume of 
0.55 mL).
See device selection table (Attachment 2 -C) for additional administration instructions.
Induction Dosing Chart -VarioJect or PFS-U Volume to be Dispensed (mL) for Week 0 and 
Week 2 Only*
Height (cm )Weight (kg)
10 15 20 25 30 35 40 45
80 0.30 0.35 0.40 0.45
90 0.30 0.35 0.40 0.45 0.50 0.55
100 0.30 0.40 0.45 0.50 0.55 0.60 0.651.00 w ith 2 
PFS-U
110 0.35 0.40 0.45 0.50 0.55 0.60 0.651.00 w ith 2 
PFS-U
120 0.35 0.40 0.50 0.55 0.60 0.65 0.701.00 w ith 2 
PFS-U
130 0.45 0.50 0.55 0.60 0.65 0.701.00 w ith 2 
PFS-U
140 0.45 0.55 0.60 0.65 0.70 0.751.00 w ith 2 
PFS-U
150 0.55 0.60 0.65 0.70 0.751.00 w ith 2 
PFS-U
160 0.55 0.65 0.70 0.75 0.801.00 w ith 2 
PFS-U
170 0.65 0.70 0.75 0.801.00 w ith 2 
PFS-U
180 0.75 0.80 0.851.00 w ith 2 
PFS-U
* See Attachment 2 -C:Device Selection Chart for device(s) and settings to achieve the total dose indicated above
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
125
Approved , Date: [ADDRESS_507511] 2019Attachment 2 -B:Dosing Chart for Maintenance Dosing Regimens at Week 4 through Week 52
Volume (mL) from VarioJect (shaded white) or 50 mg PFS -U (shaded light gray )
Body weight rounded to the nearest [ADDRESS_507512] 10 cm.
See device selection table (Attachment 2 -C) for additional adm inistration instructions.
Maintenance Dosing Chart -Vario Ject (White) or PFS-U (Light Gray) Volume to be Dispensed 
(mL) for Week 4 Through Week 52*
Height (cm )Weight (kg)
10 15 20 25 30 35 40 45
80 0.15 0.15 0.20 0.20
90 0.15 0.20 0.20 0.25 0.25 0.30
100 0.15 0.20 0.20 0.25 0.25 0.30 0.300.50 w ith 
PFS-U
110 0.15 0.20 0.25 0.25 0.30 0.30 0.350.50 w ith 
PFS-U
120 0.15 0.20 0.25 0.25 0.30 0.30 0.350.50 w ith 
PFS-U
130 0.20 0.25 0.30 0.30 0.35 0.350.50 w ith 
PFS-U
140 0.25 0.25 0.30 0.30 0.35 0.350.50 w ith 
PFS-U
150 0.25 0.30 0.35 0.35 0.400.50 w ith 
PFS-U
160 0.30 0.30 0.35 0.35 0.400.50 w ith 
PFS-U
170 0.35 0.35 0.40 0.400.50 w ith 
PFS-U
180 0.35 0.40 0.400.50 w ith 
PFS-U
* See Attachment 2 -C: Device Selection Chart for device and settings to achieve the dose indicated above
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
126
Approved , Date: [ADDRESS_507513] 2019Attachment 2 -C: Device Selection Chart
Volume (mL) from VarioJect or PFS -U
Device Selection Chart**
Volume 
(mL)Induction Dose Maintenance Dose
Number of Devices Volume Number of Devices Volume
0.[ADDRESS_507514]: 0.[ADDRESS_507515]: 0.[ADDRESS_507516]: 0.[ADDRESS_507517]: 0.[ADDRESS_507518]: 0.[ADDRESS_507519]: 0.[ADDRESS_507520]: 0.[ADDRESS_507521]: 0.[ADDRESS_507522]: 0.[ADDRESS_507523]: 0.45 mL N/A N/A
0.[ADDRESS_507524]: 0.25 mL;
2nd VarioJect : 0.25 mL1 PFS -U 50 mg PFS-U: whole volume
0.[ADDRESS_507525]: 0.25 mL;
2nd VarioJect : 0.[ADDRESS_507526]: 0.30 mL;
2nd VarioJect : 0.[ADDRESS_507527]: 0.30 mL;
2nd VarioJect: 0.[ADDRESS_507528]: 0.35 mL;
2nd VarioJect: 0.[ADDRESS_507529]: 0.35 mL;
2nd VarioJect: 0.[ADDRESS_507530]: 0.40 mL;
2nd VarioJect: 0.[ADDRESS_507531]: 0.40 mL;
2nd VarioJect: 0.45 mL
0.90 N/A N/A
0.95 N/A N/A
1.[ADDRESS_507532] PFS -U: whole 
volume; 2nd PFS -U: 
whole volume
** Due to a rare chance of excess study agent administration w ith the 0.[ADDRESS_507533], this dose 
increment is not to be used.
NA = Not applicable
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
127
Approved , Date: [ADDRESS_507534] 2019Attachment 3 :Procedures for Performing the Mixed -Meal Tolerance Test
NOTE: These procedures for performing the mixed -meal tolerance test instructions are a 
summary  of the how subjects should prepare for the MMTT and how the test should be 
performed by [CONTACT_2362]. Further detail will be provided in the Central Laboratory  manual. 
Minor adjustments of this procedure may occur by [CONTACT_72017], but not limited, to 
modifications or refinements of sample preparation and processing that will not necessitate a 
protocol amendment.
Procedures for Performing the Mixed -Meal Tolerance Test:
The MMTT is performed in the morning (between 7:00 a.m. and 10:00 a.m.), which means that 
administrati on must begin within this time. It is recommended that the test s be scheduled earl y in 
the morning (7:00 –7:30 am) because BGwill be more likely to be within the target range at that 
time.
The mixed -meal used in this protocol will be the Boost original Nutritional Energy  Drink®
(Mead -Johnson). If a subject has a known food allergy  to one or more components of Boost, an 
equivalent substitution may be used contingent upon agreement with the study  team.The 4-hour 
MMTT shou ld take [ADDRESS_507535] Instructions :
Carbohy drates (CHO) should not be restricted from the diet before the test. A general guideline 
is that preadolescent subjects should consume at least 25 kcal (6.25 g) CHO/kg/day  and 
adolescent and adult subjects should consume at least 15 kcal (3.75 g) CHO/kg/day  for 3days 
before the test. These are minimum amounts of CHO; most diets will include greater amounts of 
CHO. There is no need to alter the subject’s diet unless he or she has been on a CHO -restricted 
diet.
In preparation for the visit, each subject should:
Fast for at least 10 hours (but not more than 16 hours) before the test. Fasting should start 
the night before the test and should continue up until the start of the test. Subjects should not 
eat or drink anything except water. This means no coffee, tea, soda, cigarettes, alcohol, or 
chewing gum during the fasting period.
Refrain from vigorous exercise during the fasting period.
Refrain from working the night before the morning of the test.
Discontinue taking an y prescription medications that must be taken daily.
Glucose and Insulin Before the Test:
Short -acting insulin analogues (such as lispro or l -aspart) may be administered up to [ADDRESS_507536].
Regular insulin may  be administered up to [ADDRESS_507537].
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
128
Approved , Date: [ADDRESS_507538] 2019Intermediate -acting insulin (such as Neutral Protamine Hagedorn [NPH ]) may be 
administered on the evening before the MMTT, but not on the morning of the test. Subjects 
managed with intermediate -acting insulin (NPH or Lente) should administer their usual dose 
on the evening before the MMT T, but not on the morning of the test.
Long -acting basal (such as glargine) insulin or continuous subcutaneous insulin infusion 
may be administered before, during and after the test as usual. Subjects on glargine may take 
their usual injection at the appro priate time, and those on continuous subcutaneous insulin 
infusion may  continue with their usual basal settings.
Target Glucose Level at the Start of Test :
The target glucose level at the start of the test is between 70 and 200 mg/dL. Regular insulin or 
short-acting insulin analogues may be used up to [ADDRESS_507539] should discuss 
the individual situation for insulin administration to attain the goal of meter capi[INVESTIGATOR_402523] 70–200 mg/dL at the start of the test. For example, as a practical 
matter, subjects may be instructed to check their BGby [CONTACT_402583] 
2hours before the start of the test, so that marked hypergly cemia can be treated with a 
short -acting insulin analogue. Alternatively , subjects who arrive at the research unit with 
elevated BGcan receive additional short -acting insulin analogues at the time of their arrival, if 
the testitself does not start until at least [ADDRESS_507540]’s BGis below the limit (70 mg/dL) prior to performing the MMTT, the subject 
should be treated according to local practice, and the MMTT shou ld be rescheduled.
IV Placement During the Test :
The IV should be in place for the duration of the test and must be flushed after each draw with 
saline solution or heparin flush.
The subject should remain sitting or resting in bed quietly  throughout the test and until the test is 
completed. However, he or she may engage in quiet, non-strenuous activities, such as reading, 
playing cards, or watching TV. The subject may walk to the bathroom betw een blood draws if 
necessary .
Testing Instructions:
Timep oint −[ADDRESS_507541] 10 minutes after establishing the line(s) and when the 
subject is calm and relaxed (if possible, depen ding on age) ― this is the “ −10minute ” sample.
Draw one [ADDRESS_507542] 8 to 10 times. Chill sample in a bucket of crushed ice or in a 
refrigerator set at 4˚C for 20 to 30 minutes. At the labora tory, spin the tube in a tabletop 
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
129
Approved , Date: [ADDRESS_507543] 2019centrifuge (1000 –1300 g, ~3000 RPM) for [ADDRESS_507544]; this is the 
“0-minute” sample.
Then the MMTT dose should be given with 6 kcal/kg @ 1 kcal/mL of mixed -meal to a 
maximum of [ADDRESS_507545] collection, chill sample in a bucket of crushed ice or in a refrigerator set at 4 ˚C 
for [ADDRESS_507546]’s standard insulin plan.
Tube -Processing Instructions:
Spin the purple ---top tubes, t hen transfer the plasma into [ADDRESS_507547] be noted on the 
Comments section of the MMTT specimen transmittal form .
Sample:
Time (minutes) Sample Collection*
–[ADDRESS_507548]
15 x
30 x
60 x
90 x
120 x
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
130
Approved , Date: [ADDRESS_507549] 2019Time (minutes) Sample Collection*
150 x
180 x
210 x
240 x
*assessments to include C-peptide, insulin, glucose, and/or pro -insulin per the Central 
Laboratory manual
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
131
Approved , Date: [ADDRESS_507550] 2019Attachment 4: Hepatitis B Virus (HBV) Screening
Hepatitis B Virus (HBV) Screening
Subjects must undergo screening for hepatitis B virus (HBV). At a minimum, this includes 
testing for HBsAg (HBV surface antigen), anti-HBs (HBV surface antibody ), and anti-HBc total 
(HBV core antibod y total):
Subjects who test negative for all HBV screening tests (ie, HBsAg -, anti-HBc-, and 
anti-HBs-) areeligible for this study .
Subjects who test negative for surface antigen (HBsAg -) and test positive for core antibody 
(anti-HBc+) andsurface antibody  (anti -HBs+) areeligible for this study .
Subjects who test positive only for surface antibo dy(anti-HBs+) areeligible for this study .
Subjects who test positive for surface antigen (HBsAg+) areNOT eligible for this study , 
regardless of the results of other hepatitis B tests.
Subjects who test positive only for core antibody (anti-HBc+) areNOT eligible for this 
study .
For subjects who are not eligible for this study due to HBV test results , consultation with a 
physician with expertise in the treatment of hepatitis B virus infection is recommended.
Eligibility Based on Hepatitis B Virus T est Results
Hepatitis B test result
ActionHepatitis B surface 
antigen
(HBsAg)Hepatitis B surface 
antibody
(anti -HBs)Hepatitis B core 
antibody
(anti -HBc total)
Include— — —
— + +
— + —
Exclude+ —or+ —or+
— — +
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
132
Approved , Date: [ADDRESS_507551] 2019Attachment 5 :Study Defined AST and ALT Normal Ranges, 2x ULN, and 3x ULN
AST and ALT normal range s, 2x ULN, and 3x ULN*
Test SexAge Range
(Yrs)Norm al Range
(U/L)2x ULN (U/L) 3x ULN (U/L)
AST Fem ale Through 6 10-48 96 144
7 through 17 10-40 80 120
18 and above 9-34 68 102
Males Through 6 10-59 118 177
7 through 17 10-40 80 120
18 and above 11-36 72 108
ALT Fem ale 6and above 6-34 68 102
Male 6 through 9 6-34 68 102
10 and above 6-43 86 129
* From Covance Laboratories
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
133
Approved , Date: [ADDRESS_507552] 2019Attachment 6:Anticipated Events
An anticipated event is an AE(serious or non-serious) that commonly  occurs as a consequence 
of the underl ying disease or condition under investigation (disease -related) or background 
regimen.
For the purposes of this study  the following events will be considered anticipated events:
1.Severe hypogly cemia. This is defined as a BGreading of <70 mg/dL  and/or clinical signs 
and sy mptoms consistent with hy poglycemia even in the absence of a BGreading.
2.Diabetic Ketoacido sis (DKA). This is a condition of ketosis and metabolic acidosis that can 
occur in individuals with T1D.
Both severe h ypogl ycemia and DKA may  present along a spectrum of severity . The site principal 
investigator [INVESTIGATOR_402524] n according to the definitions in Section 
12.
Reporting of Anticipated Events
These events will be captured on the CRF and in the database andwill be reported to the sponsor 
asdescribed in Section 12.4.1 , All Adverse Events . Any event that meets SAE criteria will be 
reported to the sponsor within the appropriate timeline as described in Section 12.4.2 , Serious 
Adverse Events. These anticipated events are exempt from expedited reporting as individual 
single cases to health authorities. However ,if based on an aggregate review, it is determined that 
an anticipated event is possibly  related to study  agent , the sponsor will report these events in an 
expedit ed manner.
Anticipated Event Review Committee (ARC)
An Anticipated Event Review Committee (ARC) will be established to perform reviews of pre-
specified anticipated events at an aggregate level. The ARC is a safet y committee within the 
sponsor’s organizatio n that is independent of the sponsor’s study  team. The ARC will meet to aid 
in the recommendation to the sponsor’s study  team as to whether there is a reasonable possibility  
that an anticipated event is related to the study  agent. As this is a blinded study, an unblinded 
physician within the sponsor’s organization not involved with the study  but with subject matter 
expertise will be available to assist the ARC in the assessment and categorization of AEs if 
needed.
Statistical Analysis
Details of statistical analy sis of anticipated events, including the frequency  of review and 
threshold to trigger an aggregate analysis of anticipated events will be described in a separate 
Anticipated Events Safety Monitoring Plan (ASMP).
SIMPONI®  (golimumab)
Clinical Protocol CNTO148DML2001 Amendment 3
134
Approved , Date: [ADDRESS_507553] of the study , and the obligations of 
confidentiality .
Coordinating Investigator (where required):
Nam e (typed or printed):
Institution and Address:
Signature: [CONTACT_1782]:
(Day Month Year)
Principal (Site) Investigator:
Nam e (typed or printed):
Institution and Address:
Telephone Number:
Signature: [CONTACT_1782]:
(Day Month Year)
Sponsor's Responsible Medical Officer:
Nam e (typed or printed): Donald Raible, MD
Institution: Janssen Research & Development
Signature: [electronic signature [CONTACT_111203]] Date:
(Day Month Year)
Note :If the address or telephone number of the investigator changes during the course of the 
study , written notification will be provided by [CONTACT_68477], and a protocol 
amendment will not be required.
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 1
Status: Approved ,  Date: 24 April 2020Janssen Research & Development *
Clinical Protocol
COVID -19 Appendix
SIMPONI® to Arrest β -cell Loss in Type 1 Diabetes
T1GER
Protocol CNTO148DML2001 ; Phase 2a
SIMPONI®   (golimumab)
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited toJanssen Biotech, Inc.; Janssen Products, LP; Janssen Biologics, 
BV; Janssen- Cilag International NV; Janssen, Inc; Janssen Pharmaceutica NV; Janssen Sciences Ireland
UC; Janssen Biopharma Inc.;or Janssen Research & Development, LLC. The term “sponsor” is used 
throughout the protocol to represent these various legal entities; the sponsor is identified on the Contact 
[CONTACT_12944].
[LOCATION_002] (U S)sites of t his study  will be conducted under US Food & Drug Administration
Investigational New Drug ( IND) regulations (21 CFR Part 312).
Status: Approved
Date: 24 April 2020
Prepared by: [CONTACT_12945] & Development, LLC
EDMS number: EDMS- RIM-[ZIP_CODE], 1.0
THIS APPENDIX APPLIES TO ALL CURRENT APPROVED VERSIONS OF PROTOCOL
CNTO148DML2001 
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements. 
Confidentiality Statement
The information provided herein contains Company trade secrets, commercial or financial information that the Company
customarily holds close and treats as confidential.  The information is being provided under the assurance that the recipi[INVESTIGATOR_70281], regulations, rules, protective orders or 
otherwis e.
[STUDY_ID_REMOVED]
COVID -19 Appendix
SIMPONI® (golimumab) Clinical Protocol CNTO148DML2001
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 2
Status: Approved ,  Date: [ADDRESS_507554] DURING THE COVID -19 PA NDEMIC
It is recognized that the Coronavirus Disease 2019 (COVID -19) pandemic may  have an impact on 
the conduct of this clinical study due to, for example, self -isolation/quarantine by  [CONTACT_90830] -site personnel; travel restrictions/limited access to public places, including hospi[INVESTIGATOR_600]; study  
site personnel being reassigned to critical tasks.
In alignment with recent health authority  guidance, the sponsor is providing options for 
study  -related participant management in the event of disruption to the conduct of the study . This 
guidance does not supersede any local or government guidelines or requirements or the clinical 
judgement of the investigator to protect the health and wel l-being of participants and site staff. If 
at any time a participant’s safet y is considered to be at unacceptable risk, study  intervention will 
be discontinued, and study  follow -up will be conducted.
Scheduled visits that cannot be conducted in person at the study  site will be performed to the extent 
possible remotel y/virtually  or delayed until such time that on-site visits can be resumed. At each 
contact, participants will be interviewed to collect safet y data. Key efficacy endpoint assessments 
should be performed if required and as feasible. Participants will also be questioned regarding 
general health status to fulfill any  physical examination requirement. 
Every effort should be made to adhere to protocol -specified assessments for participants on study 
intervention, including follow up. Modifications to protocol -required assessments may be 
permitted after consultation between the participant and investigator, and with the agreement of 
the sponsor (see below). 
The sponsor will continue to monitor the cond uct and progress of the clinical study , and any 
changes will be communicated to the sites and to the health authorities according to local guidance.
If a participant has tested positive for COVID -19, the investigator should contact [CONTACT_456]’s 
medical of ficer or designee to discuss plans for study  intervention and follow -up. 
ADDITIONAL ELEMENTS, WHERE APPLICABLE:
Certain protocol -mandated visits to the study  site may not be possible during the COVID -19 
outbreak. Therefore, temporary  measures may be implemented if considered appropriate by 
[CONTACT_402584] y. 
Certain measures, such as those listed below, may be necessary  and should be instituted in 
accordance with applicable (including local) laws, regulations, guidelines, and procedures:
oremote (e.g. by [CONTACT_648] / telemedicine) or in-person, off-site (eg,in-home) interactions 
between site staff (or designees) and participants for study  procedures e.g. those related 
to safet y monitoring / efficacy  evaluation / study  intervention storage and 
administration (including training where pertinent)
COVID -19 Appendix
SIMPONI® (golimumab) Clinical Protocol CNTO148DML2001
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 3
Status: Approved ,  Date: 24 April 2020oprocurement ofstudy  intervention by [CONTACT_4317] (or designee) or shipment of study  
intervention from the study  site directly  to participants for at home administration 
(including the potential for self -administration of study  intervention )
olaboratory  assessments using a suitabl y accredited local laboratory ; for selected 
measures (eg ,urine pregnancy ), home testing may  be employ ed
oother procedures, eg, imaging, may  be conducted at an appropriate facility
Missed assessments/visits will be captured in the clinical trial management system for 
protocol deviations.  Discontinuations of study  interventions and withdrawal from the 
study  should be documented with the prefix “COVID -19-related” in the case report form 
(CRF).  
oother relevant study  data elements impacted by [CONTACT_12948] / labeled as “COVID -19-related” in CRFs and / or other study  systems, 
as directed by [CONTACT_12949]. These may include missed / delay ed / 
modified study  visits / assessments / dosing, and instances where temporar y 
measures such as those above are implemented.  
The sponsor will evaluate the totalit y of impact of COVID -19 on collection of key study 
data and additional data analy ses will be outlined in study  SAP(s). 
Exclusion: a potential participant with the following features will be excluded from 
participating in the stud y protocol:
oDuring the [ADDRESS_507555] had ANY of (a) confirmed SARS -CoV -
2 (COVID -19) infection (test positive), OR (b) suspected SARS -CoV -2 infection 
(clinical features without documented test results), OR (c) close contact [CONTACT_4490] a 
person with known or suspected SARS -CoV -2 infection 
Exception: may be included with a documented negative result for a 
validated SARS -CoV -[ADDRESS_507556]
(i)obtained at least 2 weeks after conditions (a), (b), (c)above (timed from 
resolution of key  clinical features if present, e.g. fever, cough, d yspnea)
AND
(ii)with absence of ALL  conditions (a), (b), (c) above during the period 
between the negative test result and the baseline study  visit 
COVID -19 Appendix
SIMPONI® (golimumab) Clinical Protocol CNTO148DML2001
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 4
Status: Approved ,  Date: 24 April 2020NOTES on COVID -related ex clusion:
1.If a participant is excluded due to recent COVID -19-related features, the reason for 
screen failure should be documented in the case report form under the exclusion 
criterion of having a condition for which participation would not be in the partic ipant’s 
interest or could confound study  assessments. 
2.The field of COVID -related testing (for presence of, and immunity  to, the SARS -CoV -
2 virus) is rapi[INVESTIGATOR_393364]. Additional testing may be performed as part of screening 
and/or during the study  if deem ed necessary  by [CONTACT_402585] / guidance from authorities / standards of care. 
Precaution: for those who may  carry  a higher risk for severe COVID -19 illness (e.g. those 
aged over 65 years), follow guidance from local health authorities when weighing the 
potential benefits and risks of enrolling in the study , and during participation in the study . 
COVID -19 Appendix
SIMPONI® (golimumab) Clinical Protocol CNTO148DML2001
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 5
Status: Approved ,  Date: [ADDRESS_507557] of the study , and the obligations 
of confidentialit y.
Coordinating Investigator (where required):
Nam e (typed or printed):
Institution and Address:
Signature: [CONTACT_1782]:
(Day Month Year)
Principal (Site) Investigator:
Nam e (typed or printed):
Institution and Address:
Telephone Number:
Signature: [CONTACT_1782]:
(Day Month Year)
Sponsor's Responsible Medical Officer:
Nam e (typed or printed): Frank Vercruysse MD
Institution: Janssen Research & Development 
Signature: [CONTACT_184956]:
(Day Month Year)
Note: If the address or telephone number of the investigator changes during the course of the study, written 
notification will be provided by [CONTACT_68477], and a protocol amendment will not be required.